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RESUMEN 
 
En la presente tesis doctoral se plantea el diseño y desarrollo racional de 
nanoestructuras como vehículos para la liberación de antígenos. Para ello, y con el 
objetivo de incrementar la respuesta inmune a antígenos de distinta naturaleza se 
eligieron biomateriales tales como polisacáridos, poli aminoácidos y lípidos, con 
propiedades inmunoestimulantes y/o inmunoadyuvantes. A partir de ellos, se 
desarrollaran tres tipos de nanoestructuras: i) Sistemas basados en el recubrimiento de 
antígeno particulados mediante biopolímeros tales como la protamina, la poliarginina, el 
sulfato de dextrano, el alginato o el polinucleótido, poli (I:C); ii) Nanopartículas de 
quitosano conteniendo moléculas inmunoestimulantes poly (I:C) encapsulado y 
asociadas a un péptido T-Helper; iii) Nanoemulsiones y nanoemulsiones recubiertas 
(nanocápsulas) basados en la lisofosfatidilcolina, el ácido linoléico, el escualeno y el 
quitosano.  
Estas nanoestructuras fueran constituidos por nanotecnologías sencillas y fácilmente 
escalables, tales como la complejación iónica, gelificación iónica y el desplazamiento 
del solvente según las características de los biomateriales utilizados y de la naturaleza 
del antígeno a que se destina. Los sistemas desarrollados presentan en general una 
adecuada estabilidad en suspensión y pudieron ser liofilizados sin alterar sus 
propiedades fisicoquímicas originales. A estos sistemas se asociaron diferentes 
antígenos tales como el antígeno recombinante particulado de la hepatitis B y un 
antígeno peptídico derivado del virus del papiloma humano. 
Las formulaciones resultantes fueron analizadas mediante una variedad de técnicas in 
vitro y/o in vivo. En general, las nanoestructuras desarrolladas demostraron tener un 
interesante potencial como adyuvantes de vacunas, habiendo logrado modular la 
respuesta inmune frente a antígenos de distinta naturaleza tras su administración 
parenteral y/o mucosa. Más allá de estos resultados, el trabajo recogido en esta tesis 
pone de manifiesto el valor que la nanotecnología puede aportar como herramienta 
excepcional para el desarrollo de nuevos sistemas adyuvantes para vacunas más eficaces 
y seguras. 
  
  
 
ABSTRACT 
 
The main goal of this thesis has been the design and development of a variety of antigen 
nanocarriers made of different biomaterials, such as polysaccharides, polyamino acids, 
and lipids, intended to enhance the immune response against antigens of different 
nature. From these materials, three different types of nanostructures were developed: i) 
Systems based on the multi-enveloping of virus-like particle antigens using protamine, 
polyarginine, dextran sulfate, alginate or poly (I:C); ii) Chitosan nanoparticles 
incorporating poly (I:C) and a T-Helper peptide; iii) Nanoemulsions and coated 
nanoemulsions (nanocapsules) based on lysophosphatidylcholine, linoleic acid, 
squalene and chitosan. 
These nanostructures were produced through simple and easily scalable nanotechnology 
methods as ionic complexation and solvent displacement technique, according the 
characteristics of the biomaterials and the nature of the target antigen. The developed 
systems presented, in general, an adequate stability and could be freeze dried without 
losing the original physicochemical properties. Different model antigens were 
associated to the different nanosystems including the recombinant hepatitis B surface 
antigen virus-like particle and a peptide-based antigen derived from the human 
papillomavirus.  
The resulting formulations were characterized with regard to their biologic activity 
using a range of in vitro and in vivo studies techniques. Overall, the nanostructures 
developed were shown to have a potential for potentiating and modulating the immune 
response against different types of antigen, following either parenteral and/or mucosal 
administration. Beyond these specific data, the work presented here highlights the 
potential of nanotechnology for the development of new safer and more effective 
vaccines.   
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INTRODUCCIÓN 
La mayoría de las vacunas administradas en la actualidad se basan en el uso de 
microorganismos vivos atenuados o inactivados. Estas vacunas han permitido algunos 
de los mayores logros de la medicina, como es la erradicación del viruela o la 
disminución de la incidencia de enfermedades tales como la poliomielitis [1] y el 
rotavirus [2]. A pesar de estos extraordinarios avances, estas vacunas llevan asociado el 
peligro de reversión del organismo, particularmente en individuos inmunodeprimidos, 
pudiendo provocar reacciones adversas graves [1, 3]. La seguridad y efectividad de las 
vacunas es, como para cualquier producto farmacéutico, una característica esencial, 
pero en este campo se reviste de particular importancia pues está destinada, en general, 
a individuos saludables. La preocupación frente a potenciales efectos adversos unida a 
determinadas creencias y aspectos socio-culturales ha conllevado una cierta resistencia 
hacia la vacunación [4], permitiendo así el resurgimiento de enfermedades 
anteriormente consideradas controladas [5]. Además, la aparente ineficacia de algunas 
vacunas clásicas ha contribuido al escepticismo actual en relación con su capacidad para 
prevenir enfermedades [6, 7]. 
Por otra parte, además de la necesidad de desarrollar vacunas para enfermedades 
emergentes, tales como el ébola, siguen existiendo enfermedades infecciosas de las 
cuales se destacan el sida, la tuberculosis y la malaria [8, 9], para las que aún no se ha 
podido desarrollar una vacuna eficaz. Así por ejemplo, en el caso del sida, los últimos 
ensayos clínicos de vacunas candidatas para prevenir esta enfermedad han resultado 
decepcionantes [10, 11]. Dichos resultados subrayan la necesidad de recurrir a 
estrategias innovadoras para lograr el desarrollo de vacunas efectivas. Además de estas 
enfermedades de gran impacto en un contexto global, existen otras enfermedades que 
carecen de una vacuna efectiva, y que están asociadas a importantes tasas de morbilidad 
y mortalidad, como el virus sincitial respiratorio humano, que en EEUU provoca 90.000 
hospitalizaciones y 4.500 muertes al año; el citomegalovirus, particularmente peligroso 
para recién nacidos y inmunodeprimidos [3]; y la hepatitis C, causa de cirrosis y cáncer 
hepático [12].  
Por todo ello, la producción de nuevas vacunas, seguras y con inequívoca eficacia, es 
una necesidad fundamental y una condición determinante para mantener la cobertura 
sanitaria necesaria para la prevención de brotes infecciosos. Esta necesidad ha 
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estimulado el desarrollo de vacunas más seguras y especificas basadas en antígenos 
recombinantes, entre las cuales podríamos destacar las denominadas VLP (virus-like 
particles) como son, por ejemplo el HBV y el HPV [13, 14]. Sin embargo, la reducción 
de sustancias que en las vacunas clásicas actuaban como señal de peligro [15], asociado 
al incremento de pureza de estos antígenos, se ha traducido en la necesidad de utilizar 
agentes adyuvantes. La aparición más reciente de vacunas basadas en péptidos sintéticos 
[16] que mimetizan epítopos específicos de los microorganismos, ha afianzado más la 
diferencia entre el componente antigénico y el componente inmunoestimulante, ambos 
imprescindibles para lograr vacunas protectoras. Estas vacunas basadas en péptidos 
sintéticos ofrecen una precisión y seguridad inigualables pero también dependen de 
adyuvantes particularmente potentes para generar una respuesta inmune efectiva.  
 
DESARROLLO DE RESPUESTAS INMUNES FRENTE A ANTÍGENOS: EL 
CONCEPTO DE LA VACUNACIÓN  
En general, en el curso de una infección, se produce una atracción de leucocitos hacia la 
región infectada motivada por las denominadas moléculas PAMP (Pathogen-associated 
molecular pattern) y/o DAMP (Damage-associated molecular pattern). Las primeras 
son moléculas con patrones moleculares característicos de agentes infecciosos, mientras 
que las segundas son moléculas endógenas liberadas por stress o muerte celular. Estas 
moléculas son reconocidas por receptores PRR (Pattern Recognition Receptors) 
presentes en las células presentadoras de antígeno y provocan la activación de la célula 
y su posterior migración hacia el origen de esas moléculas [17]. Entre las células 
presentadoras de antígeno, cabe destacar las células dendríticas, que son parte esencial 
en la generación de la respuesta adaptiva (Figura 1). Estas células captan los antígenos, 
los degradan en péptidos y los presentan en su superficie por medio de receptores 
específicos del complejo mayor de histocompatibilidad (MHC) I o II. En general esta 
presentación depende del origen del antígeno. Los antígenos procedentes del medio 
extracelular -antígenos extracelulares-, son presentados normalmente por medio del 
MHC tipo II. Por el contrario, los antígenos presentes en células infectadas por 
patógenos, son denominados antígenos intracelulares y son presentados por MHC tipo I. 
Excepcionalmente puede ocurrir que un antígeno extracelular sea presentado por el 
MHC tipo I, lo que se designa como presentación cruzada del antígeno.  
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Figura 1. Esquema resumido del proceso de inmunización. Un patógeno libre, una 
célula infectada o una nanopartícula provocan la migración de los APC por medio de 
señales de peligro PAMP y/o DAMP. Las células presentadoras de antígeno (APC) y en 
particular las células dendríticas, son estimuladas a fagocitar el 
microorganismo/nanopartícula (1) debido a su composición, tamaño y/o patrón 
superficial.  Mientras migra hacia los nódulos linfáticos, el APC sufre un proceso de 
maturación y procesa el antígeno, presentándolo en un complejo MHC I o II segundo la 
naturaleza del antígeno (2). En general, los antígenos extracelulares son presentados 
por el MHC II que es reconocido por Linfocitos T CD4+ (3a) mientras los antígenos 
intracelulares son presentados por el MHC I que es reconocido por los Linfocitos T 
CD8+ (3b). Los linfocitos T CD4+ maduran en linfocitos T helper (Th) (4a) mientras 
los linfocitos T CD8+ maduran en células citotóxicas (4b). Los linfocitos T helper, por 
medio de citoquinas especificas, estimulan tanto a la maduración de los linfocitos B 
activados (5a) como de los linfocitos citotóxicos (CTL) (5b). Con el refuerzo positivo de 
los linfocitos Th, los linfocitos B maduran a plasmocitos, secretando anticuerpos 
específicos contra los antígenos inicialmente identificados por las células dendríticas 
(6) generando la respuesta inmune humoral. Los CTLs por su vez destruyen las células 
infectadas que presenten a su superficie el antígeno identificado, produciéndose la 
respuesta inmune celular. 
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Mientras procesan los antígenos, las células dendríticas inician su proceso de 
maduración y migran a los nódulos linfáticos en donde presentan, conjuntamente, los 
antígenos (señal 1) y señales coestimulantes (señal 2) a linfocitos T [18]. Más 
específicamente, la señal 1 consiste en la presentación del antígeno por el MHC de la 
célula dendrítica al receptor de las células T (TCR) mientras la señal 2 consiste en la 
interacción de los correceptores CD80 y CD86 de las  células dendríticas con el receptor 
CD28 de la célula T. La célula dendrítica solo expresa los correceptores CD80 y CD86, 
cuando capta el antígeno asociado a señales de peligro como PAMP y DAMP, que 
comprueban la peligrosidad asociada a ese antígeno. En el caso de que la célula 
dendrítica presente el antígeno a la célula T sin estos correceptores, ocurre la anergia y 
tolerancia de la célula T a ese antígeno [19].  
Los antígenos presentados por las células dendríticas a través del MHC I son 
reconocidos por linfocitos T CD8+ que se convierten en linfocitos T citotóxicos, dando 
origen a una respuesta inmune de tipo celular. Una vez activados, los linfocitos T 
citotóxicos se encargan de lisar las células infectadas por el patógeno, bloqueando así la 
multiplicación del microorganismo. Por otro lado, los antígenos presentados a través del 
MHC II son reconocidos por linfocitos T CD4+, los cuales, en virtud de ese 
reconocimiento, se diferencian en linfocitos T helper [20]. Estas células promueven, por 
medio de citoquinas especificas, tanto la acción citotóxica de los linfocitos T citotóxicos 
(respuesta celular) como la producción de anticuerpos (respuesta humoral) por parte de 
los linfocitos B [21]. A su vez, los linfocitos B reconocen los antígenos extracelulares a 
través de inmunoglobulinas (Ig) en su superficie, lo que provoca su activación. Junto 
con el refuerzo positivo de los linfocitos T helper, los linfocitos B se multiplican y 
diferencian en plasmocitos que secretan anticuerpos específicos para el antígeno 
reconocido. 
Durante este proceso se generan también las células T memoria y las células B 
memoria, las cuáles se mantienen en estado de alerta ante una posible reinfección. En el 
caso de que esto ocurra, estas células se multiplican rápidamente y se diferencian en 
células efectoras, que actúan contra el agente invasor impidiendo su propagación y 
promoviendo su rápida eliminación. Este es el fundamento inmunológico del proceso de 
vacunación [17]. Es interesante observar que las células presentadoras de antígenos solo 
activan las células T (a través de la presentación de la señal 2) si adquieren el antígeno 
en presencia de una señal de peligro que compruebe que dicho antígeno está relacionado 
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con algo pernicioso al organismo. La presentación del antígeno sin la señal 2 conlleva la 
inhibición de la célula T, generándose así un proceso de tolerancia del sistema inmune 
contra ese antígeno. Este mecanismo evita que se generen respuestas contra proteínas 
endógenas y, con ello, el desarrollo de enfermedades autoinmunes, pero también supone 
una barrera a la generación de una respuesta efectiva por medio de una vacuna y obliga 
a la asociación a los antígenos, de moléculas o sistemas capaces de activar las células 
dendríticas. 
En definitiva, del análisis de este proceso de desarrollo de la respuesta inmune se 
desprende la necesidad de señales coestimulantes asociadas al antígeno, lo que obliga a 
la utilización de adyuvantes en vacunas más puras (recombinantes y péptidos sintéticos) 
para generar una respuesta inmune efectiva [22]. 
La especificidad de cada MHC por determinadas secuencias de aminoácidos y la 
variabilidad de alelos de MHC dentro de la especie humana, conlleva el hecho de que 
no todos los epítopos puedan ser reconocidos por los MHC de un individuo. Como 
consecuencia, no todos los antígenos pueden ser presentados convenientemente a los 
linfocitos T y, en definitiva, no todos los antígenos son capaces de generar una 
respuesta adaptativa inmune efectiva contra un epítopo especifico [21].  
Por otra parte, aunque un epítopo sea bien reconocido por el sistema inmune puede 
ocurrir que se encuentre en una proteína no presente en todas las estirpes del patógeno. 
En este caso, y aunque se produzca una respuesta inmune efectiva frente a ese epítopo, 
el individuo no estará protegido contra todas las estirpes del patógeno. Ejemplo de esta 
situación es la vacuna frente al virus del papiloma humano (HPV), compuesta por la 
proteína L1 del virus. Esta proteína es muy inmunogénica pero está poco conservada 
dentro de la especie del papiloma humano, por lo que la vacuna comercial solo es eficaz 
frente a un espectro limitado de estirpes (aunque cobre las estirpes más peligrosas). A 
pesar del éxito de esta vacuna, la referida limitación ha motivado el desarrollo de 
nuevas vacunas dirigidas frente a nueve estirpes distintas del microorganismo [13]. Otra 
estrategia para lograr una vacuna universal frente al HPV podría estar asociada a la 
proteína HPV L2, que en el virus se encuentra enmascarada por la proteína L1 y la cual 
se encuentra mucho más conservada dentro la especie. Sin embargo, esta estrategia está 
limitada por el hecho de que este antígeno es mucho menos inmunogénico debido a su 
incapacidad en organizarse en estructuras VLP [13]. La misma situación se presenta en 
el caso de las vacunas diseñadas frente al virus influenza, de las que forman parte las 
 20 
 
proteínas hemaglutinina y neuraminidase. Estas proteínas son inmunogénicas pero su 
estructura varia dentro de la especie del virus, lo que obliga, todos los años, a una 
adaptación de la vacuna a la estirpe relevante [23].  
La especificidad de los MHC y variabilidad de los antígenos de los microorganismos 
son problemas particularmente relevantes en vacunas con limitado número de epítopos, 
como es el caso de las vacunas basadas en péptidos sintéticos,  donde cada péptido 
representa un epítopo especifico. Una estrategia actual para abordar esta limitación, 
consiste en el diseño de vacunas constituidas por un conjunto de péptidos sintéticos, 
cada uno de los cuáles representando un epítopo distinto del virus, incrementando así la 
posibilidad de reconocimiento por los MHC. Al mismo tiempo, los distintos epítopos 
también pueden cubrir distintas estirpes del microorganismo infeccioso y originar una 
respuesta múltiple hacia el microorganismo previniendo su adaptación [24]. 
Alternativamente, se pueden utilizar epítopos altamente conservados del 
microorganismo y asociar un péptido que sea reconocido por un largo espectro de 
MHC, como son los péptidos de la familia PADRE (Pan HLA DR) [25], incrementando 
así la probabilidad de reconocimiento en la población humana. 
En resumen, el desarrollo de vacunas eficientes está altamente condicionado por la 
disposición de adyuvantes capaces de movilizar y activar las células presentadoras de 
antígenos, estimulando así la proliferación y diferenciación de células T y con ello, la 
generación de respuestas inmunes. La utilización de antígenos basados en péptidos 
sintéticos que mimeticen epítopos presentes en las varias estirpes de los 
microorganismos pueden originar vacunas más seguras y que originen una protección 
más amplia que las actuales. Dichos antígenos serán posiblemente poco inmunogénicos 
pero su potencial clínico es extraordinario. Para contrarrestar esta limitación, los 
adyuvantes cobran un papel fundamental. 
 
AGENTES ADYUVANTES DE VACUNAS 
Un adyuvante es una substancia que, al ser administrada en combinación con un 
antígeno permite incrementar su respuesta inmune [26]. Con excepción de las vacunas 
atenuadas, el uso de un agente adyuvante es esencial para lograr una respuesta 
inmunitaria efectiva [27, 28].  Además, el adyuvante puede también modular la 
respuesta inmune de modo a lograr una respuesta humoral, celular o una respuesta 
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combinada, bien sea por su interacción con receptores distintivos específicos de ambos 
tipos de respuesta, o a través del proceso de presentación cruzada [29, 30].  
En la actualidad existen agentes adyuvantes de muy distinta composición y naturaleza. 
Con frecuencia, en el ámbito de la tecnología farmacéutica hacemos la distinción entre 
moléculas activas inmunoestimulantes, cuya acción resulta de la interacción con 
receptores específicos, y agentes adyuvantes, cuya acción puede estar condicionada no 
solo a la presencia de ciertas sustancias químicas sino también a la forma física en la 
que se presentan. Aquí incluimos entre otros las sales metálicas, determinados aceites y 
biomateriales. Dependiendo de la organización de estos ingredientes, pueden o no 
constituir lo que se llama sistemas de liberación de antígenos, ya que promueven de una 
forma programada, la cesión gradual en el tiempo [8]. A continuación se describen 
brevemente estas diferentes categorías de agentes adyuvantes. 
 
MOLÉCULAS INMUNOESTIMULANTES 
Se consideran moléculas inmunoestimulantes aquéllas que presentan ligandos 
reconocibles por los PRRs, siendo los agonistas de los receptores Toll-like (TLRs), los 
más investigados. Los TLR son proteínas transmembranales y en el ser humano 
constituyen una familia de 10 receptores distintos, que se localizan en la superficie de la 
célula (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11) o en la superficie de los 
endosomas en el citoplasma de la célula (TLR3, TLR7, TLR8 and TLR9). Cada uno de 
estos receptores reconoce ligandos específicos [31] (Tabla 1). 
La identificación de estos receptores permitió el desarrollo de moléculas sintéticas y 
derivados que actúan como inmunoestimulantes específicos para determinados TLR 
como el Poly (I:C) (TLR3), el MPL (TLR4), el Imiquimod y el Resiquimod (TLR7/8) y 
el CpG ODN (TLR 9). Mientras el MPL actúa en un receptor extracelular, los restantes 
actúan en receptores intracelulares [31], por lo que, supuestamente su acción se podría 
ver beneficiada de estrategias que faciliten su liberación dentro de las células inmunes 
(Figura 2).  
El Poly (I:C), por ejemplo, es un derivado sintético de ARN de cadena doble, 
compuesto por una cadena de ácido polinosinico asociada a una cadena de ácido 
policitidilico y es capaz de potenciar la respuesta humoral y celular [32, 33], inclusive 
por ruta intranasal [34]. Sin embargo, está también asociado a toxicidad sistémica [35, 
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36]. La asociación de este poderoso inmunoestimulante a un sistema de liberación de 
antígenos capaz de liberarlo en las células inmunes ofrece la posibilidad de reducir la 
dosis necesaria y su toxicidad, y de potenciar su efecto [37]. 
 
Tabla 1. Resumen de los receptores Toll-like (TLR) conocidos, sus ligandos naturales y 
los inmunoestimulantes sintéticos desarrollados para el respectivo receptor [31]. 
 
Pam3cys: tri-palmitoyl-S-glyceryl cysteine; LTA: Lipoteichoic acid; dsRNA: Double 
Stranded RNA; ssRNA: Single stranded RNA; Poly (I:C): Polyinosinic:polycytidylic 
acid; MPL: Monophosphoryl Lipid A; LPS: Lipopolysaccharide; CpG-ODN: CpG 
Oligodeoxynucleotide; N/A: Not available.  
 
El CpG ODN, por su parte, es un derivado sintético de ADN de cadena simples 
compuesto por la repetición del dinucleótido citosina y guanina no metilados, en un 
padrón característico del DNA bacteriano y viral. Diversos estudios han demostrado la 
necesidad de entregar simultáneamente el CpG ODN y el antígeno a las células inmunes 
para lograr una respuesta inmune optima contra ese antígeno [38] y la capacidad de este 
inmunoestimulante en modular la respuesta inmune hacia el antígeno [39]. Además, el 
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CpG ODN es fácilmente degradado por las nucleases presentes en el suero, presentando 
tiempos de media vida muy cortos. Por todo ello, la asociación del CpG ODN a un 
sistema capaz de protegerlo y liberarlo en las células dendríticas se presenta como un 
requisito fundamental a su utilización como inmunoadyuvante [40]. En el caso del 
Imiquimod y el Resiquimod, consisten en imidazoquinolinas con acción 
inmunoestimulante por interacción con el receptor TLR7 y TLR8 cuyo ligando natural 
es el ARN de cadena simples. Estas moléculas estimulan una intensa secreción de 
citoquinas pro-inflamatorias y, como tal, su administración sistémica puede originar 
fenómenos de toxicidad [41]. La encapsulación de estas moléculas en sistemas de 
liberación de vacunas puede disminuir la toxicidad asociada y mejorar su acción 
inmunoadyuvante [41-43]. Por último, el MPL es un derivado de los lipopolisacáridos 
bacterianos de las bacterias Gram-negativas, que presenta menor toxicidad que la 
molécula original, aunque conserva su efecto inmunoestimulante. Debido a su carácter 
liposoluble, esta molécula ha sido asociada a liposomas, habiendo logrado mejorar su 
perfil de seguridad. Al contrario de los demás agonistas de TLR referidos, en el caso del 
MPL, es importante que esté expuesto en la superficie de la nanoestructura una vez que 
el TLR4 es extracelular (Figura 2). Al actuar sobre este receptor provoca la producción 
de citoquinas y el incremento en la presentación de antígenos por los complejos MHC, 
resultando en un incremento de la respuesta inmune hacia los antígenos asociados [44].   
 
AGENTES ADYUVANTES Y SISTEMAS DE LIBERACIÓN DE ANTÍGENOS  
Existen numerosos compuestos y excipientes farmacéuticos cuya capacidad 
inmunoestimulante, además de ser inherente a su estructura y composición molecular, 
está reforzada por el hecho de presentarse bajo una forma física específica. En esta 
categoría podemos incluir los geles de aluminio, las emulsiones y también los sistemas 
de liberación de antígenos de forma micro- o nanoparticulada. Estos últimos sistemas, 
adquieren en la actualidad especial relevancia ya que, según se comentó en el apartado 
anterior, permiten incluir en su estructura junto con los antígenos, moléculas de 
inmunoestimulantes específicos, tales como los agonistas de TLR e inespecíficos tales 
como aceites, lípidos y biopolímeros.  
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Figura 2. Estrategia sinérgica de la asociación de inmunoestimulantes con 
nanopartículas. Los agonistas de TLR deben ser asociados a las nanopartículas de 
acuerdo con la localización de sus receptores. Así, para los agonistas de receptores 
intracelulares, la encapsulación permite protegerlos de factores de degradación 
externos como nucleases y concentrar su acción en las células inmunes mientras para 
los agonistas de receptores extracelulares es importante que quede expuesto en la 
superficie de la nanopartícula de forma que pueda interaccionar con su receptor sin 
limitaciones. La asociación de los inmunoestimulantes y antígenos a nanopartículas 
permite su más eficaz fagocitosis por parte de los APC (1). Una vez las partículas 
captadas, ocurre su degradación liberándose inmunoestimulantes y antígenos. La 
interacción de los inmunoestimulantes con sus respectivos receptores TLR provoca la 
maturación de los APC, estimulando entre otras cosas, el procesamiento y presentación 
de los antígenos en complejos MHC a los linfocitos T (2).  
 
ADYUVANTES UTILIZADOS EN CLÍNICA 
Las sales de aluminio, cuya capacidad adyuvante fue descubierta en 1926, representan 
el único adyuvante universalmente utilizado en humanos [31, 45]. Sin embargo, estas 
sales presentan limitaciones importantes, que han estimulado la búsqueda de nuevos 
adyuvantes. Concretamente, la congelación de las vacunas con sales de aluminio 
conlleva la inactivación de la vacuna [45]. Además, estas sales resultan ineficaces para 
antígenos poco inmunogénicos, así como para generar respuestas inmunes de tipo 
celular [46]. Finalmente, su acción está limitada a la ruta parenteral y puede generar 
reacciones adversas locales como eritemas y nódulos subcutáneos [45, 46]. 
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Para mejorar la eficacia de las sales de aluminio se ha optado por asociarlo a otras 
moléculas inmunoestimulantes tales como el MPL [47], constituyendo ambos el 
adyuvante AS04. Asimismo, se ha procedido al desarrollo de sistemas lipídicos 
nanométricos que se describen en el apartado siguiente. 
 
NANOTECNOLOGÍA Y VACUNAS 
Las limitaciones asociadas a las sales de aluminio han llevado al desarrollo de 
adyuvantes innovadores basados en el uso de la nanotecnología (Figura 3) [48]. Entre 
dichos adyuvantes se encuentran los virosomas, el AS03 y el MF59 [47, 49], cuyas 
características y utilidad se describen a continuación. 
Los virosomas son liposomas de 150 nm con componentes virales en la membrana 
lipídica [50], cuya estructura y composición facilita la presentación del antígeno a las 
células inmunes. Los virosomas fueron comercializados como vacunas para la hepatitis 
A y la influenza en 1996 y 1997, respectivamente [49, 51]. Su eficacia es 
incuestionable, habiendo sido contrastada incluso en poblaciones con un sistema 
inmune débil como ancianos [52] y niños y bebes [53]. 
El AS03 y el MF59 son nanoemulsiones (tamaño entre 150 y 160 nm) constituidas por 
un núcleo oleoso (escualeno más tocoferol y escualeno solo, respectivamente) 
estabilizado por surfactantes (Polisorbato 80 y Polisorbato 80 más Trioleato de 
sorbitano, respectivamente) [49]. El primero ha demostrado ser un adyuvante muy 
potente para la vacuna del influenza, al permitir la generación de niveles más elevados 
de anticuerpos que la vacuna inactivada con 20 veces menos antígeno [54]. Se cree que 
tiene una acción pro-inflamatoria, promoviendo la llegada y activación de las células 
inmunes [49]. El MF59 es utilizado como adyuvante en la vacuna de influenza, porque 
tiene la capacidad de generar una respuesta humoral más completa que el Alum 
haciendo uso de una dosis inferior de antígeno [27]. El mecanismo de acción del MF59 
aun no es claro pero se cree que actúa como sistema reservatorio de antígenos, a la vez 
que estimula la producción de citoquinas pro-inflamatorias por las células inmunes [46]. 
El éxito del MF59 y el AS03 llevó a su aplicación como adyuvantes en estudios clínicos 
para vacunas para el virus sincitial respiratorio humano (RSV) [55] y el citomegalovirus 
(CMV) [56] o para el Dengue [57], respectivamente. 
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Otros sistemas nanométricos que debido a su elevado potencial inmunoadyuvante están 
siendo evaluados en ensayos clínicos son el AS01, AS02, ISCOM e ISCOMATRIX. 
El AS01 y AS02 son sistemas adyuvantes de la misma familia de adyuvantes 
nanométricos que el AS03 (pertenecientes al GlaxoSmithKline) y que consisten en uno 
liposoma y una emulsión con núcleo oleoso de escualeno, respectivamente, que se 
caracterizan por tener en su composición el inmunoestimulante MPL. Estas estructuras 
ya demostraran su potencial como sistemas adyuvantes en estudios clínicos para el HIV, 
en el cual fueran capaces de estimular respuestas inmunes intensas del tipo linfocito 
CD4+ [58]. Su potencial inmunoadyuvante ha llevado más recientemente, a su 
utilización, en estudios clínicos, como adyuvantes para una vacuna contra el malaria 
[59, 60]. 
Los ISCOM (Immunostimulatory complexes) son sistemas nanométricos (40 nm) en el 
cual el antígeno se encuentra encapsulado en una matriz compuesta por colesterol, 
fosfolípidos y la saponina Quil A. La saponina Quil A es un triterpenoide obtenido de la 
cascara del árbol Quillaja saponaria y es un fuerte inmunoestimulante aunque su 
mecanismo de acción es aún desconocido [46]. Desafortunadamente, presenta además 
una fuerte acción hemolítica, por lo que es considerada demasiado toxica para uso 
humano. Una estrategia para reducir su toxicidad ha consistido en la formación de un 
complejo con el colesterol y determinados fosfolípidos. De este modo, la saponina 
queda menos disponible para interaccionar con las membranas plasmáticas y, como tal, 
se reduce drásticamente su efecto hemolítico aunque retiene su efecto 
inmunoestimulante. Esta mejora en las propiedades del Quil A ilustra la aplicabilidad de 
la nanotecnología con vista a la obtención de sistemas adyuvantes seguros y eficaces 
[46]. Por último y para solventar la limitación de los ISCOM a antígenos hidrofóbicos, 
se han desarrollado los ISCOMATRIX, en los cuales el antígeno en vez de encapsulado 
en la matriz, se encuentra asociado al superficie del sistema. Debido a la capacidad de 
generar fuerte respuestas humorales y celulares con diversos antígenos y en distintos 
modelos animales [61], el ISCOM actualmente está siendo testado en ensayos clínicos 
para el Herpes (HSV) [62], Malaria [63] y Influenza [64] mientras el ISCOMATRIX es 
evaluado como adyuvante para una vacuna terapéutica para el cáncer [65]. 
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MICRO Y NANOPARTÍCULAS POLIMÉRICAS COMO SISTEMAS DE 
LIBERACIÓN DE ANTÍGENOS Y ADYUVANTES 
El desarrollo de nuevos adyuvantes ha estado también asociado a los avances en el 
diseño de micro y nanopartículas poliméricas [49]. Estas partículas ofrecen, además de 
su capacidad adyuvante, la ventaja, con relación a las sales de aluminio, de poder ser 
liofilizadas y almacenadas bajo la forma de polvo seco [66]. A continuación, se 
describen brevemente los avances más significativos en este ámbito de conocimiento, 
entre los que se centran el desarrollo de vacunas mono-dosis y también de vacunas no 
inyectables destinadas a ser administradas por vía nasal. 
Partiendo del trabajo seminal publicado en 1976 por Spiel y Kruger [67], en el que 
proponían el uso de nanopartículas de polimetilmetacrilato (PMMA) como vehículos 
adyuvantes de vacunas, han sido numerosos los sistemas poliméricos testados en el 
desarrollo de sistemas adyuvantes de vacunas. Dentro de los polímeros sintéticos 
destacan en particular los polímeros derivados del ácido láctico y del ácido glicólico 
(PLGA) debido a su biodegradabilidad y capacidad para controlar la liberación de 
antígenos [68] y incrementar la respuesta inmune hacia el antígeno asociado [69, 70], 
con reacciones locales mínimas por ruta subcutánea al reverso de los sales de aluminio 
[71]. Nuestro grupo ha realizado un trabajo pionero en el desarrollo de micro y 
nanopartículas de PLGA como sistemas de liberación controlada de proteínas y 
antígenos [72-74], así como en la identificación de la PEGylación de las nanopartículas 
de PGA, como propiedad esencial para facilitar el paso de antígenos a través de barreras 
mucosas [75, 76]. Trabajos posteriores nos permitieron demostrar la influencia 
simultanea del tamaño y de la densidad de PEG en la superficie de las nanopartículas en 
su capacidad para atravesar la mucosa nasal [77, 78], y generar una respuesta inmune 
hacia el antígeno encapsulado, el toxoide tetánico [79, 80]. Sin embargo, a pesar del 
gran potencial de los sistemas de liberación de antígenos basados en PLGA, nuestra 
experiencia en el uso de estos biomateriales nos llevó a concluir que parte del antígeno 
encapsulado era degradado por la acumulación de productos resultantes de la 
degradación del proprio polímero en la matriz polimérica [81]. Este problema pudo ser 
parcialmente soslayado a través de diferentes estrategias que incluyen desde la 
constitución de un núcleo oleoso [82] o de gelatina [83] hasta la introducción de 
aditivos como el poloxamer [84, 85]. Además del toxoide tetánico, este sistema fue 
utilizado para la asociación de antígenos más complejos, como el antígeno 
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recombinante de la hepatitis B (rHBsAg), que presenta una estructura semejante a virus 
(virus-like particle) [86]. En conjunto, más allá del uso que nuestro grupo ha hecho de 
los polímeros PLGA y sus copolímeros con el PEG, existe una abundante bibliografía 
que, sin duda, ha influido en el desarrollo clínico de vacunas basadas en los mismos y 
particularmente vacunas frente al cáncer [87] y también una vacuna para la prevención 
del tabaquismo [88].  
Como alternativa a los polímeros sintéticos tipo PLGA, también han recibido una 
extraordinaria atención los polisacáridos y, de forma particular el quitosano. El 
quitosano es un polímero compuesto por una cadena linear de D-glucosamina y N-
acetil-D-glucosamina obtenido de la deacetilación de la quitina presente en el 
exosqueleto de los crustáceos y en la pared de los hongos. El quitosano es un polímero 
soluble y catiónico, capaz de constituir sistemas nanométricos en virtud de su 
complejación con polímeros negativos o gelificación con agentes entrecruzantes como 
el tripolifosfato. Estas características, junto con su adecuada biocompatibilidad y 
mucoadhesividad, hacen del quitosano una de las moléculas mas estudiadas en el 
desarrollo de sistemas adyuvantes para vacunas [89]. En esta área, nuestro grupo 
también ha contribuido de forma decisiva al desarrollar por la primera vez las 
nanopartículas de quitosano como sistemas de liberación de proteínas y antígenos [90, 
91]. El uso de las mismas permitió la administración efectiva del toxoide tetánico (TT) 
por vía nasal [92, 93], así como también  ejercer un efecto adyuvante tras la 
administración de antígenos más complexos, tales como el antígeno VLP de la hepatitis 
B (rHBsAg) [66]. Esta capacidad adyuvante ha sido posteriormente confirmada por 
otros autores, no solo para antígenos virales como el antígeno rHBsAg [94] y la 
hemaglutinina del influenza [95], sino también para antígenos bacterianos, como el 
extracto proteico del Streptococcus equi [96].  
El carácter catiónico y flexibilidad de la cadena del quitosano, ha permitido, más 
recientemente, su utilización como recubrimiento de nanoemulsiones para la 
constitución de nanocápsulas como sistemas adyuvantes de vacunas [97]. La asociación 
de la mucoadhesividad del quitosano con la capacidad adyuvante intrínseca de las 
nanoemulsiones, identificada en adyuvantes como el MF59, permitió el desarrollo de 
sistemas nanocapsulares capaces de asociar eficazmente el antígeno rHBsAg y generar 
una respuesta humoral efectiva tras su administración por vía intranasal [42]. Asimismo, 
estas nanocápsulas han permitido la inmunización frente a HB tras la inyección de una 
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sola dosis del antígeno [98], mostrando así su potencial en el desarrollo de vacunas 
mono-dosis. Estudios posteriores de biodistribución han revelado la capacidad de las 
nanocápsulas de CS de formar un reservatorio en el local de administración y presentar 
un drenaje sostenido hasta los nódulos linfáticos, en donde se concentran una gran 
población de células inmunes. Es posible que esta estimulación sostenida del sistema 
inmune sea la causa de la capacidad adyuvante observada con estas nanocápsulas [99]. 
Las excepcionales características del CS como materia prima para el desarrollo de 
sistemas de liberación de vacunas ha estimulado igualmente la combinación con otros 
polímeros así como el desarrollo de derivados sintéticos para la constitución de sistemas 
adyuvantes nanoparticulados. Asimismo, estudios con nanopartículas de quitosano 
cargadas con el rHBsAg pero recubiertas con el polisacárido alginato, demostraran la 
capacidad de estos sistemas en generar respuestas inmunes por la ruta subcutánea [100], 
nasal [101] y oral [102], lo que comprueba la versatilidad de estos sistemas. Dentro de 
los derivados sintéticos cabe destacar el N,N,N-trimetilquitosano (TMC), que producto 
de la metilación de los grupos amino del quitosano, presenta una solubilidad acrecida 
pero que mantiene la capacidad de constituir sistemas nanométricos por gelificación 
iónica [103]. Dicho sistema ha demostrado su capacidad adyuvante con el antígeno 
H3N2 del influenza A, a través de la vía nasal [104] y estudios posteriores con el 
antígeno modelo ovalbumina y el toxoide diftérico confirmaron la capacidad 
inmunoadyuvante de este sistema tanto por la vía nasal como por la vía intramuscular 
[105] y  intradermal [106]. 
En general, los sistemas poliméricos permiten una liberación prolongada en el tiempo 
del antígeno asociado, extendiendo así el proceso de estimulación del sistema inmune y, 
consecuentemente, la generación de células inmunes de memoria [107]. Por otra parte, 
la elevada superficie específica de las nanostructuras permite la adsorción y exposición 
de los antígenos asociados, algo que ha sido relacionado con una mayor respuesta 
inmune [108]. Además, el propio carácter particulado que estos sistemas confieren a los 
antígenos solubles, facilita su reconocimiento por las células inmunes y, por tanto, una 
más eficiente captación de los antígenos [109]. Dicho efecto puede resultar de la 
similitud de las nanopartículas con los virus, que las células dendríticas reconocen como 
partículas para  fagocitar y contra las cuales activarse (Figura 1) [109, 110]. Asimismo, 
se ha observado que los sistemas especialmente pequeños (<100 nm) pueden llegar a 
alcanzar directamente los nódulos linfáticos, modificando así el perfil de respuesta 
 30 
 
inmune [111]. Además del tamaño, otros factores como la carga superficial, la 
hidrofobicidad del sistema nanométrico o su geometría contribuyen también a la 
respuesta inmune [109, 112]. Los avances logrados en cuanto al comportamiento 
biológico de estos sistemas aparece reflejado en diversas revisiones relacionadas con 
este tema [8, 49, 113]. 
 
 
Figura 3. Progresión histórica de las vacunas y de los sistemas adyuvantes 
La administración de la vacuna atenuada de la viruela por Jenner en 1768, marca el 
inicio de la investigación en el campo de las vacunas y desde entonces diversas vacunas 
atenuadas han sido desarrolladas y aplicadas  en la clínica. El peligro de reversión del 
patógeno de estas vacunas llevó a la busca de vacunas más seguras basadas en 
microorganismos inactivados o en sus toxoides y posteriormente, en antígenos 
recombinantes y péptidos sintéticos debido a su inigualable precisión y seguridad. El 
surgimiento de vacunas no basadas en organismos atenuados obligó al desarrollo de 
sistemas adyuvantes capaces de incrementar la respuesta inmune de la vacuna. Así, 
poco después de desarrolladas las primeras vacunas inactivadas, se introduce el 
primero sistema adyuvante, los sales de aluminio. La progresiva pureza de las vacunas 
y las limitaciones de los sales de aluminio llevó al desarrollo de sistemas adyuvantes 
lipídicos como los liposomas, las nanoemulsiones y los sistemas poliméricos y a la 
identificación de moléculas con acción inmunoestimulante especifica como el Poly 
(I:C) [114]. Una tendencia actual y que se prevé incrementar en el futuro es la 
combinación de los sistemas nanométricos con los inmunoestimulantes con vista a un 
efecto sinérgico capaz de garantizar una efectiva inmunización con antígenos 
peptídicos sin efectos adversos asociados.   
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Como se comentó anteriormente, en la actualidad se está investigando el beneficio de la 
combinación de sistemas nanoparticulados con inmunoestimulantes [9, 46] con el 
objetivo de lograr la liberación simultánea de antígenos e inmunoestimulantes a las 
células dendríticas (Figura 2). El sinergismo potencial entre estos dos elementos podría 
resultar particularmente interesante para conseguir la potenciación de la respuesta 
inmune frente a antígenos poco inmunogénicos como os antígenos peptídicos (Figura 
3). Finalmente, esta asociación puede permitir también la modulación de la respuesta 
inmune hacia respuestas inmunes más equilibradas [42] y una protección más completa. 
 
CONCLUSIONES 
El innegable impacto de las vacunas en la salud y el mejor conocimiento del sistema 
inmune han estimulado el trabajo orientado a la optimización de vacunas ya 
establecidas. Paralelamente, la mayor inocuidad de los nuevos antígenos y las 
limitaciones de los adyuvantes clásicos han propiciado la búsqueda de sistemas 
adyuvantes capaces de promover la generación de respuestas inmunes más robustas y 
duraderas. En este sentido, los sistemas de liberación de antígenos podrían suponer un 
gran progreso al permitir no únicamente fortalecer y prolongar la respuesta inmune 
frente al antígeno asociado, sino también su administración por rutas no parenterales, 
tales como la vía nasal. Los avances en esta línea han llevado al concepto de vacuna 
mono-dosis y vacuna no inyectable. Además, la posibilidad de liofilizar estas partículas 
podría conferir a estas nanovacunas una mayor estabilidad que las vacunas 
convencionales. Estos avances, en gran medida asociados a los hallazgos de nuestro 
grupo de investigación, ponen de manifiesto el gran potencial de los sistemas de 
liberación de antígenos en el desarrollo de nuevas vacunas. El éxito de sistemas 
nanométricos comercializados, tales como el MF59 o el AS03, así como los desarrollos 
clínicos de nanosistemas poliméricos permiten suponer que, en un futuro cercano, la 
nanotecnología puede contribuir de forma decisiva a desarrollo de nuevas vacunas 
contra patógenos para los cuales no existe aún una vacuna efectiva y la mejoría de 
vacunas ya existentes, permitiendo así una mejor cobertura sanitaria frente a las 
enfermedades infecciosas. 
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ABSTRACT 
 
Vaccination is undoubtedly the most effective health intervention for disease prevention 
and eradication. Nevertheless, currently there is still a need for improving immunization 
coverage worldwide. A promising strategy to achieve this goal nowadays relies on the 
use of delivery carriers capable of inducing an effective immune response and providing 
improved stability, safety and cost effectiveness. This article focuses on analyzing the 
critical aspects in the design of these carriers, and reviewing the state of the art of 
currently marketed formulations and those in advanced clinical development. These 
vaccine delivery carriers include emulsions, liposomes and polymeric particulate 
carriers. Finally, particular attention is given to the evolution in the design of polymeric 
nanocarriers, which have been receiving increasing attention and hold promise to 
generate novel platforms for needle-free administration and single-dose vaccination.  
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1. INTRODUCTION 
 
The impact of vaccines in global health is beyond question. Since Jenner in 1796 to the 
present, vaccines have permitted the control of many infectious diseases [1] and even 
the eradication of smallpox [2]. Not limited to prophylactic treatment, vaccines have 
recently started to be applied with success also as therapeutic agents in allergy, 
autoimmune treatment, cancer therapy and infectious diseases [3-6]. 
While important achievements in vaccination have relied on the use of attenuated 
vaccines or whole killed pathogens, nowadays research is mostly focused on subunit 
vaccines. This is because subunit vaccines are purer, safer and easier to produce than 
classical vaccines [7]. Unfortunately, the high purity of the subunit vaccines often 
renders them poorly immunogenic [8, 9] and, thus, dependent on the use of effective 
adjuvants that can assist them in generating an effective immune response.   
An adjuvant is by definition any molecule, macromolecular structure or system capable 
of amplifying an immune response against a specific antigen [10]. Fundamental for this 
response are the antigen presenting cells (APC), especially the dendritic cells (DC). 
These cells capture the antigen, process it and modulate the cellular and humoral 
immune response [11]. While antibody titers have been the classical parameter used to 
evaluate the relevance of a specific adjuvant, in recent years there is an increasing 
interest in achieving strong cellular responses to overcome challenging intracellular 
pathogens, such as malaria or HIV or to develop effective therapeutic vaccines against 
tumor cells [12-14].  
According to the above definition, immune adjuvants are a large and heterogeneous 
group, which could be divided into two subgroups: immunostimulants and delivery 
systems [10, 13]. The first category of adjuvants stimulates the immune system by 
interacting with specific receptors, while the second type can increase the immune 
response by multiple mechanisms, depending on their particular characteristics [15]. In 
this review we pay particular attention to antigen delivery systems especially those 
having a size in the micro/nanometer range.  
Besides the potential of antigen delivery carriers as adjuvants, there is increasing body 
of evidence supporting their potential as single-dose and needle-free vaccine delivery 
strategies. Indeed, major entities in global health such as the World Health Organization 
(WHO) and the Center for Disease Control and Prevention (CDC) have claimed the 
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necessity to invest research efforts in developing advanced delivery technologies, which 
could simplify immunization schedules [16-18]. The accomplishment of these 
objectives would generate an improvement in the vaccination coverage for several 
infectious diseases, especially in developing countries. 
Taking this into account, this review article is intended to highlight and analyze the 
most relevant advances achieved so far in the development of antigen delivery carriers. 
Furthermore, this article aims to provide the reader with the understanding of the basis 
for future improvements in the design of antigen delivery systems. 
 
2. CRITICAL ASPECTS IN THE DESIGN OF ANTIGEN DELIVERY 
CARRIERS 
As indicated above, antigen delivery carriers not only have the possibility to facilitate 
the antigen uptake by the immunocompetent cells and provide controlled antigen 
delivery, but also the capacity to overcome mucosal barriers. This section describes the 
main factors and mechanisms governing such special features.  
 
2.1. Parameters affecting the ability of delivery carriers to transport antigens 
across mucosal barriers 
Vaccine delivery systems have been shown to improve antigen passage through relevant 
biological barriers, such as the intestinal and nasal mucosa and hold some promise 
towards the generation of needle-free vaccines. Regarding the oral route, the size of the 
delivery carrier is a fundamental parameter for adequate immune stimulation. It has 
been known for more than two decades that small microspheres are preferable to the 
large ones for oral immunization [19, 20]. However, the issue of optimal size is still a 
controversial matter. For example, using BSA as a model antigen, Gutierro et al. [21], 
observed a better immunostimulating ability for microspheres of 1 μm than for those of 
0.2 – 0.5 μm.  he same group found that the oral administration of SPf66 antigen (a 
synthetic malaria peptide) encapsulated into 1- μm PLGA microparticles generated a 
strong immune response, similar to the one achieved following subcutaneous 
administration of the antigen adjuvanted with alum. The authors attributed these 
positive results to the ability of microparticles to be taken up by the Peyer's patches 
[21]. Interestingly, over the last decade the trend observed is that the smaller particle 
size, the greater their ability to transport antigens across the intestinal barrier [22-24]. 
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Consequently, it could be argued that the ideal size for an oral vaccine carrier would be 
within the nanometer range, although affected by other characteristics such as surface 
composition and release properties. In this sense, our group found that providing PLA 
nanoparticles with a protecting PEG coating helps in maintaining their stability in 
gastrointestinal fluids and facilitates the transport of the associated antigen (tetanus 
toxoid) across the intestinal mucosa [25]. 
The nasal route is another promising alternative for needle-free administration due to its 
particular physiological characteristics and immunological features. Indeed, despite the 
limitations associated to the mucociliarly clearance, the nasal mucosa displays several 
characteristics that make it attractive for antigen delivery. Namely, it has a limited 
enzymatic activity and a relatively leaky epithelium accompanied by specialized cells 
(M cells) that harvest the antigens present in the mucosa and deliver them to associated 
lymphoid tissues [26]. 
The first work showing the potential of nanoparticles for nasal antigen delivery was 
reported by Almeida et al. [27]. In this work, tetanus toxoid (TT) was adsorbed onto 
PLA nanoparticles of 800 nm size and administered to guinea-pigs by the nasal route. 
The immune response achieved with the adsorbed antigen was about 10 times stronger 
than the free antigen administered by the same route, evidencing the potential of 
nanoparticles for an effective nasal vaccination. A few years later, using PLA-PEG 
nanoparticles, our group demonstrated the importance of size and surface hydrophilicity 
on the ability of particles to efficiently deliver antigen through the nasal route. As 
indicated for the oral route, the idea of using PEGylated PLA came from the 
observation that PLA nanoparticles aggregated upon contact with mucosal fluids and, 
therefore, PEGylation was conceived as a way to preserve the stability of nanoparticles 
[28]. The results of the absorption and biodistribution of TT associated to these 
nanoparticles clearly evidenced the positive effect of the PEGylation (Figure 1). In fact, 
it was observed that the antigen could penetrate through the nasal mucosa much more 
efficiently when encapsulated into PLA-PEG particles. These results were corroborated 
by a work of Vila et al. [29] in which it was found that both particle size and 
PEGylation degree influenced the uptake by the nasal mucosa and the subsequent 
biodistribution of the associated antigen. The same authors found that this improved 
transport of the tetanus toxoid antigen was the explanation for the important and long-
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lasting response [30]. These results emphasize the importance of an adequate design of 
the delivery system to achieve an effective vaccine formulation.  
 
 
Figure 1. Tissue distribution of 125I-labelled tetanus toxoid at 24 h (A) and 48 h (B) 
after nasal administration of 125I-TT-loaded PLA and PLA-PEG nanospheres. Adapted 
from [28] with permission. 
 
Besides the mucosal routes, the transdermal route is also progressively becoming a 
feasible option for vaccination. This method takes advantage of the high concentration 
of immune cells in the epidermal and dermal tissues [31] and the ability of nanoparticles 
to cross the epidermal barrier by the hair follicles pathway. This ability has been found 
to be related to particle size. For example Vogt et al. [32] compared the skin penetration 
of fluorescent nanoparticles of 40, 750 and 1500 nm size and observed that only the 40 
nm particles could penetrate deeply through the follicular epithelium and interact with 
the epidermal Langerhans cells. Later  Mahe et al., reported also the greater penetration 
of 40-nm particles as compared to that of  200-nm particles [33]. Other groups tried to 
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increase the flexibility of liposome carriers in order to improve their ability to penetrate 
the skin and generate an immune response [34, 35]. This area has been gaining much 
interest in more recent years and it is possible to find complete and up to date 
information regarding this field in the reviews of Combadiére and Mahé et al. [36] and 
Li et al. [37]. 
 
2. 2. Parameters affecting the biodistribution of antigen delivery systems and their 
ability to target antigen presenting cells (APC) 
The adequate control of size of a delivery system can also influence its biodistribution 
and consequently, also that of the antigen. When administered by intramuscular or 
subcutaneous route, particles with a size of 20–100 nm can penetrate the extracellular 
matrix and enter directly into the lymphatic vessels. Once in the lymph, the particles 
travel to the lymphatic nodes where they are captured by the dense population of 
immune cells, mostly by dendritic cells (DC), and generate effective immune responses 
[38, 39]. These mechanisms have been summarized in Figure 2. 
 
 
Figure 2. Schematic representation of size dependent particle processing following 
s.c./i.m. administration. 
 
The size of the polymeric particles seems to influence the distribution of the particles 
after subcutaneous, intradermal or intramuscular administration. Several authors seem 
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to agree that polymeric particles larger than 100 nm, will mainly linger at the 
administration point as they cannot pass through the extracellular matrix´s pores and 
reach the lymph directly [38, 40-43]. These particles can still raise an effective immune 
response as they are subsequently scavenged by peripheral DC. After capturing the 
particles, these DC migrate to the lymphatic nodes and initiate a systemic immune 
response [44]. As for particles smaller than 20 nm, they will drain mainly to the blood 
capillaries and suffer elimination from the organism, although a fraction can eventually 
also reach the lymph nodes [38, 45]. 
In addition to the critical role of the particle size, some authors observed in vitro that the 
uptake of model polystyrene nanoparticles by macrophages and DC can be strongly 
enhanced if the particles have a cationic surface [46, 47]. Interestingly, Foged et al., 
when comparing the dendritic cell uptake of polystyrene spheres of 100 nm and 1000 
nm with different surface charge, observed that the cationic surface increased the uptake 
of larger particles but smaller particles seem to undergo equal uptake independently to 
their surface charge [47]. 
Altogether, irrespective of the influence of the size and surface charge, there is no doubt 
that the association of antigens to micro- or nanosized particulate carriers facilitates 
their uptake by DC [48]. A possible explanation for such behavior could be found on 
the resemblance between the particles and the bacteria and virus that the APC are 
programmed to capture [44, 49]. Moreover, it has been suggested that the particulate 
character given to the antigen not only facilitates its uptake by immune cells but also 
induces their activation and can further assist to the so called cross presentation 
phenomenon [50]. As a result, particulated antigens do not only stimulate humoral but 
also cellular responses [51]. 
 
2. 3. Improving the stability and providing controlled antigen release  
An advantage of vaccine delivery carriers over immunostimulant molecules is their 
ability to protect the associated antigen from adverse physiologic conditions such as 
enzyme degradation or non specific interaction with other molecules in the extracellular 
matrix and provide a prolonged release profile, more similar to a real infection. The 
antigen (generally a protein or peptide), is susceptible to chemical and enzymatic 
degradation as well as physical alteration like aggregation or precipitation [52]. Besides, 
it can establish nonspecific interactions with extracellular components, leading to the 
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inefficient stimulation of the immune system. All these problems can be highly 
attenuated when the antigen is incorporated into an adequate vaccine delivery system 
[53, 54]. 
Vaccine delivery carriers can be designed to offer sustained release of the antigen and 
thus, to extend the time available for immune stimulation. Some authors have found that 
this continuous stimulation provided by controlled release systems may even surpass the 
effect of strong immunostimulants such as lipopolysaccharide (LPS). This has been, for 
example, the case of polyanhydride nanoparticles containing OVA when administered 
by the oral route [24].  
In addition to the value of controlled release systems in terms of enhancing the immune 
response, their ability to extend antigen release for prolonged periods of time has been 
regarded as a promising strategy for single-shot immunization protocols [18]. As 
discussed later in section 4, the idea of using controlled release technologies to simplify 
vaccination schedules was first proposed by Preis and Langer [55]. After a few decades 
of work in this field it has become clear that antigen release mainly depends on the way 
it is incorporated within the delivery carrier, i.e. encapsulated/entrapped into or simply 
adsorbed/associated onto the polymer. In the first case, the release rate depends on the 
degradation, erosion or dissolution of the polymer surrounding the antigen. In the 
second case, antigen release is governed by the interaction forces between the polymer 
and the antigen. Frequently, there is a combination of associated and encapsulated 
antigen in the particles, generating a characteristic release profile with an initial burst 
release due to the release of the more loosely associated antigen and a subsequent more 
sustained release of the encapsulated protein [56-58]. However, as important as the 
release profile is the fact that the loaded antigen should be delivered in its antigenically 
active form, capable of generating an adequate immune response. Regarding this point, 
the formulation conditions are of critical importance since the use of organic solvents, 
extreme temperatures or high energy inputs can degrade or aggregate the proteic 
material. In addition, the materials themselves used in the elaboration of the delivery 
systems or their degradation products can be an important source of protein 
deterioration [59-62]. 
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Finally, an important additional advantage of controlled release carriers relies on the 
possibility of co-delivering an immunostimulant agent, thus providing means to further 
enhance the stimulation of the immune system [63]. 
 
3. CURRENT ANTIGEN DELIVERY SYSTEMS ON THE MARKET OR 
UNDER CLINICAL DEVELOPMENT 
 
Currently, the most widely used immune adjuvants are the alum salts. The traditional 
explanation for their adjuvant action is the formation of a depot structure at the injection 
site, from which the antigen is slowly released [64]. However, more recently, the 
adjuvant ability of the alum salts has also been attributed to their ability to trigger the 
so-called “inflammasome” mechanism in the cells. According to this mechanism, the 
alum salts would be recognized as a danger signal or would promote the release of 
danger signals from the cells, thereby generating a pro-inflammatory environment, 
which leads to the activation of the immune system [65]. 
These adjuvants have been successfully used since 1926 [66, 67] and have an 
impressive record of safe administrations and robust immunizations rates [64]. 
Nevertheless, they have some limitations, such us their inability to stimulate cellular 
immune responses [14, 63], their potential adverse local reactions [67] and their 
degradation upon freeze-drying [68]. In addition, this type of adjuvant requires a 
multiple administration schedule to guarantee long lasting protection. Altogether, the 
limitations of alum salts have stimulated the search for new adjuvants and particularly, 
for novel vaccine delivery systems with the potential to solve the limitations of present 
vaccines. Those currently on the market (Table 1) or under clinical investigation (Table 
2) will be described in this section.  
 
3.1. Emulsions  
 he investigation of emulsions as vaccine adjuvants started in the late 30’s with Freunds 
Complete Adjuvant (FCA), (a water-in-oil (w/o) emulsion of a mineral oil, paraffin and 
killed mycobacteria) [69]. Although capable of generating high immunization titers, this 
emulsion led to strong adverse reactions, which hampered its clinical use. A less toxic 
version, the Freunds Incomplete Adjuvant (FIA) which lacks the mycobacterial 
component, was used instead until the mid-1960s, when it was finally abandoned in 
favor of the safer alum-based adjuvants [70]. Since those early days, there has been an 
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intensive research leading to other w/o formulations such as the Montanide Series, 
Adjuvant 65™ and Lipovant™. These formulations share the same mechanism of 
action, which is the formation of a depot at the injection site capable of attracting 
immune cells. The most intensively studied among them is the Montanide series, 
particularly the Montanide™ ISA51.  his w/o emulsion has squalene as the oil fraction 
and mannide-mono-oleate as the surfactant and has been used as an adjuvant in an 
epidermal growth factor (EGF) protein vaccine for lung cancer treatment [71]. 
Unfortunately, the adverse reactions associated to this adjuvant and its questionable 
success make the future for this adjuvant uncertain [72, 73]. Oil-in-water (o/w) 
emulsions have been presented as interesting alternative vaccine adjuvants [74, 75]. 
MF59™ was the first o/w emulsion approved in 1997 for human use in Europe as an 
adjuvant in an  influenza vaccine (Table 1) [76]. This emulsion is composed of 
squalene oil, dispersed in the form of 160 nm droplets, conveniently stabilized with a 
mixture of a high HLB (polysorbate 80) and a low HLB surfactant (sorbitan trioleate) 
[77, 78]. This adjuvant renders the vaccine more efficacious than other commercially 
available influenza vaccines [79] specially in elderly people [80]. Equally important, is 
the good safety profile shown in several clinical trials, where no major adverse effects 
were detected [77]. Regarding its mechanism of action, besides a depot effect, MF59™ 
is able to activate the immune cells directly [81]. Currently, this adjuvant is being tested 
in clinical trials as a vaccine against Hepatitis Virus C (HCV) and Cytomegalovirus 
(CMV) (Table 2). Another o/w emulsion (AS02™) is composed of squalene and two 
hydrophobic immune adjuvants, MPL1™, a synthetic derivative of LPS, and QS-21, a 
purified saponin plant extract. While the first adjuvant is able to promote immune cell 
recruitment and activation [82], the second one stimulates strong antibody responses 
against the associated antigens [83]. AS02™ is capable of inducing both strong humoral 
and cellular responses, making it a promising adjuvant. It has shown remarkable results 
when tested in infants as an adjuvant for the RTS malaria antigen [84] constituting, 
currently, the leading vaccine candidate against this disease. The same adjuvant has also 
been evaluated with tuberculosis [85] and HIV antigens [86], showing promising 
immunization results.  
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Table 1. Delivery systems present in marketed human vaccines 
Delivery System Antigen Vaccine Disease Reference 
AS03 
 
HA 
Arepanrix 
TM
 
(GSK) *
1
 Influenza 
[87] 
HA 
Pandemrix
T
 
(GSK) Influenza [88] 
Virosomes 
Inactivated 
virus 
Epaxal 
TM
 
(Crucell) Hepatitis A [89] 
HA and NE 
Inflexal 
TM
 V 
(Crucell) Influenza 
[90] 
MF59 
 
HA 
Fluad
TM
 
(Novartis) 
Seasonal 
influenza [77] 
HA from 
influenza 
A/H1N1 
Focetria
TM 
(Novartis) Influenza [91] 
AF03 
HA from 
H1N1 
Humenza
TM
 
(Sanofi) *
2
 Influenza [92] 
HA: Hemagglutinin; NE: Neuraminidase; 
*1
 Withdrawal of marketing authorization in 
the European Union at 18/01/2011; 
*2
 Withdrawal of marketing authorization in the 
European Union at 30/06/2011. 
 
A similar emulsion formulation named as AS03™ is composed of squalene and 
tocopherol dispersed in the form of nanodroplets (150 nm) thanks to the use of Tween® 
80 as the surfactant [78]. This formulation has already been commercialized as an 
adjuvant for a pandemic influenza vaccine (Pandemrix), showing an improved 
response compared to that of the alum adjuvanted vaccine [93]. Another clinical trial is 
currently in progress to assess the relevance of this adjuvant system in a different 
influenza vaccine (Table 2). The work of Morel et al. suggests that this adjuvant does 
not act through a depot effect but solely as a danger signal that attracts and activates 
immune cells [94].  
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Table 2.  Antigen delivery systems in clinical development 
Delivery System Antigen Disease Route Phase End 
Clinical Trial 
Identifier 
MF59 
glycoprotein B CMV IM II Ongoing NCT00133497 
  IM II 2010 NCT00125502 
glycoprotein gp E1/E2 HCV n.d. I 2005 NCT00500747 
AS02A FMP2.1 Malaria IM II 2009 NCT00460525 
ISCOM HA Influenza IM I Ongoing NCT00868218 
ISCOMATRIX™ L1 protein VLP  HPV IM I 2009 NCT00851643 
PLGA HER-2 derived peptide 
HER-2 positive 
cancers 
IM; SC I 2009 NCT00005023 
Virosome 
AMA-1 & CSP peptides Malaria n.d. I 2009 NCT00513669 
n.d. HIV IM; IN I 2010 NCT01084343 
n.d. 
Hepatitis A 
IM IV 2011 NCT01349829 
n.d. IM II Ongoing NCT01405677 
HA Influenza IM III 2010 NCT01229371 
n.d. Candidiasis IM; IV I Ongoing NCT01067131 
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Delivery System Antigen Disease Route Phase End 
Clinical Trial 
Identifier 
AS01 & AS02 
RTS,S 
Malaria 
IM II 2006 NCT00197054 
FMP 2.1 IM I & II 2007 NCT00385047 
AS01 
RTS,S 
Malaria 
n.d. II & III Ongoing NCT00872963 
VMP001 IM I & II 2011 NCT01157897 
FMP011 IM I & II 2007 NCT00312663 
RTS,S n.d. I & II 2006 NCT00075049 
FMP010 IM I 2009 NCT00666380 
RTS,S IM II 2007 NCT00307021 
AS03 n.d. Influenza H5N1 IM I & II Ongoing NCT01353534 
 CMV: cytomegalovirus; HPV: Human Papilloma Virus; VLP: virus-like particle; AMA-1: apical membrane antigen 1; CSP: circumsporozoite 
protein; n.d.: not disclosed; FMP011: falciparum malaria protein 11; FMP010: Plasmodium falciparum malaria protein 010. Data retrieved 
from [95].
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In parallel with the development of emulsions, there has been intensive research on 
several alternative technologies such as liposomes, immunostimulating complexes and 
polymeric delivery systems, which will be described in the following sections.  
 
3.2. Liposomes 
Liposomes are composed of phospholipid bilayers in the form of small vesicles which 
can efficiently incorporate antigens [96]. Liposomes are among the most promising 
delivery vehicles and have received an impressive amount of attention from the 
literature analysis point of view (Figure 3). They have been described as antigen 
carriers which are able to deliver their content to the APCs [97] facilitate the cross 
presentation of antigens and promote cellular immune responses [98]. These carriers 
also allow the co-encapsulation of immunostimulants [99, 100]. There are recent review 
articles describing the specific advances on liposomes as antigen carriers [97, 101, 102]. 
In the present review we focus on those liposomal compositions that have reached 
clinical development.  
An example of a composition in clinical development is AS01 which contains two 
lipophilic immunostimulants, MPL1 and QS-21 [103]. In a clinical trial for a HIV 
vaccine, this adjuvant system was found to stimulate a higher immune response than the 
one observed for the o/w emulsion AS02 [86]. In addition, clinical trials are in 
progress to evaluate the potential of this adjuvant for a malaria vaccine (Table 2). 
The most advanced liposomal structures for vaccine application are currently the 
immunopotentiating reconstituted influenza virosome (IRIV) vaccines, generally 
denoted as virosomes. These liposomes have integrated into their surface two 
glycoproteins from influenza, hemagglutinin (HA) and neuraminidase (NA). The 
antigen associate by covalent or electrostatic interactions with the lipid bilayer [104]. It 
has been reported that these glycoproteins increase capture by APCs and improve the 
processing of the antigens. This improvement seems to be related with the ability of the 
HA protein to fuse with the endosomal membrane after the endocytosis of the virosome. 
By fusing with the endosomal membrane, the HA facilitates the escape of the virosome, 
avoiding the destruction of the antigen in the lysosome vesicles, and making it available 
for class I antigen presentation. The first virosome-based vaccine for human use was 
licensed in 1996 as a hepatitis A vaccine (Epaxal®) and later on it was also licensed in 
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an influenza vaccine (Inflexal V ®) [90]. Currently, several clinical trials are in progress 
to evaluate different vaccines containing this adjuvant (Table 2).  
Finally, an alternative liposome technology is the Supramolecular Biovector (SMBVe). 
This liposome has a cross-linked polysaccharide core inside and a global size of about 
60 nm [105]. By controlling the nature of the core or the lipid composition, this system 
can be easily adapted to the association of specific antigens. This composition generated 
high IgG antibodies levels, cytotoxic T lymphocyte (CTL) responses as well as mucosal 
IgA antibodies in mice when used as a vaccine carrier for nasal immunization against 
hepatitis B [106]. More recently, this adjuvant entered in clinical evaluation phase using 
an influenza antigen [107]. 
 
Overall, despite the long time required for antigen-associated liposomes to reach the 
clinical development stage, it is now clear that they offer great versatility and promising 
features. At this point, it seems realistic to say that the success of the vaccines recently 
commercialized or under clinical trials will dictate the way to proceed in this specific 
adjuvant approach.  
 
3.3. Immunostimulating complexes 
The immunostimulating complexes (ISCOMs) are colloidal antigen delivery systems 
with a 40 nm size and a cage-like structure [108]. They are composed of saponins, 
cholesterol, phospholipids (traditionally phosphatidylcholine) and an entrapped antigen 
[109]. Antigens are entrapped by hydrophobic interactions in the interior of the 
complex. For hydrophilic antigens the ISCOM components are assembled in the 
absence of the antigen generating the ISCOMA RIX™. As the ISCOMA RIX surface 
is negative, due to the glucuronic moieties of the saponin, the hydrophilic antigen is 
then associated to the surface by electrostatic interactions [108]. 
The adjuvant ability of these delivery systems rises from a combination of factors. 
Beside the intrinsic immunostimulant ability of saponins, the structure of the complex 
itself also work as an activation signal for the immune cells [44] and as a promoter for 
antigen cross presentation [110, 111]. Interestingly, free saponins are known to be toxic 
compounds [112], however, when they are complexed with cholesterol, their toxicity is 
significantly reduced and their immune stimulant ability enhanced [113]. 
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The efficacy of ISCOMs has been reported in terms of generating strong antigen-
specific cellular and humoral immune responses in animal models following either 
parenteral [114] or nasal administration [115]. Furthermore, these complexes are 
currently being evaluated as adjuvants in clinical trials for influenza and Human 
Papilloma Virus (HPV) vaccines (Table 2). 
Overall there is clear evidence of the potential of these nanocarriers as adjuvants. The 
further development of these composite carriers will greatly depend on their toxicity and 
efficacy profile all along their clinical path towards commercialization. Some authors 
have suggested that the presence of saponin might pose safety concerns and thereby 
impede their clinical development [116].  
 
In summary, as a consequence of the significant amount of research devoted to 
adjuvants and delivery carriers over the last decade we have attractive strategies that 
warrant clinical evaluation. Clinical trials of these nanocompositions will significantly 
influence the future scientific developments in this area. 
 
 
Figure 3. Evolution of the number of publications related to different vaccine delivery 
systems from 1975 to 2010. Data retrieved from [117] 
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4. ADVANCES IN THE SEARCH FOR NEW ANTIGEN DELIVERY SYSTEMS. 
A PERSPECTIVE OF POLYMER-BASED NANOCARRIERS 
 
In addition to the advances made over the last decades in the clinical development of 
emulsions, liposomes and immunostimulating complexes, there are new delivery 
platforms based on the use of polymers which also hold promise for the future 
development of new adjuvants and innovative vaccine formulations. As illustrated by 
Figure 3 [117], over the last couple of decades there has been a continuous increase in 
the number of publications regarding antigen delivery carriers. The dramatic increase in 
the use of nanoparticles as antigen delivery carriers is particularly noteworthy. In fact, 
yearly rate of publications has been multiplied by 10 (from 20 to 200) over the last 
ten years. Given this tendency, we decided to concentrate on the advances made in the 
development and application of polymer-based micro and nanoparticles. 
 
The first evidence of the potential of polymeric nanoparticles as vaccine delivery 
vehicles was reported in 1976 by Birrenbach and Speiser [118] where they 
demonstrated the ability of polyacrylamide nanostructures to increase immune 
responses against the associated antigen following subcutaneous administration. Some 
years later, Preis and Langer proposed the use of ethylene-vinyl acetate beads as a 
single-dose vaccine delivery strategy [55]. The idea was based on the ability of these 
polymer matrices to control the release of the associated antigen, thus leading to a 
prolonged presentation of an antigen to the immune system. Even though none of these 
delivery vehicles have found their way towards the clinical development stage due to 
their toxicity, they provided a strong proof-of-principle which has motivated the 
development of new polymer-based antigen delivery carriers. A summary of the 
advances made on the use of these carriers is briefly described in the following sections.  
 
4.1. Polyester-based microparticles 
The family of polylactic acid and polylactic-co-glycolic acid (PLA/PLGA) is very well-
known for their safety profile and ability to control the release of drugs for extended 
periods of time [119]. The interest in their use for controlled antigen delivery started in 
the late 70’s following their commercialization for the delivery of peptide drugs [120]. 
Indeed, it was in that period, when the World Health Organization (WHO) proposed the 
initiative of developing a single-dose vaccine for tetanus toxoid in order to prevent 
 64 
 
neonatal tetanus [121]. Overall, the results from several groups working on this 
initiative showed the potential of these particles in controlling the release of the 
encapsulated antigen, thus supporting their potential for generating long-lasting 
responses [57, 122-125]. Unfortunately, despite the initially promising data, we 
subsequently observed that a large fraction of the antigen was damaged during the 
process of encapsulation and release from the PLGA and PLA microparticles [60]. The 
cause for the antigen degradation has been mainly attributed to the drastic decrease of 
pH inside the particles, due to the accumulation of degradation products of the polymer 
matrix [61]. To solve this problem, we have developed a number of strategies, which 
involve the protection of the antigen by preventing its interaction with the polymer’s 
degradation products. One of these strategies involved the use of a protective oil-core 
surrounded by a PLGA wall. Such microcapsules were able to provide extended antigen 
delivery for more than two months [126]. An alternative approach to the antigen 
degradation problem was proposed by Tobío et al. [127]. Through the addition of 
poloxamer 188 to the formulation, the authors found a way of avoiding unwanted 
interactions between PLGA and the antigen. I.m. administration of this formulation to 
mice revealed the efficacy of this approach. Both IgG levels and neutralization titers to 
tetanus toxoid were higher and much more prolonged than those achieved with the 
alum-adsorbed antigen formulation. These promising results have motivated the 
development of new formulations of PLGA/PLA microparticles containing antigens 
from other diseases such as Rabies [128], Brucellosis [129] Tuberculosis [130] or 
Malaria [131]. More recent work, using the hepatitis B antigen, has also shown the 
ability of PLGA microparticles to generate strong cellular immune responses [132]. 
This response is critical in the case of chronically infected people where the cellular 
immune response could overcome immune tolerance and lead to the clearance of the 
persisting virus.  
Recently, PLGA microparticles have been tested as adjuvant in a clinical trial for a 
cancer vaccine using a HER-2 derived peptide as antigen (Table 2).  
There are also some recent strategies aimed at improving the efficacy of PLGA 
microparticles as antigen delivery vehicles by coating them with cationic polymers 
[133, 134]. For example, the polypeptide protamine has been used as a surface coating 
material due to its ability of increasing cell penetration. When encapsulating the purified 
phospholipase A2(PLA2) and ovalbumin (OVA) as model antigens, the authors found 
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that the protamine coating led to an impressive improvement of the humoral responses 
in mice against both antigens [134].  
Another recent trend in this field is the association of immunostimulant molecules with 
PLGA microparticles in order to obtain a synergistic effect between them. For example, 
Sharp et al. observed a strong increase in the production of Interleukin-1β, through the 
incorporation of LPS, CpG or PAM3Csk (a synthetic analogue of a bacterial 
lipoprotein) into PLGA microparticles [135]. Such synergistic effect of 
immunostimulant molecules and PLGA microparticles has been further confirmed for 
CpG [136]. In another work, Kazzaz et al. [137] encapsulated either  MPL or its 
synthetic analogue (RC529) into PLGA microspheres. Antigens from either Neisseria 
meningitides B or from HIV-1 were associated to the surface of the microspheres. The 
results showed that immune responses were much superior when the immunostimulants 
were incorporated into the microparticles instead of being administered separately. 
Therefore, the conjunct formulation seemed to enhance the adjuvant properties of both 
the particles and the immunostimulants.   
 
4.2. Polyester-based nanoparticles 
 he size reduction of PLGA microparticles to the nanometer’s range has been mainly 
motivated by the necessity to develop needle-free delivery vehicles and new adjuvants 
for mucosal immunization. As indicated in section 2.1, there are some pioneering works 
that have shown the importance of submicron range size and the presence of a PEG 
coating on the ability of PLGA particles to facilitate the transport of antigens across 
mucosal barriers [27, 28, 138]. The same nanocarriers were also shown to generate long 
lasting immune responses against tetanus following intranasal administration [30]. The 
evidence of the positive effect of a PEG corona represented a major breakthrough 
because it was generally assumed that hydrophobic particles were preferable over 
hydrophilic particles as carriers for mucosal antigen delivery [139]. This classical 
assumption was based upon the idea that hydrophobic particles are preferentially taken 
up by the APC of the mucosal surfaces [140]. This theory failed to take into 
consideration the stability problem of hydrophobic particles as well as the fact that 
small nanoparticles can be internalized in the nasal mucosa not only through direct 
uptake by the associated lymphoid cells but also by transport into the epithelial cells. 
Beyond establishing the potential of PLA-PEG as nasal vaccine delivery carriers, the 
 66 
 
above results highlight the importance of a rational design of nanocarriers for an 
optimal delivery of proteins through mucosal tissues.  
Another approach chosen by our group for improving the controlled release of 
macromolecules from PLGA nanoparticles and their delivery across the nasal mucosa, 
has been the formation of intimate blends of PLGA and surfactants from the poloxamer 
and poloxamine series [141, 142]. Working with a model genetic vaccine, we observed 
the possibility of modulating its release and facilitate its transport across the nasal 
mucosa [143]. More recently, we have applied the same kind of nanostructures for the 
controlled delivery of recombinant hepatitis B surface antigen (rHBsAg), which 
assembles into 22 nm particles [144]. A selected prototype was additionally coated with 
chitosan (CS) in order to further improve the presentation of the nanocarrier to the 
immunocompetent cells. As shown in Figure 4, these nanostructures were able to 
control the release of rHBsAg without altering its integrity and antigenicity.  
PLA/PLGA nanoparticles have also been modified with specific ligands, such as RGD 
peptide [145] or lectins [146], in order to increase their uptake by the M cells associated 
to the intestinal mucosa. For example, in the work of Garinot and coworkers, OVA 
antigen was encapsulated in PLGA nanoparticles surface-modified with RGD. Although 
an increased uptake of the modified particles in vitro and an effective targeting in vivo 
of the M cells were observed, the improvement of immune response was found to be 
minimal. A possible explanation for these results is the degradation of the ligand by the 
harsh conditions of the GI tract [145]. On the other hand, Gupta and coworkers 
modified PLGA nanoparticles with the UEA-1 lectin for the oral delivery of the 
recombinant hepatitis B surface antigen (rHBsAg). In this case, the surface modification 
resulted in a significantly enhanced immune response. Nevertheless, carbohydrates 
present in ingested food can complex with lectins and prevent its targeting activity 
which can be a source of interference in a clinical application of such systems [146]. 
In addition to a mucosal route, polyester nanoparticles are also interesting systems for 
parenteral vaccination. In a work by Ataman-Önal et al. [147], the HIV-1 p24 protein 
was associated to the surface of PLA nanoparticles and administered subcutaneously to 
mice, rabbits and macaques. In all animal models, both a strong humoral and a cellular 
immune response were detected against the presented antigen.  
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Figure 4. Schematic representation of PLGA-based nanoparticles for the delivery of 
rHBsAg (A), their corresponding release profiles (B) and the analysis of the structural 
integrity of the antigen (C). Lane 1: bulk rHBsAg; lanes 2 and 3: rHBsAg recovered 
from PLGA:POE NPs after 4 and 7 days; lanes 4 and 5: rHBsAg recovered from CS-
coated PLGA:POE NPs after 4 and 7 days. rHBsAg: recombinant hepatitis B surface 
antigen; PLGA:POE NP: poly(d,l-lactide-co-glycolide):poloxamer nanoparticle; CS: 
chitosan. Reproduced from [148] with permission. 
 
More recently, Moon et al. [149] used PLGA nanoparticles as substrates to create 
pathogen-mimicking polymeric nanoparticles for a malaria vaccine. The PLGA 
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nanostructure was coated with a lipid membrane integrating MPL and then a malaria 
recombinant antigen (VMP001) was linked covalently to this membrane. Using this 
carrier by subcutaneous route in mice, Moon et al. could achieve increased VMP001-
specific IgG titers for over 6 months together with enhanced cellular immune responses. 
 
4.3. Polyanhydride-based Nanocarriers 
Synthetic polyanhydrides, such as poly(methyl vinyl ether-co-maleic anhydride) 
(PVM/MA), have been regarded as interesting materials for antigen delivery due to their 
bioadhesive properties [150] and their ability to specifically interact with immune cells 
[151], combined with their low oral toxicity [150]. Using ovalbumin (OVA) as a model 
antigen, Gómez et al., evaluated the behavior of PVM/MA nanoparticles as carriers for 
intradermal vaccination. The results indicated that the OVA-loaded nanoparticles 
generated stronger humoral responses (IgG titers) than alum [152]. As noted in the 
section 2.3., the same particles were also capable of producing high and sustained 
immune response following oral administration with the model antigen (OVA) [24], 
showing the versatility of this delivery carrier.  
 
4.4. Polysaccharide-based Nanocarriers 
Several polysaccharides, such as inulin [153] alginate [154] and hyaluronic acid [155], 
have attracted interest as biomaterials for vaccine delivery. However, chitosan (CS) is 
by far the most intensively investigated polysaccharide for antigen delivery. This 
biodegradable polymer has interesting mucoadhesive and immune modulating 
properties [156-158] that make it a promising biomaterial for mucosal antigen delivery. 
In fact, the early recognition of its potential motivated the pioneering work by our group 
on the development of CS nanoparticles and their use for nasal immunization [138, 
159]. These nanoparticles, formed under very mild conditions by the ionotropic gelation 
of CS with counter-anions (e.g. tripolyphosphate), have a size in the range of 150-450 
nm and are specifically adapted to carry significant amounts of antigens. As a proof-of-
concept, we have shown that tetanus toxoid-loaded nanoparticles administered 
intranasally were able to generate higher antibody levels than the soluble antigen, 
increasing to 10 times higher values after 24 weeks (Figure 5). This long-lasting and 
increasing response revealed the potential of the formulation for needle-free 
administration. In a further work, it was shown that these particles are internalized by 
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the nasal mucosa [160], thus suggesting an alternative pathway, via the nasal-associated 
lymphoid tissue, for the antigen to reach submucosal immunocompetent cells. 
 
 
Figure 5. IgG antibody levels following intranasal administration of TT entrapped in 
CS nanoparticles (70 kDa) (mean ± SEM, n = 6–9). Reproduced from [161] with 
permission. 
 
The promising initial results observed for CS-based nanocarriers has stimulated 
research intended to further enhance their potential. For example, our group observed 
that the immunogenicity of CS nanoparticles after the intranasal delivery of diphtheria 
toxoid could be enhanced using PEGylated chitosan [162]. Other authors have 
investigated the potential of N-trimethyl chitosan (TMC) in the form of nanoparticles as 
a delivery vehicle for a influenza subunit antigen following intramuscular 
administration [163] and also for the model OVA antigen [164]. TMC nanoparticles 
displayed an interesting adjuvant effect after i.m. injection, but did not show increased 
immunogenicity after oral administration, as compared to the unmodified CS 
nanoparticles. 
The reliability of chitosan nanoparticles as vaccine delivery vehicles has been further 
confirmed by our group using the viral protein rHBsAg. Specifically, we observed that 
rHBsAg-loaded chitosan nanoparticles, with a size of about 180 nm, were able to 
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control the release of the associated antigen while preserving its integrity [165]. 
Moreover, following intramuscular administration to mice, these nanoparticles 
generated immune responses that were higher than those observed for the alum-
adjuvanted vaccine. The same nanoparticles have also shown their capacity for 
generating protective antibody levels following nasal administration. Finally, an 
additional advantage of this formulation, as compared to the commercial alum-based 
rHBsAg vaccine, has been found in their possibility to be converted into an easily 
resuspendable freeze dried powder.  
The promising results achieved with these chitosan-based nanoparticles together with 
the solid antibody titers achieved previously with o/w emulsions, recently motivated the 
development of a new type of system called chitosan nanocapsules. The rationale for the 
application of this system in immunization is to take advantage of a potential synergistic 
effect of an oily core and the chitosan coating. Moreover, the core-shell structure of 
these nanocapsules permits the co-association of a hydrophobic immunopotentiator 
(within the core) and a hydrosoluble protein antigen (in the polymer coating). These 
versatile nanocapsules have been loaded with rHBsAg and administered either 
intranasally or intramuscularly. The results have provided evidence of their potential 
either as a needle-free (nasal) vaccine delivery strategy or as a single-dose parenteral 
formulation [166, 167]. 
In summary, a number of recent reports illustrate the potential of chitosan nanocarriers 
as antigen delivery systems. They pave the way for subsequent optimization 
approaches, which will be mainly determined by the nature of the specific antigen to be 
delivered. 
 
5. CONCLUDING REMARKS 
The limitations of present vaccines have prompted the investigation of novel vaccine 
delivery technologies with improved efficacy, safety and stability. Among the great 
number of different strategies under exploration, particulate delivery carriers have 
emerged as strong and promising candidates. Besides improving antigen stability and its 
presentation to immunocompetent cells, depending on their specific characteristics 
(composition, size and surface properties), these vehicles can also offer the ability to 
overcome biological barriers and provide controlled release of the antigen, properties 
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that are fundamental for the development of needle-free and/or single dose vaccine 
formulations. 
Despite the intense efforts to develop more efficient vaccines based on the application 
of micro- and nanometric vaccine delivery systems, there is still a relatively low number 
of such products in clinical use. The most advanced antigen nanocarriers are those 
composed on lipid materials containing immunostimulatory molecules. Nevertheless, 
judged by the large number of recent publications related to this field and the 
encouraging clinical results reported so far, it is reasonable to presume that, novel 
vaccine delivery systems will be increasingly applied in the near future, hopefully 
leading to major improvements in worldwide immunization coverage. 
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ANTECEDENTES 
 
1. La nanotecnología se presenta como una estrategia prometedora en el desarrollo de 
nuevas vacunas, denominadas nanovacunas, destinadas a prevenir enfermedades para 
las cuales aun no existe una vacuna efectiva o para mejorar aquéllas que ya se 
encuentran en el mercado. Estas nanovacunas pueden ofrecer interesantes ventajas, tales 
como: i) proteger el antígeno de factores de degradación externos; ii) incrementar la 
interacción del antígeno con las células del sistema inmune; iii) permitir la interacción 
simultánea del antígeno e inmunoestimulantes con las células inmunes a fin de 
potenciar la respuesta inmune; iv) mejorar el transporte del antígeno a través de barreras 
mucosas, permitiendo así la administración sin agujas [1].  
 
2. Existen determinados biopolímeros tales como los poli(aminoácidos) (protamina y 
poliarginina) y los polisacáridos (quitosano y sulfato de dextrano) que ofrecen un 
especial atractivo en el diseño de sistemas de liberación de vacunas debido a una serie 
de propiedades, y en particular, por su capacidad para i) organizarse formando 
diferentes nanoestructuras; ii) promover la translocación de estas estructuras a través de 
membranas [2, 3] y iii) estimular el sistema inmune [2, 4, 5]. 
 
 
 
 
 
________________________ 
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3. Existen determinados aceites y materiales lipídicos de interés en la formulación de 
vacunas debido a su demostrada capacidad adyuvante, como es el escualeno, aceite 
utilizado en nanoemulsiones adyuvantes presentes en el mercado [6], el ácido linoléico 
[7, 8] y la lisofosfatidilcolina. 
  
4. La amplia variedad de nanotecnologías disponibles hacen factible la co-asociación de 
diversos biomateriales de naturaleza polimérica y oleosa, junto con uno o varios 
antígenos y moléculas immunomoduladoras. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________ 
10 
Fox, C.B. et al. Squalene Emulsions for Parenteral Vaccine and Drug Delivery. Molecules, 2009. 14 
(9): p. 3286-3312. 
11 
Mena, J. et al. Linoleic acid increases adhesion, chemotaxis, granule release, intracellular calcium 
mobilisation, MAPK phosphorylation and gene expression in bovine neutrophils. Veterinary Immunology 
and Immunopathology, 2013. 151(3–4): p. 275-284. 
12 
Perrin-Cocon, L. et al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune 
responses. Vaccine, 2006. 24(9): p. 1254-63 
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HIPÓTESIS 
 
1. El recubrimiento de los antígenos proteicos particulados mediante polímeros con 
propiedades bioadhesivas y/o inmunoadyuvantes, tales como la protamina, poliarginina, 
sulfato de dextrano, alginato y el poly (I:C), pueden mejorar el transporte del antígeno a 
través de barreras mucosas, favorecer la interacción con las células inmunes y potenciar 
la respuesta de estas células contra el antígeno asociado. 
 
2. La asociación de antígenos peptídicos, poco inmunogénicos, junto con moléculas 
inmunoestimulantes tales como el poly (I:C), a nanopartículas basadas en el 
biopolímero quitosano pueden permitir la eficiente co-liberación de ambos en las 
células inmunes, siendo así capaz de inducir respuestas inmunes sinérgicas y efectivas. 
 
3. La asociación de un conjunto biomateriales adyuvantes, tales como la 
lisofosfatidilcolina, el ácido linoléico, el escualeno y el quitosano, en la forma de 
estructuras nanométricas tipo nanoemulsión y nanocápsulas, permite optimizar y 
combinar las propiedades inmunoadyuvantes de estas moléculas a la vez que aportar 
una adecuada protección y presentación del antígeno asociado a las mismas.  
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OBJECTIVOS 
 
Teniendo en cuenta los antecedentes expuestos y las hipótesis planteadas, el objetivo 
global de la presente tesis doctoral ha sido el diseño y desarrollo de diversos sistemas 
nanométricos destinados a actuar como adyuvantes de vacunas. Estos nanosistemas 
están constituidos a partir de biomateriales con propiedades adyuvantes intrínsecas, a fin 
de potenciar y modular una respuesta inmune especifica frente a antígenos particulados 
y peptídicos tras su administración por vía parenteral y/o nasal. Para lograr este objetivo 
global se han planteado los siguientes objetivos experimentales: 
 
Diseño y desarrollo de nanovacunas basadas en el recubrimiento de proteínas 
virales particuladas: 
Partiendo del antígeno de la hepatitis, el objetivo ha sido el de recubrirlo con diferentes 
biopolímeros con propiedades bioadhesivas e inmunoadyuvantes tales como la 
protamina, poliarginina, sulfato de dextrano, alginato y el poly (I:C), formando una o 
múltiples capas a fin de dotarlo de diferentes propiedades. Los sistemas resultantes han 
sido caracterizados en cuanto a sus propiedades fisicoquímicas, estabilidad y actividad 
biológica por medio de ensayos in vitro e in vivo. Estos resultados aparecen recogidos 
en el capítulo 3 de la presente memoria. 
 
Diseño y desarrollo de sistemas nanométricos como vehículos transportadores de 
antígenos peptídicos 
En este apartado se han seguido dos estrategias: 
1. Diseño y desarrollo de nanoestructuras a base de quitosano capaces de co-asociar uno 
o varios antígenos peptídicos de baja capacidad inmunogénica junto con otros agentes 
inmunoestimulantes tales como el poly (I:C). Los sistemas resultantes han sido 
caracterizados en cuanto a sus propiedades fisicoquímicas, estabilidad y actividad 
biológica por medio de ensayos in vitro e in vivo. Estos resultados aparecen recogidos 
en el capítulo 4 de la presente memoria.  
2. Diseño y desarrollo de nanoemulsiones y nanocápsulas basadas en lípidos con 
propiedades inmunoadyuvantes (lisofosfatidilcolina, ácido linoléico y escualeno) y 
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quitosano capaces de incrementar la interacción de antígenos peptídicos con las células 
inmunes y provocar la activación de las mismas. Los sistemas resultantes han sido 
caracterizados en cuanto a sus propiedades fisicoquímicas, estabilidad y actividad 
biológica mediante ensayos in vitro e in vivo. Estos resultados aparecen recogidos en el 
capítulo 5 de la presente memoria.  
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CAPÍTULO 3 
MULTI-ENVELOPING OF PARTICULATED ANTIGENS WITH 
BIOPOLYMERS AND IMMUNOSTIMULANT POLYNUCLEOTIDES 
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ABSTRACT 
 
The main objective of this work was to study the possibility of enveloping particulated 
antigens using biomaterials and polynucleotides with immunostimulant properties, and 
to assess the value of this potential adjuvant strategy. The nanoparticulated structure (22 
nm) of the recombinant Hepatitis B surface antigen (rHBsAg) virus-like particle (VLP) 
has inspired us to use it as a substrate in the design of multi-enveloped nanoparticles. 
Our approach has relied on the adsorption of polymers and immunostimulants by 
electrostatic interactions. For the first layer, and taking into account the negative charge 
of the rHBsAg, we studied its interaction with the positively charged polymers 
protamine (PR) and polyarginine (PARG). These polymer-coated antigen 
nanostructures were further enveloped using negatively charged polymers such as 
dextran sulfate (DS) and alginate (ALG), as well as the immunostimulant 
polynucleotide poly (I:C) (pIC). The combination of these materials, allowed us to 
design four different prototypes of multi-enveloped nanoparticles (HB:PR; HB:PR:DS; 
HB:PARG:ALG; HB:PARG:pIC) with very small sizes (< 50 nm). The inversion of the 
surface charge observed upon the sequential adsorption of the macromolecular layers, 
confirmed the multilayer structure of the nanoparticle. We evaluated selected multi-
enveloped antigen nanostructures, i.e. HB:PR:DS and HB:PARG:ALG, with respect to 
their ability to be internalized by macrophages and also for their capacity to generate 
humoral immune responses (IgG titers), following either intranasal or intramuscular 
administration to mice. The results showed that although these novel formulations 
generated modest IgG titers, the IgG1/IgG2a ratio was more balanced that the one 
observed for the alum-adsorbed antigen. Overall, here we show how to envelop 
particulate antigens with immunoadjuvant layers and the impact of this enveloping 
process for the antigen presentation to the immune system. Beyond the variables 
investigated in this work, the results highlight the possibility to protect and modify 
antigens presentation using a simple layer-by-layer approach.  
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1. INTRODUCTION 
Vaccination is the most cost-effective preventive intervention against disease to date 
[1], and while the majority of the present vaccines are based on attenuated and 
inactivated whole-cell vaccines, the current tendency is to design vaccines based on 
subunit antigens. These subunit vaccines are based on specific components of pathogen, 
and so are less prone to provoke adverse reactions [2]. Among the subunit antigens, 
virus-like particles (VLP), formed by self-assembled viral proteins, are particularly 
interesting due to their superior immunogenicity [3, 4]. Notable examples of VLP based 
vaccines are the present hepatitis B (HB) and the human papillomavirus (HPV) 
vaccines, which are based on the recombinant hepatitis B surface antigen (rHBsAg) [5] 
and on the HPV L1 protein, respectively [6]. In addition, other VLP based vaccines, 
such as RTS,S for malaria and ACAM-FLU-A for Influenza A, are currently in the 
clinical development stage [7]. Despite their immunogenicity, these particulated 
antigens still need to be associated to a suitable vaccine adjuvant in order to generate an 
effective immune response. Most commonly, subunit antigens are adsorbed onto alum 
salts as adjuvant, due to their long record of safe use and effectiveness [8]. However, 
these adjuvants present several limitations. The use of alum requires the tight control of 
the storage conditions, as freezing provokes aggregation and loss of effectiveness [9]. 
This is a particularly important problem because the maintenance of the global cold 
chain has significant limitations [10] and can lead to a decreased immunization 
coverage worldwide [11]. Additionally, the use of alum is limited to parenteral 
administration, which requires specific training to perform and can cause blood-borne 
pathogen contamination by the re-use of syringes [12]. Finally, alum salts generate a 
Th2 biased immune response and they lack the capacity to stimulate cell-mediated 
immunity [13]. 
The use of nanotechnology-based approaches is known to offer opportunities for 
improving the formulation of vaccines. Specific advantages of the nanoformulations 
described in the literature include: i) their improved thermostability, as compared to the 
alum-adjuvanted vaccines [14, 15]; ii) their capacity to facilitate the transport of 
antigens across mucosal barriers and generate humoral and mucosal responses [15, 16]; 
iii) their ability to enhance and prolong the immune responses (single-dose vaccination) 
[17]; iv) their potential to modulate Th1/Th2 immune responses [16, 17]. 
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It has been hypothesized that nanocarriers may facilitate antigen presentation to T cells 
due to their resemblance with virus in terms of size and surface characteristics [18, 19]. 
These antigen-loaded nanocarriers are captured in the region of administration by local 
antigen presenting cells (APC), particularly dendritic cells (DCs) [20]. Then, DCs 
process the antigen while migrating to the lymph nodes through the lymphatic vessels 
[18]. In the lymph nodes, once the antigen is processed, the DC present individual 
peptides associated to the major histocompatibility complex (MHC) class II molecules 
to specific T lymphocytes, triggering the adaptive immune response, with the generation 
of memory T and B cells [21]. In addition to this peripheral uptake of antigen-loaded 
nanocarriers by DCs, it has been recently proposed that small nanoparticles (< 100 nm) 
could target antigens directly to the DCs in the lymph nodes [18, 22, 23]. As the 
immune cell population in these locations is much more concentrated that in peripheral 
tissues [24], such strategy could potentially provide a better and higher antigen 
presentation to immune cells, increasing the immune response and decreasing local 
reactions to the vaccine [23, 25]. An additional advantage of these ultra-small 
nanocarriers, as compared to larger particles or alum- based vaccines, relies on the fact 
that they could be sterilized by filtration.  
Despite this information, most of the antigen delivery carriers described until now 
presents a size larger than 100 nm [26]. Therefore, taking into account this 
technological gap, our main goal was to rationally design enveloped virus-like particle 
antigens with a final size less than 50 nm. For this purpose, our approach has been to 
use the antigen itself as a substrate for the adsorption of polymers and polynucleotides 
with adjuvant properties. As a model antigen we have chosen the recombinant hepatitis 
B surface antigen (rHBsAg) in its VLP form [5]. This antigen is formed by the self-
assembly of rHBsAg proteins with associated lipids, and presents an average particle 
diameter of 22 nm with surface negative charge [27]. Because of its negative surface 
charge, we have selected for the first enveloping layer two different cationic polymers: 
polyarginine (PARG) and protamine (PR). The second enveloping layer consisted of 
anionic polysaccharides, such as dextran sulfate (DS) or alginate (ALG), or a synthetic 
double stranded based RNA, poly (I:C) (pIC). 
The rational for the selection of the polymers was as follows. Polyarginine is a cationic 
polyamino acid, which has been shown to favor the uptake of antigens by antigen 
presenting cells [28] and, as a consequence, to enhance the T cell responses in vivo 
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against associated antigens [29]. These interesting adjuvant properties have led to its 
inclusion in a hepatitis C vaccine (HCV), which is currently in clinical trials [30]. On 
the other hand, Protamine is a mixture of arginine-rich polypeptides, with membrane 
translocating properties [31], which has also shown the capacity to increase the uptake 
of both microparticles [32] and nanoparticles by phagocytic cells [31]. With regard to 
the selection of the negatively charged polysaccharides, dextran sulfate and alginate are 
both linear anionic polymers exhibiting immunoadjuvant properties. Alginate has been 
found to activate macrophages [33] inducing the production of pro-inflammatory 
cytokines [34], possibly through the interaction with Toll like receptors (TLR) [35]. 
There is also evidence of the capacity of dextran sulfate to increase cell-mediated 
immunity [36] and antibody responses [37] in different animal models. Finally, the 
polynucleotide poly (I:C) is an agonist of the Toll like receptor 3 (TLR-3) that is present 
in dendritic cells. TLR-3 recognizes double strand RNA (dsRNA) associated to viral 
infection, leading to the cell activation and secretion of interferon alpha/beta, playing an 
important role in the defense against viruses. Through these mechanisms  poly (I:C) can 
promote cell activation and maturation [38], potentiating both humoral and cellular 
immune responses [39, 40]. The adsorption of the poly (I:C) onto the enveloped antigen 
was thought to be particularly important in order to achieve simultaneous delivery of the 
antigen and the immunostimulant to the immune cells. 
In brief, this work describes the development of small nanovaccines (<50 nm) through a 
multi-enveloping method using HB VLP as model antigen, and their characterization 
regarding physicochemical properties, uptake by immune cells and in vivo capacity to 
generate an effective immune response to the HB antigen after intramuscular (i.m.) and 
intranasal (i.n.) administration. 
 
2. MATERIAL AND METHODS 
 
2.1. Materials 
Poly-L-arginine hydrochloride with molecular weight of 5 – 15 kDa (P4663), dextran 
sulfate sodium salt with molecular weight of 9 – 20 kDa (D6924) and Phosphate Buffer 
saline (PBS) were obtained from Sigma–Aldrich (Madrid, Spain). Alginate with 
molecular weight of 4kDa was obtained from Danisco (Copenhagen, Denmark). 
Protamine sulfate was kindly donated by LEO Pharma (Denmark). Polyinosinic-
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polycytidylic acid of low molecular weight (0.2 – 1 kB) (Poly(I:C)-LMW) was 
purchased from Invivogen (San Diego, USA). 
The recombinant hepatitis B surface antigen (rHBsAg) was kindly donated by Shantha 
Biotechnics Ltd. (Hyderabad, India) as an aqueous suspension in PBS with a protein 
concentration of 1.13 mg/mL. 
The 5-carboxytetramethylrhodamine, succinimidyl ester (5-TAMRA, SE) *single 
isomer* (Catalogue # C2211) and the Slide-A-Lyzer Dialysis Cassettes, 2K MWCO 
were purchased from ThermoFisher Scientific (Massachusetts, USA). 
The Amicon Ultra-4 mL Centrifugal Filters with 100kDa pore and low-binding 
regenerated cellulose membrane were purchased to Merck Millipore (Massachusetts, 
USA). 
DMEM (Dulbecco's Modified Eagle Medium) was purchased from Life Technologies 
Corporation (CA, USA). 
 
2.2. Preparation of multi-enveloped particles using hepatitis B antigen as substrate 
First, an aliquot of the antigen suspension diluted with ultrapure water was introduced 
in an Amicon-4 100 kDa filtration tube and centrifugated at 5,000 rpm for 5 minutes at 
15 ºC in a Universal 32 centrifuge (Hettich, Tuttlingen, Germany). After repeating this 
procedure three times, the antigen was recovered from the filter and diluted to the final 
concentration of 0.1 mg/ml. This final solution was then used as template for the 
adsorption of the first polymer layer. 
 
2.2.1. Preparation of HB:PR and HB:PARG – First layer adsorption 
A volume of 0.8 ml of protamine or polyarginine solution (0.1 mg/ml) was mixed in a 
glass tube with 0.8 ml of HB solution (0.1 mg/ml) under magnetic stirring (200 rpm). 
The magnetic stirring was maintained for 5 minutes and, then, the resulting suspension 
was incubated for 20 minutes at room temperature in order to allow the complex 
formation. Afterwards, the formulation was filtered using an Amicon-4 100 kDa and 
diluted to a final volume of 4 ml with ultrapure water. This ultrafiltration procedure was 
repeated 3 times and subsequently the concentrated dispersion of the complexes HB:PR 
or HB:PARG was recovered and diluted to a final HB concentration of 0.1 mg/ml). 
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2.2.2. Preparation of HB:PR:DS, HB:PARG:ALG and HB:PARG:pIC – Second 
layer adsorption 
A volume of 0.785 ml of dextran sulfate (0.4 mg/ml), alginate (0.4 mg/ml) or poly (I:C) 
(0.1 mg/ml) solution was mixed in a glass tube with 0.785 ml of HB:PR or HB:PARG 
formulation (HB at 0.1 mg/ml) under magnetic stirring (200 rpm) to constitute the 
HB:PR:DS, HB:PARG:ALG or the HB:PARG:pIC formulation, respectively. The 
formulations were kept under stirring for 5 minutes and then they were incubated at 
room temperature for 20 minutes. Likewise the first layer, the formulations were filtered 
with an Amicon-4 100 kDa and diluted to a final volume of 4 ml. This ultrafiltration 
procedure was repeated three times and subsequently the concentrated dispersion of the 
complexes HB:PR:DS, HB:PARG:ALG and HB:PARG:pIC was recovered and diluted 
to a final HB concentration of 0.1 mg/ml. The final theoretical mass ratio for 
HB:PR:DS, HB:PARG:ALG and HB:PARG:pIC was  1:1:4, 1:1:4 and 1:1:1, 
respectively. 
 
2.3. Physicochemical characterization   
The particle size and polydispersity index (PdI) were evaluated by Dynamic Light 
Scattering (DLS) and its surface charge (zeta potential) by Electrophoretic Light 
Scattering (ELS) using a Zetasizer Nano ZS90 (Malvern Instruments, UK). The 
measurements were performed at 25ºC with a detection angle of 173º, in ultrapure 
water. 
 
2.4. Determination of protamine and polyarginine adsorption and antigen 
enveloping efficiency 
The protamine and polyarginine adsorption to the HB particles was evaluated by an 
indirect measurement based on the free polyamino acid in solution (micro BCA 
(mBCA) protein assay from Pierce (Thermo Fisher Scientific, MA, USA) after 
incubation with the antigen. The efficiency of adsorption (E.A.%) was calculated based 
on the difference between the theoretical concentration of the polyamino acid (0.1 
mg/ml), and the concentration determined by the mBCA. 
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The amount of antigen coated by the polymers was determined indirectly using a 
microtiter plate-based sandwich ELISA kit (Murex HBsAg Version 3, Murex Biotech 
Ltd.; Dartford, UK). The HB enveloping efficiency (E.E.%) was calculated by the 
difference between the theoretical amount of antigen and the amount of non-enveloped 
antigen determined in suspending medium. It was assumed that the enveloped antigen 
particles with polymers, when incubated in the microwells, would not be recognized by 
the anti-HB antibodies of ELISA assay. 
 
2.5. Stability of the multi-enveloped particles in aqueous suspension  
2.5.1. Stability during storage  
The multi-enveloped nanoparticles,HB:PR1:1, HB:PR:DS1:1:4, HB:PARG:ALG1:1:4 
and HB:PARG:pIC1:1:1, at HB concentration of 0.1 mg/ml, were stored at 4 ºC for up 
to a 1 month and then their size and PdI were determined as described in the section 2.3. 
 
2.5.2. Stability upon dispersion in simulated biological medium 
The stability of the multi-enveloped nanoparticles HB:PR 1:1, HB:PR:DS 1:1:4. 
HB:PARG:ALG 1:1:4 and HB:PARG:pIC 1:1:1, at HB concentration of 0.05 mg/ml, in 
PBS at 37 ºC, was tested for up to 4 hours. 
 
2.6. Preparation of fluorescently labeled HB:PR:DS and HB:PARG:ALG multi-
enveloped particles 
In order to perform in vitro cell uptake studies, HB:PR:DS and HB:PARG:ALG 
particles were prepared with fluorescently labeled protamine (PRF) and polyarginine 
(PARGF), respectively. The dye chosen was the 5-carboxy tetramethylrhodamine 
succinimidyl ester (TAMRA) and the labeling was performed based on the 
manufacturer’s instructions. Briefly, protamine and polyarginine were dissolved in 0.1 
M sodium bicarbonate buffer, pH 8.0, at 10 mg/ml concentration. In parallel, TAMRA 
was dissolved in dimethyl sulfoxide (DMSO) at 10 mg/ml. An aliquot of the TAMRA 
solution (0.1 ml) was poured slowly over 1 ml of the polyamino acid solution under 
magnetic stirring and left for 1 hour at room temperature. After incubation, the labeled 
polyamino acid solution was dialyzed in Slide-A-Lyzer Dialysis Cassete 2K MWCO for 
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48 h, to remove free TAMRA. After dialysis, the labeled protamine (PRF) or 
polyarginine (PARGF) was adsorbed onto the HB antigen and then the polysaccharide 
dextran sulfate or alginate was added over the PRF or PARGF layers to form the 
fluorescently labeled HB:PRF:DS or HB:PARGF:ALG particles, respectively. The 
labeled formulations were, then, characterized for their size, PdI and surface charge as 
described in 2.3. 
 
2.7. In vitro cell studies 
2.7.1. Cells and culture 
The adherent RAW 264.7 cells, a murine macrophage cell line (ATCC, Manassas, VA),  
were cultured in RPMI supplemented with 10% (v/v) fetal bovine serum (FBS) (PAA; 
Pasching, Austria), 2 mM glutamine and 100 U/ml of penicillin/streptomycin, in a 
humidified atmosphere at 37 °C in 5% carbon dioxide atmosphere. Cells were split 
every other day to maintain 70–80% of confluent cultures.  
 
2.7.2. Internalization studies in macrophages 
The uptake of HB:PR:DS and HB:PARG:ALGby Raw 264.7 cells was examined using 
a confocal microscope (Leica SP5, Germany). Briefly, cells (3 x 10
5
) were seeded on a 
glass cover-slip (Menzel-Gläser, Braunschweig, Germany) in a 24-well plate (Falcon 
3047, BD Biosciences, USA) and left overnight at 37 ºC to permit cell adhesion. The 
following day, cells were incubated with TAMRA-labeled HB:PRF:DS and 
HB:PARGF:ALG formulation (in a mass equivalent to 10 μg of HB), in RPMI with 
10% FBS for 30 min at 37 ºC, in the dark. After several washes with PBS to remove 
non-internalized particles, the cells were fixed with 4% formaldehyde for 10 min and 
then incubated with Alexa Fluor 488-phalloidin (Invitrogen, Thermo Fisher Scientific, 
USA) for 20 min to stain the cellular cytoskeleton. Finally, the cover-slips containing 
the attached cells were mounted on slides in the presence of ProLong® Gold Antifade 
mounting medium (Invitrogen, Thermo Fisher Scientific, USA), containing DAPI as 
nucleus stain, and analyzed in a confocal microscope (Confocal Laser Scanning 
Microscopy (Leica SP5)). 
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2.8. In vivo studies 
2.8.1. Animals 
Female BALB/c mice (4–5 weeks) were housed in filter-top cages in a 12 h light/12 h 
dark cycle at constant temperature (22 °C) and provided with a standard diet and water 
ad libitum. The animals were kept conscious during the immunizations and bleeding. 
All protocols were in accordance with the guidelines of the Spanish regulations (Royal 
Decree 1201/2005) regarding the use of animals in scientific research and under the 
approval of the Ethical Committee of the University of Vigo. 
 
2.8.2. Preparation of the control vaccine using alum as adjuvant. 
The HB antigen was used either soluble (suspended in PBS) for intranasal (i.n.) 
administration or adsorbed in aluminum hydroxide (HB-Alum) for intramuscular (i.m.) 
administration as positive control. Briefly, Alum (Alhydrogel ®, Sigma-Aldrich, St. 
Louis, MO) was incubated with the HB antigen in a 3:1 (v:v) ratio for 30 minutes at 4 
ºC under gentle agitation. Afterwards, the suspension was centrifuged (10,000 x g, 10 
minutes, 4ºC) and the pellet was resuspended in an isotonic saline solution. The dose of 
antigen administered (10 μg) was the same in the control vaccines, as in the rest of 
formulations. 
 
2.8.3. Immunization and bleeding schedule 
In total, three in vivo trials were performed in mice, in order to evaluate the capacity of 
1) the HB:PR, 2) the HB:PR:DS and HB:PARG:ALG and 3) the HB:PARG:pIC 
systems, to stimulate an immune response against the HB antigen by i.n. and i.m. 
routes. 
In all cases, the initial pool of mice was randomly distributed in groups of ten animals 
for each formulation and administration route (i.m. or i.n.).  he antigen dose was 10 μg, 
either for test formulations or controls. In the i.m. mice test groups, the test formulations 
and control were administered at day 0 and 28 (0 and 4 weeks) in the hind leg of the 
mice, in a volume of 0.06 ml (HB at 0.167 mg/ml). In the i.n. mice test groups, the 
formulations and control were administered at day 0, 28 and 112 (0, 4 and 16 weeks), in 
a volume of 0.02 ml (HB at 0.5 mg/ml) by instillation of 0.01 ml in each nostril.  
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The blood samples were collected in all cases from the mouse maxillary vein at day 42, 
126 and 183 (corresponding to weeks 6, 18 and 26). 
 
2.8.4. Determination of anti-HB IgG in the serum of immunized mice by ELISA 
Specific antibody levels against HB in mice sera were evaluated by ELISA at different 
time points. For this purpose, MaxiSorp ® 96-well plates (Nunc, Denmark) were coated 
with a HB solution at 5 μg/ml, in carbonate buffer (pH 9.6), and incubated overnight at 
4 ºC. Plates were then blocked with BSA 1% in PBS for 1 hour at 37ºC. In order to 
quantify specific anti HB-IgG, both serum samples and a mouse monoclonal anti-HB 
IgG antibody (Acris Antibodies GmbH; Hiddenhausen, Germany), were serially diluted 
and incubated for 2 hours at 37 ºC. Afterwards, secondary antibodies (goat anti-mouse 
IgG from Southern Biotech, AL, USA) were added to the wells and incubated for 1 hour 
at 37 ºC. Bound antibodies were finally revealed with 2,2´-azino-bis-3-
ethylbenzothiazoline-6-sulfonic acid (ABTS) and the absorbance read at 405 nm. To 
transform antibody levels in µg/mL to international units (mIU/mL), a similar protocol 
was carried out in parallel using a control rabbit anti-HB IgG (Biokit, Barcelona, Spain) 
of known concentration (mIU/ml). 
The IgG1/IgG2a ratio was also evaluated in a pool of sera from mice immunized with  
HB:PARG:pIC and HB-Alum by i.m. route. In this case, the same protocol was 
followed but specific anti-mouse IgG1 and IgG2a secondary antibodies were used. The 
ratio IgG1/IgG2a was then calculated based on the absorbance levels detected. All 
serum samples were tested at least twice and in duplicate. 
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3. RESULTS AND DISCUSSION 
 
Virus-like particles (VLP) antigens are having an increasing presence in the 
immunization protocols. Despite their good safety profile and immunogenicity, these 
new vaccines need to be administered in association with adjuvants in order to generate 
robust immune responses. Inspired by the nanoparticulated nature of the VLP, we have 
designed, a strategy intended to increase the immune response against these antigens. 
This strategy relies on the use of a particulated antigen as a substrate for the adsorption 
of polymers with immune adjuvant properties. The antigen chosen was the hepatitis B 
VLP antigen (HB), due to its nanometric size (22 nm) and negative surface charge. On 
the other hand, the biomaterials selected for the enveloping process were: protamine 
(Pr), polyarginine (PARG), dextran sulfate (DS), alginate (ALG). Finally, the 
immunomodulator poly (I:C) (pIC), was also associated to the nanostructures in order to 
evaluate its potential for enhancing the immune response against the enveloped antigen. 
With this strategy, four multi-enveloped systems (HB:PR; HB:PR:DS; HB:PARG:Alg; 
HB:PARG:pIC) (Figure 1) were developed and characterized. Finally, their behavior 
upon contact with dendritic cells and upon in vivo administration was assessed.  
 
3.1. Preparation and characterization of multi-enveloped nanoparticles  
The HB antigen in a PBS stock solution was washed with ultrapure water (by 
ultrafiltration) in order to decrease the salt content before its enveloping with the 
polymers. As the adsorption of the polymers was based on electrostatic interactions, it 
was found important to reduce the presence of salts that could shield the electrostatic 
attraction between molecules of opposite charge [41]. This operation lead to a decrease 
of the antigen sample number-distribution, as before ultrafiltration it presented a size of 
53 nm while after this process the size was of 22 nm (data not shown). After incubation 
of the antigen with the polymers, the formulation was also ultrafiltered to separate the 
multi-enveloped nanosystem from free polymer and allow the concentration of the 
formulation. This was considered an important step, particularly after the first coating 
(protamine and polyarginine), in order to eliminate the free polymer molecules that 
could complex with the negatively charged polymers (dextran sulfate, alginate and poly 
(I:C)) and interfere with the antigen enveloping process.  
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Figure 1. Illustration of the sequential Protamine (PR) and Dextran Sulfate (DS) 
adsorption to the antigen HB to originate the HB:PR and HB:PR:DS compositions (A) 
and of the polyarginine (PARG) and alginate (ALG) or poly (I:C) (pIC) to form the 
HB:PARG and HB:PARG:ALG or HB:PARG:pIC compositions, respectively (B) and of 
the polymers involved in the multi-enveloping process. * The protamine is a mixture of 
polyamino acids molecules composed majorly by Arginines. 
 
 113 
 
The DLS and ELS techniques were considered the most practical techniques to 
characterize the antigen and to monitor its progressive coating by the polymers. In order 
to have a reliable signal with these techniques, the minimal HB concentration needed 
was 0.05 mg/ml and this concentration was taken as reference for characterization of the 
multi-enveloped systems. The initial DLS intensity-distribution size analysis of the 
antigen alone indicate a size greater than 100 nm (Annex 1A), which is in contradiction 
with previously published work [27, 42]. However, when the DLS signal was evaluated 
through a volume-distribution (Annex 1B) and number-distribution size (Annex 1C), 
we observed that the majority of the HB particles in solution had in fact a size close to 
22 nm (22 ± 1) and that most part of antigen volume was from particles with this size. 
Such difference between intensity and number evaluation can be due to the presence of 
a small number of big particles resultant from HB particles agglomeration. In DLS, the 
intensity signal is directly proportional to the size of the particles, so even if the quantity 
of small particles is greater than that of the large ones, the intensity distribution profile 
will predominantly reflect the presence of large particles [43]. As the number-
distribution size matched perfectly with the referenced size of the HB particles, this 
parameter was considered to be the most adequate for the characterization of antigen 
and to follow its progressive coating through the multi-enveloping process. The 
presence of the refereed HB particles aggregates could explain the high polydispersity 
(PdI 0.3). As this nanostructure was used as a template for the polymer adsorption, all 
the multi-enveloped structures developed presented also a significant high PdI (Figure 
2). The ELS analysis of the antigen alone confirmed its negative surface charge 
potential. After the addition of the protamine or polyarginine, this surface charge 
became positive, suggesting that the antigen surface was coated by the positive 
polyamino acids. Finally, when the dextran sulfate, alginate or poly (I:C) were added to 
the formulations, the zeta potential detected was again negative, thus indicating that the 
antigen particles had been coated by the negative polymer. The adsorption of 
subsequent polymer layers led to consecutive negative-positive-negative surface charge 
inversions and also to a subtle increase of the size from the original 22 nm to about 40 
nm, upon formation of the multilayer structure.  
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Figure 2. Evolution on the size (Size), polydispersity index (PdI) and surface charge 
(zeta potential) of the multi-enveloped systems HB:PR and HB:PR:DS (A) upon the 
adsorption of protamine (PR) and dextran sulfate (DS) onto the hepatitis B antigen 
(HB), of the systems HB:PARG and HB:PARG:ALG (B) upon the adsorption of 
polyarginine (PARG) and alginate (ALG) and of the system HB:PARG:pIC (C) upon 
the adsorption of polyarginine and poly (I:C) (pIC), respectively. 
 
3.2. Determination of protamine and polyarginine adsorption and antigen 
enveloping efficiency 
To evaluate the percentage of protamine and polyarginine adsorbed onto the antigen 
particles, the concentration of the non-associated polymers was determined by mBCA. 
Under the selected experimental conditions, the percentage of polyarginine and 
protamine adsorbed was 23% and 13%, respectively (Table 1). This indicates that the 
amount of polymers used exceeded the amount required for the enveloping process. 
These positively charged polymers are hydrophilic and the mechanism driving the 
interaction with the antigen is based on the ionic interaction with the negatively charge 
antigen HB, as illustrated in Figure 1.  
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Table 1.Summary of the adsorption efficiency (E.A.) of protamine and polyarginine on 
the HB antigen and percentage of enveloped antigen (HB Enveloped). 
Formulation  E.A. (%) HB Enveloped (%) 
 HB:Protamine  13 ± 5 67 ± 2 
 HB:Polyarginine  23 ± 0.4 65 ± 3 
 
On the other hand, the amount of HB antigen coated by the polymers was determined 
by ELISA. Interestingly, although the amounts of protamine and polyarginine adsorbed 
to HB were quite different, the HB enveloping efficiency was relatively high (> 60%) 
for both polyamino acids (Table 1). A possible explanation for the higher amount of 
polyarginine adsorbed could be found in the greater density of positive charges in this 
polymer. In addition, the higher molecular weight of polyarginine (5-15kDa) vs. 
protamine (5 kDa) could have also influenced the amount of polymer adsorbed. The 
slightly larger size and higher positive surface charge identified for HB:PARG 
compared with the HB:PR are also supporting this hypothesis (Figure 2). 
 
3.3. Stability of multi-enveloped particles in aqueous suspension 
A critical aspect of the colloidal carriers is the preservation of their stability upon 
storage and also upon incubation in simulated biological fluids. Indeed, very small 
nanoparticles, especially those formed by ionic complexation, often have a tendency to 
destabilize themselves. Interestingly, irrespective of the nature of the coating polymer, 
the nano-enveloped particles remained stable in terms of particle size distribution, upon 
storage for at least one month at 4 ºC (Annex 2). On the other hand, the behavior of the 
different nanostructures upon incubation in PBS at 37 ºC, was slightly different. The 
HB:PR formulation showed a slight and rapid size increase (from 40 to 60 nm size) 
(Figure 3A) upon incubation in PBS. However, following this initial increase, the size 
and also the PdI remained stable for the rest of the assay. On the other hand, the 
HB:PR:DS prototype exhibited an adequate stability in PBS (Figure 3B) while the 
HB:PARG:ALG system, aggregated rapidly when dispersed in this media. Finally, the 
HB:PARG:pIC preserved its size and PdI for up to 4 hours in PBS (Figure 3C).  
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Figure 3. Evaluation of size number distribution (Size) and polydispersity index (PdI) 
after 4 hours at 37 ºC in PBS of the formulations HB:PR (A), HB:PR:DS (B) and 
HB:PARG:pIC (C). 
 
The different behavior of HB:PARG:ALG and HB:PARG:pIC systems (which share the 
same HB:PARG core) in PBS, could be related to the different ionic forces between the 
first and second enveloping layers. The great negative charge density of poly (I:C) 
might be responsible for the firm association between the two layers.  
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Overall, the conclusion is that the stability of the multiple enveloping of antigen 
nanoparticles is dependent on the balance between the attractive forces of the polymer-
polymer and polymer-antigen layers and between the polymer layer and the components 
of the incubation medium.  
 
3.4. In vitro internalization studies of fluorescently labeled multi-enveloped 
particles 
As indicated in the introduction, in order to facilitate the antigen presentation to the 
immune system, nanoparticles should have the capacity to enter the APCs. To verify the 
possibilities for this internalization process to occur, the HB:PR:DS and 
HB:PARG:ALG nanosystems were prepared using TAMRA-labeled polymers and 
incubated with macrophages (RAW 264.7). The dye was covalently linked to the 
polyamino acids prior to the enveloping process. The DLS and ELS analysis of the 
labeled formulations confirmed that all the physicochemical parameters of the 
multilayer systems remained constant, with only a small decrease in the zeta potential 
values of the HB:PARG:ALG formulation (Annex 3). 
The internalization process of the nanosytems into the macrophages was visualized by 
confocal microscopy (Figure 4).  
 
 
Figure 4. Evaluation of the uptake of fluorescent HB:PR:DS (A) and HB:PARG:ALG 
particles (B) by RAW 264.7 cells by confocal microscopy (red channel: TAMRA 
(labeled particles); green channel: Alexa Fluor 488-phalloidin (cytoskeleton); blue 
channel: DAPI (nucleus)).  
B A 
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The images obtained suggest a more pronounced presence of the HB:PR:DS 
nanoparticles, with respect to the HB:PARG:ALG ones, into the cells although more 
detailed studies should be realized to confirm this data. 
 
3.5. In vivo studies 
The ability of the HB:PR, HB:PR:DS and HB:PARG:ALG or HB:PARG:pIC 
formulations to promote a systemic humoral immune response by i.n. or i.m. routes 
against the hepatitis B antigen, was assessed in three different in vivo trials with 
BALB/c mice.  he antigen dose was 10 μg for the formulations and for the alum-
adsorbed antigen used as positive control (same mass ratio as in licensed vaccines) [44]. 
The specific anti-HB IgG concentration (μg/ml) in mouse sera was determined by 
ELISA and converted to international units (mIU/ml) in order to be able to compare 
with the protective anti-HB IgG levels observed in humans (10 mIU/ml) [45]. 
Following intramuscular immunization, it was found that the prototypes investigated, 
led to a steady anti-HB IgG profile close to 100 mIU/ml (values between 179 and 62 
mIU/ml) during the whole experiment (Figure 5). Although these levels were lower 
than those observed for the alum-adjuvanted vaccine, it is important to mention that 
they were always superior to 10 mIU/ml, a concentration known to be protective in 
humans. On the other hand, the effect of the presence of poly (I:C) in the formulation 
was only shown at early times.  
When testing the formulations by intranasal route and in order to better understand the 
adjuvant effect of enveloping the antigen, the antigen alone was also administered by 
the i.n. route. Despite being a highly immunogenic antigen, the HB alone generated 
almost undetectable IgG titers (2 mIU/ml). Overall, the responses were similar for the 
different prototypes and were low at short times (below 10 mIU/ml), however, they 
increased over time reaching IgG levels close to 60 mIU/ml (Figure 6). These values 
were also significantly higher than those attained for the free antigen.  
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Figure 5. Systemic humoral (IgG) immune response observed in mice upon 
intramuscular (0 and 4 weeks) immunization with Hepatitis B antigen coated with 
Protamine (HB:PR), Protamine and Dextran Sulfate (HB:PR:DS), Polyarginine and 
Alginate (HB:PARG:ALG) or Polyarginine and poly (I:C) (HB:PARG:pIC). Hepatitis B 
antigen adsorbed to Alum (HB:Alum) was used as positive control. The plot represents 
the average of anti-HB IgG quantified at different time points after primary 
immunization (mean ± SEM, n = 10). 
 
The modest humoral response observed for all the multi-enveloped systems, suggests 
that there might be an intrinsic limitation of the multi-enveloping strategy for the 
hepatitis B antigen. This limitation might be related to the recent theory that underlines 
the importance of the exposure of a repetitive epitope array in the generation of an 
effective immune response [3]. Such theory has been used to justify the superiority of 
VLP antigens as compared to soluble antigens [6, 7]. However, despite of this, it is clear 
that rHBsAg antigen needs to be associated with Alum in order to activate the immune 
cells and generate an effective immune response. On the other hand, the improved 
behavior of the multi-enveloped formulations as compared to the VLP antigen alone, 
following intranasal administration, suggests that the enveloping polymers exert a 
certain role. This role could be simply related to the capacity of polyarginine to 
facilitate the transport of proteins across the nasal mucosa [46] or it could also be 
related to the adjuvant effect of the biomaterials [29, 31, 33, 37, 39].  
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Figure 6. Systemic humoral (IgG) immune response observed in mice upon intranasal 
(0, 4 and 16 weeks) immunization with Hepatitis B antigen coated with Protamine 
(HB:PR), Protamine and Dextran Sulfate (HB:PR:DS), Polyarginine and Alginate 
(HB:PARG:ALG) or Polyarginine and poly (I:C) (HB:PARG:pIC). Hepatitis B antigen 
dispersed in PBS (HB in PBS) was used as positive control. The plot represents the 
average of anti-HB IgG quantified at different time points after primary immunization 
(mean ± SEM, n = 10). 
 
The theory about the limited exposure of the antigen epitopes in the enveloped systems 
would agree with the positive results previously obtained by our group for a chitosan 
nanocapsules prototype, which have VLP rHBsAg antigen exposed on their surface [16, 
17]. However, this theory would be in disagreement with the results of previous works 
that have shown that the coating of rHBsAg antigen [47] or its entrapment within 
polymers such as chitosan [14], may also lead to significant responses following either 
i.m. or i.n. administration. Therefore, given the different nature of the biomaterials and 
the different sizes of the vaccine nanostructures it is difficult to draw a conclusion at 
this point. Another explanation for the limited response obtained for the enveloped 
nanosystems could be related to the small size of the nanostructures. Even though, we 
have postulated that small size could facilitate the direct access of the antigen to the 
lymph nodes, the possibility that these ultra-small particles would be less recognizable 
by the antigen presenting cells, cannot be discarded. 
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Finally, based on previous works [39, 40], it was expected that the association of poly 
(I:C) to the nanostructure would lead to an enhanced response. Keeping in mind that 
this immunostimulant would mainly have an impact on the cell responses (associated to 
Th1 responses) [48], the IgG1/IgG2a ratio of the mice immunized with the 
HB:PARG:pIC formulation were compared with those observed for the alum-absorbed 
antigen (Figure 7).  
 
Figure 7. Ratio between the IgG1 and IgG2a subtypes in the serum of mice immunized 
with the multi-enveloped system composed by the Hepatitis B antigen coated with 
polyarginine and poly (I:C) (HB:PARG:pIC) (grey squares) and with the same antigen 
adsorbed to alum (HB:Alum) (black circle). 
 
As the IgG1 and IgG2a are characteristic of a Th2 and Th1 biased-response, respectively 
[49], we assumed that a IgG1a/IgG2 ratio superior to 1 was indication of a Th2 
polarized response while a IgG1/IgG2a ratio inferior to 1 was the indication of a Th1 
polarized response [50]. The activation of lymphocytes Th2 has been associated to a 
more preponderant humoral response while the activation of Th1, to an enhanced 
cellular based immunity [51]. The IgG1/IgG2a ratio indicates that the alum markedly 
shifted the lymphocytes towards a Th2 profile, which is a well known characteristic of 
this adjuvant [13]. On the contrary, in the case of the HB:PARG:pIC formulation, it was 
found that the initially balanced Th1/Th2 response (IgG1a/IgG2 = 0.97) shifted, at the 
end of the assay, towards a clear polarization of a Th1 response (IgG1a/IgG2 = 0.54). 
The increased activation of Th1 cells by the HB:PARG:pIC formulation can be an 
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interesting advantage of this system, as these cells stimulate the development of cellular 
based immune responses capable of eliminating virus infected cells [52].  
 
CONCLUSION 
Here we present the design and evaluation of a new strategy for the immunomodulation 
of immune responses associated to particulated antigens. The strategy involves using 
the HB particulated antigen as a model template, and its enveloping with a number of 
biomaterials and immunostimulators. The HB multi-enveloped systems were capable of 
generating protective IgG titers (>10 mIU/ml) but the IgG titers achieved were lower 
than those of the alum-adsorbed antigen. There were no important differences between 
the activity of the HB:PR, HB:PR:DS and HB:PARG:ALG systems despite their 
diverse composition and structure, which suggests an intrinsic limitation of this multi-
enveloping strategy. Nevertheless, the association of the immunostimulant poly (I:C) to 
the enveloped antigen led to a more balanced Th1/Th2 response, as compared to the one 
observed for the alum-absorbed antigen. This could be taken as an indication of the 
improved cellular responses, which would be of importance for the complete 
elimination of viral infections. Overall, this work provides new insight on the properties 
that are determinant of the behavior of the antigen delivery nanocarriers and underlines 
the fact that a very small size might not be a good option for enhancing the immune 
response against particulated antigens.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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SUPPORTING INFORMATION 
 
Annex 1. Comparison of the DLS signal analysis of the HB antigen alone through three 
different size distributions: Intensity (A), Volume (B) and Size (C). 
 
 
 
 
 
 
 
A 
A 
C 
A 
B 
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Annex 2. Evolution of size (Size number) and polydispersity index (PdI) after one 
month at 4 ºC of the HB coated with protamine (HB:PR), with protamine and dextran 
sulfate (HB:PR:DS), with polyarginine and alginate (HB:PARG:ALG) or with 
polyarginine and poly (I:C) (HB:PARG:pIC). 
 
 
Annex 3.Comparison of the size number distribution (Size), polydispersity index (PdI) 
and surface charge (Zeta potential) of non labeled and labeled HB:PR formulations (A) 
and of non labeled and labeled HB:PARG and HB:PARG:ALG formulations (B). 
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ABSTRACT 
 
The favorable safety profile of peptide antigens has prompted the search of adjuvants 
capable of increasing the immunization efficiency of these intrinsically poor 
immunogenic antigens. The integration of both immunostimulants and peptide antigens 
within nanometric delivery systems for their co-delivery to the immune cells is 
currently considered a promising peptide-based vaccination strategy. With this idea in 
mind, the potential synergistic effect of the immunostimulant poly (I:C) and chitosan, 
integrated into a nanostructure, was explored. In addition, a universal T-Helper peptide 
(PADRE) was incorporated into the nanoparticles in order to promote a strong T helper 
response. The value of this nanostructured combination of materials was assessed for a 
peptide antigen, 1338aa, which contained the amino acid sequence of a specific epitope 
(17-36aa) from the HPV-16 L2 protein. Nanoparticles consisting of chitosan (CS) and 
poly (I:C) (pIC) could be obtained by the ionic gelation technique by adjusting the 
amount of both components to promote their adequate interaction. These nanoparticles 
exhibited a nanometric size (<300 nm), a high positive surface charge (> +40 mV) and a 
very high pIC association efficiency (>96%). They also showed capacity for the 
association of both the 1338aa and PADRE peptides. The influence of the presence of 
pIC and PADRE in the nanocomposition, as well as that of the peptide presentation 
form (encapsulated versus surface adsorbed) on the antibody induction was evaluated in 
a preliminary in vivo study. The data obtained highlights the possibility to engineer 
nanoparticles through the rational combination of a number of adjuvant molecules 
together with the antigen.  
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1. INTRODUCTION  
 
The advent of synthetic peptide-based antigens has brought new opportunities and also 
new challenges to the development of effective vaccines. These synthetic and 
chemically well-defined molecules, designed from known epitopes of tumor cells and 
pathogens, present no risk of mutation or reversion associated to whole pathogen-based 
vaccines. From the technological point of view, they are easy to produce under 
appropriate quality control practices [1] and present little risk of contamination by 
pathogenic or toxic substances [2]. However, due to their purity, these entities lack of 
“danger signals” [3] and consequently are incapable of activating immune cells. 
Furthermore, the peptide-based antigens present in general limited MHC recognition, 
which contributes to their poor intrinsic immunogenicity [4]. Therefore, there is a need 
to design adjuvant systems specifically adapted to facilitate the efficient presentation of 
peptide-based antigens without compromising their favorable safety profile. Within this 
frame, nanoparticles made of biodegradable polymers are receiving increasing attention.  
Among the different nanotechnology-based adjuvant systems, nanoparticles made of 
chitosan (CS), a biodegradable polysaccharide [5], are particularly attractive since these 
nanoparticles have already proven to be efficient adjuvant systems for a variety of 
protein antigens [6, 7]. In addition to their capacity for the association of peptides and 
proteins, CS nanoparticles are well known for their ability to efficiently complex 
polynucleotides, protect them from enzyme degradation, and deliver them to cells [8]. 
Therefore, in principle, such delivery system could offer the possibility of associating 
simultaneously antigens and polynucleotide-based immunostimulants and delivering 
them to the target site in a controlled manner. 
As a model peptide-based antigen that would potentially benefit from the chitosan-
based nanotechnology, we have chosen the peptide (1338aa), which comprises a 
specific amino sequence (13-38aa) from the Human Papilloma Virus 16 (HPV-16) L2 
capsid protein. Currently available HPV vaccines are based on the L1 protein from the 
HPV capsid, which self assembles into virus-like particles (VLPs) [9]. These vaccines 
induce high levels of type-specific neutralizing antibodies, however these antibodies 
have a limited ability to protect against all oncogenic HPV types [10, 11]. On the other 
hand, the L2 minor capsid protein does not assemble into VLPs and is less 
immunogenic but it contains conserved domains that elicit broad cross-type neutralizing 
antibodies [12], which makes L2 a potential target for a novel HPV vaccine. The amino 
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acid sequence 17-36aa of this protein has been identified as a highly conserved 
neutralizing epitope among the HPV strains [13] and presents a great potential as 
antigen for a cross-protective HPV vaccine.  
In order to enhance the adjuvant properties of chitosan nanoparticles, we have 
incorporated into the nanostructure the immunostimulant poly (I:C) (pIC), a synthetic 
analog of the viral double-stranded RNA (dsRNA). This compound mimics a molecular 
pattern associated with viral infections and it is an agonist of the Toll-like receptor 3 
(TLR3), present in the endosomes of antigen presenting cells (APC). The activation of 
TLR3 promotes dendritic cell maturation and the production of T cell chemokines [14], 
thereby potentiating both humoral and cellular immune responses [15, 16]. 
Nevertheless, the systemic delivery of pIC can also provoke adverse effects, such as 
autoimmunity [17] and chronic inflammatory diseases [18], as observed in rodent 
models. In the context of this work it has been assumed that the incorporation of this 
immunostimulant into CS nanoparticles could protect it from serum nucleases and 
facilitate its uptake by the APCs, consequently leading to a reduction of the effective 
dose and potential adverse effects [19, 20].  
Finally, in addition to the HPV L2 antigenic peptide and the pIC immunostimulant, we 
associated a T-Helper Pan HLA-DR epitope (PADRE) peptide to the composition. 
These peptides present specific amino acid sequences that can bind to the majority of 
MHC class II alleles [21] and have already shown to be capable of increasing the 
immune response of associated peptide-based antigens [22, 23]. Accordingly, the 
inclusion of the PADRE peptide in the nanoparticle is expected to provide a greater 
MHC recognition of the 1338aa peptide and consequently, an increased immune 
response against the antigen.  
To summarize, the objective of this work was to design and develop a CS based 
nanoparticle with the capacity to co-deliver a peptide-based antigen with the 
immunostimulants pIC (as danger signal) and the PADRE peptide (to increase T helper 
responses). The ultimate goal has been the identification of potential synergistic effects 
among the three major components with regard to their ability to generate an effective 
antibody response. The expected low immunogenicity of the L2 peptide 1338aa allied 
with its great potential as antigen for an improved HPV vaccine makes it an excellent 
antigen model for the study of novel particle-based vaccines with intrinsic adjuvant 
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activities. Even though the synergistic effect of the combination of the T helper peptides 
and pIC for immunization purposes has already been observed for a peptide-based 
antigen from HPV [23] this is, to the best of our knowledge, the first time that both 
molecules are combined in nanoparticles as an adjuvant system to solve the specific 
limitations of peptide-based antigens.  
 
2. MATERIALS AND METHODS 
 
2.1. Materials 
Peptide 1338aa and peptide PADRE were chemically synthesized (95% and 99% purity, 
respectively) by Genemed Synthesis (San Antonio, USA). Amino acid sequence and 
physicochemical characteristics are described in Table 1. Polyinosinic-polycytidylic 
acid of low molecular weight (0.2 – 1 kB) (Poly (I:C)-LMW) was purchased from 
Invivogen (San Diego, USA). Ultrapure chitosan hydrochloride salt (Protasan UP Cl 
113, Mw: 50,000-150,000 g/mol) was purchased from Novamatrix (Norway). Degree of 
deacetylation was confirmed by elemental analysis to be 75 ± 2%. Pentasodium 
tripolyphosphate (TPP), trehalose,  FA ( rifluoroacetic acid ≥99%), ammonium 
hydroxide and heparin were obtained from Sigma-Aldrich (Madrid, Spain). Chitosanase 
10U purified from Streptomyces griseus (C4163-01) was purchased from United States 
Biological (MA, USA). SYBR Gold® and Nunc Maxisorp™ MicroWell™ flat-bottom 
96-well plates were purchased from Thermo Fisher Scientific (Waltham, USA). HPLC-
grade acetonitrile and water were purchased from Scharlab (Spain) and Fisher Chemical 
(Thermo Fisher Scientific, USA). 
Human serum adsorbed and peroxidase labeled anti-mouse IgG (H+L) goat antibody 
was purchased from KPL (MD, USA). The secondary anti-Rabbit IgG horseradish 
peroxidase linked whole antibody from donkey was purchased from Amersham (GE 
Healthcare Life Sciences, UK). ABTS was acquired from Roche (Basel, Switzerland). 
Imject® Alum was obtained from Pierce Biotechnology (USA). 
 
2.2. Design and preparation of CS and pIC based nanoparticles 
In order to obtain a monodisperse population of nanometric particles with efficient pIC 
incorporation, different TPP and pIC concentrations were tested. The TPP 
concentrations were 0, 0.25, 0.625 mg/ml while the pIC were 0.25, 0.625 and 1.25 
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mg/ml, with a constant volume of 0.2 ml. The CS concentration and volume was fixed 
at 1 mg/ml and 0.5 ml, respectively.  
The formulation was produced upon addition of the TPP and/or pIC phase over the CS 
solution under magnetic stirring during 5 minutes. The resulting nanoparticles were let 
to stay for 30 minutes and, then, they were isolated by ultracentrifugation at 20,000 
RCF, 4 ºC for 2 hours (Centrifuge 5430R, Eppendorf AG, Germany) on a glycerol bed. 
The supernatant was removed and the pellet (0.1 ml) was resuspended in ultrapure water 
with a pipette. The resulting particles were evaluated in terms of hydrodynamic 
diameter (size), polydispersity (PdI), derived count rate (DCR) and surface charge (zeta-
potential). The positive-to-negative charge (P/N) ratio was defined as the ratio between 
the maximum number of protonable primary amines in CS (considering the 75% 
deacetylation degree determined by elemental analysis) and the sum of negative 
phosphate groups from TPP and pIC. 
 
2.3. Physicochemical characterization   
Particle size, PdI and DCR were evaluated by Dynamic Light Scattering (DLS) and 
zeta-potential by Electrophoretic Light Scattering (ELS) using a Zetasizer Nano ZS90 
(Malvern Instruments, UK). The measurements were performed at 25 ºC with a 
detection angle of 173º, in distilled water. The morphology of the nanoparticles was 
examined by transmission electron microscopy (CM 12 Philips, Eindhoven, The 
Netherlands). The nanoparticles were placed on copper grids with Formvar films and 
stained with 2% (w/v) phosphotungstic acid solution. The grids were left overnight in 
an oven at 60 ºC to dry and then observed with TEM. The solutions and formulation pH 
was determined with a Sartorius Docu-pH Benchtop Meters (ThermoFisher Scientific, 
USA). 
 
2.4. Evaluation of pIC loading in nanoparticles 
The encapsulation efficiency of pIC in the nanoparticles was calculated from the 
amount of free pIC detected in the supernatant collected upon ultracentrifugation. The 
free pIC was determined by absorbance at 260 nm (Abs 260 nm) with a NanoDrop 2000 
(Thermo Fisher Scientific) and quantified by interpolation in a linear standard curve (R
2
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= 0.9988) produced with solutions of pIC solubilized in the nanoparticles supernatant in 
a concentration range from 2.5 to 80 μg/ml.   
The indirect evaluation of the encapsulation of pIC was confirmed by electrophoresis in 
a 1% agarose gel using a Sub-Cell GT 96/192 electrophoresis system (Bio-Rad 
Laboratories Ltd., England). Briefly, the isolated nanoparticles were stained with SYBR 
Gold® and then 0.025 ml of formulation was added (equivalent to 8.4 μg pIC) to the 
agarose gel wells. After applying 90 V for 45 minutes, the gels were evaluated with an 
UV transilluminator (Molecular Imager® Gel Doc™ XR, Bio-Rad, CA, USA) and 
analyzed with Image Lab™ Software (Bio-Rad, CA, USA). 
The stability of the pIC encapsulation was tested by incubating the nanoparticles with 
anionic heparin, based on the method by Csaba et al [24], and verifying its release in an 
agarose gel. In summary, fresh isolated nanoparticles and freeze dried nanoparticles 
were incubated in a 1.2 mg/ml heparin solution for 2 hours at 37 °C in order to have an 
excess of heparin in relation to the pIC (mass ratio pIC/heparin 1/3) and induce the 
competitive displacement of the pIC by the strong anionic polymer.  
In order to verify that the pIC remained intact after encapsulation, the nanoparticles 
were incubated with chitosanase (an enzyme capable of hydrolyzing the CS into 
oligosaccharides, releasing the associated pIC) [7, 24]. In summary, 0.1 ml of fresh 
isolated nanoparticles (0.4608 mg), were incubated with 1.1 U of chitosanase in a 50 
mM acetate buffer pH 5.5, for 4 hours at 37 ºC under agitation. After incubation, an 
aliquot (0.019 ml) was taken and tested in an agarose gel 1%. This same protocol was 
also applied to freeze dried particles (described below) to verify pIC stability in the 
nanoparticles after the freeze drying process.  
 
2.5. Peptide Association to Nanoparticles  
Firstly, the 1338aa peptide was solubilized in sterile water at the concentration of 10 
mg/ml while the PADRE peptide, due to its higher hydrophobicity, was solubilized in a 
0.07 M ammonium hydroxide solution to the final concentration of 5 mg/ml. The 
association of the peptides to the CS/TPP/pIC nanoparticles was achieved either by 
incorporation of the peptides into the TPP/pIC containing phase (Protocol A), during 
the nanoparticles formation process (section 2.2.), or by their incubation with the 
preformed nanoparticles (Protocol B), as illustrated in Figure 1. In the first case, the 
peptides were added to the aqueous phase containing TPP and pIC, at the concentration 
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of 0.125 mg/ml (pH 8.8). The whole mixture of components was added to the CS phase 
(1 mg/ml, pH 4.80) under magnetic stirring, and then left for 1 hour at room 
temperature to produce the formulation NP E2. In the second case, a 0.1 ml of the 
solution of 1338aa alone (pH 6.4) or of the solution of 1338aa and PADRE (pH 9.6) at 
the concentration of 0.25 mg/ml, was poured over the nanoparticle suspension (pH 5) 
under magnetic stirring to generate the formulation NP A1 and NP A2, respectively. 
The stirring was maintained for 5 minutes, and then the formulation was left for 1 hour 
at room temperature. Finally, a loaded nanoparticle formulated with the same method as 
NP A2, but without pIC (NP C), was also produced as a control. The theoretical loading 
of each peptide with respect to the CS mass was 5% in all cases. After the incubation 
period, the formulations were isolated by ultracentrifugation at 20,000 RCF, 4 ºC for 2 
hours on a glycerol bed (Centrifuge 5430R, Eppendorf AG, Germany).  
 
2.6. Evaluation of the 1338aa and PADRE association 
To evaluate the peptide association efficiency, the loaded nanoparticles were first 
isolated by ultracentrifugation, as previously described. The supernatant was eliminated 
and the nanoparticles pellet was recovered and digested with chitosanase in the same 
conditions as reported above (section 2.4). The peptide released after nanoparticle 
digestion was determined by an ultra performance LC (UPLC) coupled with UV 
detection system (ACQUITY UPLC H-Class, Maryland, USA) using an a reverse phase 
Acquity UPLC BEH C18 column (1.7 um 130 Å 2.1 x 100 mm) and a gradient elution. 
The mobile phase A consisted of TFA 0.1% (v/v) aqueous solution and the mobile 
phase B of TFA 0.1% (v/v) in acetonitrile. The rest of UPLC conditions are described in 
the Annex 1. For the standard curve, the peptides were diluted in the digested matrix of 
nanoparticles (NP B) at concentrations between 3.125 and 100 μg/ml. 
 
2.7. Freeze-drying of nanoparticles 
Lyophilization was conducted in a VirTis Genesis 25L lyophilizer (Model SQ EL-85, 
SP Scientific, Pennsylvania, USA). The samples were frozen overnight at -20 °C and 
then transferred to the lyophilizer. They underwent an initial drying step for 24 h at -35 
°C at 2-10 millitorr (mtorr) followed by a secondary drying for another 24 h at 0 °C and 
finally a third step of 16 hours at 20 °C at the same pressure. Trehalose was used as a 
cryoprotectant at different concentrations (0, 2.5%, 5% and 10% w/v), while the 
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nanoparticle concentration was evaluated at 42% and 25% (v/v). After freeze drying, 
loaded nanoparticles were reconstituted with ultrapure water (0.1 ml) in order to analyze 
their particle size and PdI. The same freeze drying cycle was used to dehydrate the 
isolated formulations and determine the formulation process yield and the nanoparticle 
concentration by gravimetric analysis. 
 
2.8. Immunization studies 
The ability of nanoparticles to induce an antibody response against the 1338aa peptide 
was assessed in 6- to 8-week-old female BALB/c mice obtained from the National 
Cancer Institute (NCI), housed and handled under specific pathogen–free conditions in 
the animal care facilities at the NCI, Bethesda. Groups of 5 mice were randomly 
assigned and immunized intramuscularly (i.m) in the anterior thigh, with a first and 
second boost given 21 and 42 days after, respectively. The immunization dose of 
1338aa was 5 μg (0.05 ml). 
The control, alum-adsorbed antigen, was prepared according to the manufacturers 
specifications. Briefly, the Imject® Alum was agitated until complete homogenization 
of the dispersion and then it was added dropwise over a 1338aa solution in PBS, 
producing a final dispersion of alum salt and 1338aa at the concentration of 0.1 mg/ml. 
This dispersion was left under agitation for 1 hour at room temperature before 
administration. As an additional control, the same formulation without pIC (NP C) was 
used. 
The blood samples (0.2 ml) were collected by retro-orbital bleeding at 0, 3, 6 and 8 
weeks after the first vaccination. The animals were anesthetized (isofluorane 5% in 
oxygen vapor) before each immunization and blood sample collection. The blood 
samples were ultracentrifugated for 10 minutes at 14,926 RCF and then 0.05 ml of 
serum was collected. Serum IgG levels for 1338aa were determined for each sample by 
ELISA. For this purpose, Maxisorp® 96-wells were coated with 0.1 ml of the 1338aa 
peptide at 5 μg/ml in PBS and incubated overnight at 4 ºC. After washing with PBS, the 
wells were blocked with 0.2 ml of 5% bovine serum albumin in carbonate-bicarbonate 
buffer for 2 hours at 37 ºC. After washing again with PBS, 0.1 ml of the respective 
serum, diluted 1:50 in PBS with 2% FBS, was added and incubated 1 hour at 37 ºC. 
After new wash with PBS and 0.05% Tween 20, 0.1 ml of secondary antibody (goat 
anti-Mouse IgG (H+L) labeled with HPR) diluted 1:1000 in PBS with 1% FBS was 
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added to the wells, and left incubating for 1 hour at room temperature. Finally, the wells 
were washed again with PBS, and then the ABST substrate was added to the wells. 
After 40 minutes incubation, the absorbance was determined in a microplate reader (405 
nm, POLARstar OPTIMA, BMG-Labtech Gmbh, Germany). All the washing and 
blocking steps were done with an automated microplate washer (ELx405 Select Deep 
Well Microplate Washer, Biotek, USA). All serum samples were tested in duplicate.  
As positive control for the 1338aa peptide coating of the wells, HPV16 L2 peptide 17-
36aa rabbit antiserum was used in a dilution of 1:1000 [13], and as secondary antibody, 
an anti-rabbit IgG was used in a dilution of 1:2000. 
 
3. RESULTS AND DISCUSSION 
The objective of the present work was to design a nanocarrier, specifically adapted for 
the co-association of antigens and different kinds of immunostimulants. The final goal 
was to explore the synergistic effect of different adjuvant molecules assembled together 
in a nanostructure. With this idea in mind we chose three main components for the 
formation of the nanostructures: chitosan, known for its capacity to facilitate antigen 
presentation to the immune system when presented in a nanometric structure [6, 7], poly 
(I:C), a potent immunostimulant and a T-Helper peptide (PADRE). To assess the value 
of this nanocomposition, we selected a challenging HPV related peptide-based antigen 
(1338aa) (Figure 1). This peptide was either adsorbed onto the nanoparticles surface, or 
incorporated within the nanoparticle structure. Here we present the key aspects of the 
development and characterization of these new nanostructures and the results of an 
exploratory in vivo efficacy assay. 
 
3.1. Design and characterization of Chitosan-Poly (I:C) based nanoparticles  
The development process of the multicomponent nanocomposition consisted of several 
subsequent steps. The first step involved the encapsulation of poly (I:C) in CS based 
nanoparticles. Based on previous work from our group [26], we selected CS/TPP mass 
ratios of 4/1 and 8/1 for the formation of the nanoparticles. The TPP is an ionic cross-
linking agent that promotes the gelation of chitosan and facilitates the formation of well 
defined spherical nanoparticles. The CS/pIC mass ratio tested was 4/2, 4/1 and 4/0.4, 
which is equivalent to a pIC theoretical loading of 10, 25 and 50%, respectively, in 
relation to the total amount of CS used for particle preparation (Table 2). Simple 
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complexes of CS and pIC, without TPP, were also produced as previously described 
[24, 27]. These nanoparticles and nanocomplexes were expected to protect poly (I:C) 
from degradation [24, 28], and facilitate its delivery in the immune cells, where its 
receptor (TLR3) is located.  
 
Table 1. Physicochemical characteristics of the peptides 
Peptide  Amino acid sequence  MW  Purity   pI 
Charge at pH  
5.7 6.4 8.8 9.6 
 1338aa    ASAWQLYKTCKQAGTCPPDIIP 
  KVEGDDDDDD  
3411  95%  3.94  -4  -9  -6  -7  
PADRE    (D-Ala)K(Cha)VAAWTLKA(D-Ala)  
  DDDDDD  
1973  99%  3.85  -4  -4  -4  -5  
MW: Molecular weight as provided by manufacturer; (Cha): Cyclohexylalanine; (D-
Ala): D-Alanine; pI: Theoretical pI predicted by online software [25]; Charge at pH: 
Charge calculated according to the method described in Annex 2). 
 
The nanoparticles were formed spontaneously upon the addition of TPP and pIC to the 
CS phase. As shown in the Table 2, the CS/TPP/pIC mass ratio 4/1/1 and 4/1/2 (25% 
and 50% pIC loading, respectively) led either to the formation of aggregates or to highly 
polydisperse particles, as the P/N ratio was close to neutrality (1/1.13 and 1/0.95). The 
aggregation of the colloidal system at these mass ratios could result from the lack of 
inter-particular repulsive force due to the saturation of the CS amino groups. 
Accordingly, the CS/TPP/pIC 4/1/0.4 (correspondent to 10% pIC loading), presented a 
higher P/N ratio (1/0.85) and formed nanometric population of particles with low 
polydispersity.  
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Figure 1. Illustration of peptide-loading into nanoparticles either by encapsulation of 
both peptides to generate the formulation NP E2 (A), by adsorption of 1338aa or of 
1338aa and PADRE to generate the formulation NP A1 and NP A2, respectively (B). 
Representation of both peptides, divided in their active part (1338aa sequence and 
PADRE sequence) and its six aspartic acid segment designed to promote their 
interaction with the CS amino groups. 
 
At CS/TPP 8/1 mass ratio it was possible to obtain nanometric structures with greater 
proportion of pIC (higher pIC loading), possibly due to the greater number of available 
amino groups for interaction with the pIC and to avoid colloidal aggregation. 
Accordingly, an increase in the surface charge of the resulting particles was also 
observed with increasing P/N ratios. 
The complexes formed by ionic interaction of CS and pIC without TPP, presented a 
high PdI as compared with nanoparticles produced by ionic gelation of CS with TPP 
[24].  
A 
B 
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Table 2. Physicochemical characterization of Chitosan-Poly (I:C) nanoparticles at 
different mass ratios 
CS/TPP/pIC  P/N pIC (%)  Size (nm) PdI ζ (mV) 
Derived 
Count Rate 
       4/1/2      1/1.13 50     Aggr.  - - - 
       4/1/1      1/0.95 25    369 ± 27  0.5 +32 ± 3      108264 
       4/1/0.4      1/0.85 10    284 ± 15  0.2 +41 ± 1        46537 
       8/1/4      1/0.74 50    363 ± 14  0.3 +42 ± 2        64724 
       8/1/2      1/0.56 25    290 ± 25  0.2 +43 ± 5        24955 
       8/1/0.8      1/0.46 10    302 ± 23  0.2 +55 ± 3        10495 
       8/0/4      1/0.35 50    350 ± 24  0.3 +49 ± 1        49503 
       8/0/2      1/0.17 25    243 ± 8  0.3 +56 ± 1        19691 
       8/0/0.8      1/0.07 10    172 ± 5  0.2 +56 ± 1          6064 
CS/TPP/pIC mass ratio: Mass ratio between chitosan, TPP and poly (I:C); P/N charge 
ratio: Charge ratio between the amine groups of CS and the sum of the phosphate 
groups of TPP and pIC; pIC (%): Loading of poly (I:C) in particles in relation to the 
chitosan mass; PdI: Polydispersity Index; ζ: Zeta potential. (Means ± S.D., n=4).  
 
The entanglement of the pIC in the gelled matrix of CS and TPP may provide a better 
entrapment of the polynucleotides in comparison to the simple electrostatic interaction 
between CS and pIC, as observed previously for pDNA [24] and dsRNA [28]. Thus, the 
gelled nanostructure could be more adequate for preventing the premature release of 
pIC. This is a critical issue given the potential toxicity associated to the systemic release 
of pIC [29]. 
Among the CS/TPP/pIC mass ratios tested, those consisting of 4/1/0.4 and 8/1/2 led to 
the formation of nanoparticles with an acceptable size (<300 nm) and PdI (<0.3). On the 
other hand, the yield of the nanoparticles formation process was much higher for the 
ratio 4/1/0.4 than for 8/1/2 (yield of 77 and 47%, respectively). Therefore, the 
CS/TPP/pIC mass ratio 4/1/04 (from now on named NP B) was selected for further 
 147 
 
experiments. These nanoparticles, exhibited a spherical shape (Figure 2) and a high 
positive surface charge (+41 mV). This positive charge, which indicates that pIC was 
conveniently entrapped within the chitosan matrix, is an important feature for the 
subsequent adsorption of the anionic peptides 1338aa and PADRE and also to facilitate 
nanoparticle uptake by antigen presenting cells [30]. 
 
 
Figure 2. Morphology of Chitosan/TPP/Poly (I:C) nanoparticles (NP B) visualized by 
transmission electron microscopy. The scale bars correspond to 200 nm. 
 
3.2. Association and release of pIC from CS/TPP/pIC nanoparticles 
As determined by spectrophotometry, the association efficiency of pIC in the selected 
mass ratio composition CS/TPP/pIC 4/1/0.4 was close to 100%. This high pIC 
association efficiency was further confirmed by agarose gel electrophoresis. The 
migration patterns presented in Figure 3, show the absence of bands corresponding to 
free pIC in the nanoparticles suspending medium (obtained upon centrifugation of the 
suspension) (well 7) or in the nanoparticle suspension (well 8). This high efficiency is in 
agreement with previous work showing the high capacity of CS/TPP nanoparticles for 
the association of DNA and dsRNA [24, 28]. To verify if the pIC was firmly associated 
to the nanoparticles, the system was incubated with heparin, a strong polyanion that 
might compete for the CS amino groups and displace loosely attached polynucleotide 
material [27]. The results showed that after incubation with an excess of heparin (1.2 
mg/ml), only a small amount of pIC migrated (well 9), which illustrates the high affinity 
of pIC towards CS/TPP nanoparticles. This is an important result as it is known that the 
cell extracellular matrix contains polyanions similar to heparin that might favor the 
disassociation of polynucleotides [31]. In order to assess the stability of the pIC, the 
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nanoparticles were digested with chitosanase to facilitate the release of pIC, which was 
then evaluated by agarose gel electrophoresis. The results showed that the migration 
pattern of the released pIC molecules was the same as that of the control pIC. 
Consequently, it can be concluded that pIC was firmly associated to the nanoparticles 
and could be released in an appropriate manner as a result of the polymer degradation. 
These results are in agreement with those previously reported showing the capacity of 
chitosan/TPP nanoparticles to deliver DNA [24] and dsRNA to different cells [28], 
including macrophages [32]. However, from our knowledge, this is the first report 
disclosing the potential of chitosan nanoparticles for the association of pIC as a strategy 
for enhancing the immunogenic response to the associated antigens.  
 
 
Figure 3. Agarose gel assay on pIC release from NP B (Chitosan/TPP/Poly (I:C) 
without peptides): 1) DNA Ladder; 2) 8 μg pIC; 3) 4 μg pIC; 4) 2 μg pIC; 5) 1 μg pIC; 
6) 0.5 μg pIC in solution; 7) NP B Supernatant; 8) NP B Pellet; 9) NP B Pellet 
incubated with heparin; 10) NP B Pellet digested with chitosanase; 11) NP B Pellet 
freeze dried; 12) NP B Pellet freeze dried and incubated with heparin; 13) NP B Pellet 
Freeze dried incubated with chitosanase. 
 
3.3. Evaluation of the 1338aa and PADRE peptide association to CS/TPP/pIC 
nanoparticles 
The peptides 1338aa and PADRE were designed to incorporate HPV16 L2 neutralizing 
and T-helper amino acid sequences, respectively. In addition to these active sequences, 
a segment of six aspartic acid molecules was also incorporated at the C-terminus region 
of both peptides (Table 1). This segment was intended to work as an electrostatic 
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anchor for the positively charged chitosan molecules, thus leaving the active region of 
the peptide available for interaction with its specific receptors (Figure 1). As shown in 
Table 1, at the formulation pH (5.74) the peptides are expected to present a high 
negative charge, which would enable the electrostatic interaction with the positively 
charged nanoparticles (Table 2).  
Two different protocols were used for the association of the peptides to the 
nanoparticles in order to promote their localization, either inside (Protocol A) or on the 
surface of the nanoparticles (Protocol B) (Figure 1). The nanoparticles obtained, 
following both protocols, presented a nanometric size, a low pDI and a positive zeta-
potential (Table 3).  
 
Table 3. Physicochemical characteristics and loading efficiency of Chitosan/TPP/Poly 
(I:C) nanoparticles (Chitosan/pIC) loaded with 1338a and PADRE peptides 
Formulation    Code  
Size  
(nm) 
PdI  
ζ  
(mV) 
1338aa 
(%) 
PADRE 
(%) 
Chitosan/pIC without peptide 
(Blank)  
  NP B  284 ± 15  0.2 +41 ± 1 N/A N/A 
Chitosan/pIC-1338aa 
Adsorbed  
  NP A1 299 ± 23  0.2 +49 ± 5  39 ± 1 N/A 
Chitosan/pIC/PADRE-1338aa 
Adsorbed  
  NP A2 274 ± 9  0.2 +47 ± 5  50 ± 5 75 ± 13 
Chitosan/pIC/PADRE-1338aa 
Entrapped  
  NP E2 290 ± 28  0.2 +48 ± 4  67 ± 8 71 ± 3 
 
Chitosan/pIC-1338aa Adsorbed: Chitosan/TPP/Poly (I:C) nanoparticle with 1338aa 
adsorbed at surface; Chitosan/pIC/PADRE-1338aa Adsorbed: Chitosan/TPP/Poly (I:C) 
nanoparticle with PADRE and 1338aa adsorbed at surface; Chitosan/pIC/PADRE-
1338aa Entrapped: Chitosan/TPP/Poly (I:C) nanoparticle with PADRE and 1338aa 
encapsulated; Size: Particle size distribution; PdI: Polydispersity Index; ζ: Zeta 
potential; 1338aa (%): Percentage of peptide 1338aa associated to the nanoparticle; 
PADRE (%): Percentage of peptide PADRE associated to the nanoparticle. Loading 
values were obtained from the direct determination of the peptide released peptide after 
the digestion of the nanoparticles with chitosanase. (Means ± S.D., n=3). 
 150 
 
In both methods, the resulting peptide-loaded nanoparticles presented a positive surface 
charge, which in the case of the particles produced by the Protocol B indicates that their 
surface was not totally covered by the adsorbed peptide molecules. In Protocol A, the 
peptides were dissolved together with TPP and pIC and added to the CS phase to 
facilitate simultaneous 1338aa and PADRE entrapment within the nanoparticle matrix 
(loading efficiency of 67 and 71%, respectively) (Table 3). The basic pH of the 
TPP/pIC/peptides phase (pH 8.8) possibly increased the anionic character of the 
peptides (Table 1), thereby improving their interaction with CS. In Protocol B, the 
peptides were simply adsorbed onto the nanoparticle surface and, as expected, the 
antigen association efficiency was lower (39 – 50%) [33] although the PADRE 
association remained almost unaltered (75%). Interestingly, when the peptide 1338aa 
was adsorbed onto the nanoparticles in combination with the PADRE peptide, it had 
higher association than when added alone (50% and 39%, respectively) (Table 3). 
A possible cause for this could be that the combined solution of 1338aa and PADRE 
had a higher pH (9.6) than that of the 1338aa peptide alone (6.4). This could have 
increased the negative charge of 1338aa (Table 1) and, consequently, provide a more 
important interaction with the positively charged CS. The higher charge density of 
PADRE compared with 1338aa peptide (1 charge/3 amino acids and 1 charge/3.6 amino 
acids, respectively) could explain its overall higher association (loading efficiency of 
70-75% vs 50%-67%). By digesting the nanoparticles and analyzing the released 
peptides by UPLC, it was also possible to verify that both peptides maintained their 
stability upon association to the nanoparticles (Annex 3). The mild formulation 
conditions probably contributed to the stability observed both for the pIC and peptides 
associated to the nanoparticles. In addition, all the formulations maintained their 
physicochemical characteristics for at least one year at 4 ºC (Figure 4).  
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Figure 4. Particle size distribution (Size) and polydispersity index (PdI) after 1 year 
storage at 4 ºC in suspension of nanoparticles without peptides (NP B), nanoparticles 
with 1338a adsorbed at surface (NP A1), with 1338aa and PADRE adsorbed at surface 
(NP A2) and both peptides entrapped in the matrix (NP E). 
 
3.4. Freeze-drying of CS/TPP/pIC nanoparticles  
In general, the dehydration of the nanoparticle formulations helps preventing particle 
aggregation and degradation [34]. For this reason, the feasibility of freeze-drying the 
CS/TPP/pIC nanoparticles was explored. For this, trehalose was chosen as a 
cryoprotectant [34] and the influence of the formulation concentration (42 and 25% 
(v/v)) and the trehalose concentration (10, 5 and 1% (w/v)) in the resuspension of the 
dried formulation was studied. The resulting powder cakes were resuspended with 0.1 
ml of ultrapure water to provide for a final antigen concentration of 0.1 mg/ml. A 42% 
(v/v) nanoparticle concentration at 5% trehalose (w/v) generated an adequate cake, 
which could be easily resuspended. The resuspended particles presented only a modest 
variation in size, PdI and zeta-potential (between 10-15%), as shown in Annex 4. An 
additional positive effect of the developed freeze-drying method is that due to the final 
trehalose concentration (12%), the resuspended solution was close to isotonic.  
The stability of the pIC associated to the freeze-dried nanoparticles upon one week 
storage at room temperature was analyzed by agarose gel electrophoresis (Figure 3). 
Similar to the fresh particles, the absence of the free pIC band in the gel (well 12) 
indicates that the pIC remains firmly attached to the particle after the freeze-drying 
(well 11) even after incubation with heparin at 37 ºC (well 12). Furthermore, upon 
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digestion of the nanoparticle with chitosanase, the pIC band became visible with a 
migration pattern and intensity (well 13) similar to those of the control (well 2). This 
indicates that these nanoparticles can effectively protect the pIC from degradation 
during freeze-drying and upon storage in a dry powder form. After confirming the 
suitability of the freeze drying procedure for the pIC-containing nanoparticles, the 
peptide-loaded CS/TPP/pIC formulations were freeze-dried in the same conditions. The 
results showed that these formulations also preserved their physicochemical 
characteristics after resuspension, with only minor variation in size and zeta-potential 
(Figure 5). 
 
 
 
Figure 5. Physicochemical evaluation of nanoparticles without peptides (NP B), 
nanoparticles with 1338a adsorbed at surface (NP A1), with 1338aa and PADRE 
adsorbed at surface (NP A2) and both peptides entrapped in the matrix (NP E) after 
freeze drying and resuspension operation. Size: Size of the formulation before Freeze-
Drying; Size F: Size after Freeze-Drying; PdI: Polydispersity of formulation before 
Freeze-Drying; PdI F: PdI after Freeze-Drying; ζ: Zeta-potential of formulation before 
Freeze-Drying; ζ F: Zeta-potential after Freeze-Drying.  
 B 
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3.5. Immunization studies  
A preliminary vaccination study was conducted to evaluate the influence of the different 
components and their organization on the ability of the nanoparticle to generate a 
humoral immune response. The formulations selected, presenting different 1338aa and 
PADRE arrangements, were: nanoparticles with the peptide 1338aa alone adsorbed at 
the surface (NP A1), with the peptide 1338aa and PADRE both adsorbed at the surface 
(NP A2) and the nanoparticles with both peptides encapsulated (NP E2). These 
formulations and also three controls, the alum-adsorbed antigen, nanoparticles without 
peptides (NP B) and nanoparticles with peptides but without pIC (NP C), were 
administered to mice by the intramuscular route and the IgG response was monitored 
for up to 8 weeks (Figure 6). 
 
 
 
Figure 6. 1338aa peptide-specific IgG responses in diluted serum (1/50) of mice 
immunized with different formulations by intramuscular route. NP B: 
Chitosan/TPP/Poly (I:C) nanoparticles without peptides; NP C: Chitosan/TPP 
nanoparticles with 1338aa and PADRE adsorbed on their surface; NP A1: 
Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa adsorbed on their surface; NP A2: 
Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa and PADRE adsorbed on their 
surface; NP E: Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa and PADRE 
encapsulated. (Number / 5): responsive mice in the total 5 mice per group.  O.D. 4 
times higher than those of the control NP B (0.2) was considered a positive response.  
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The O.D. values for IgG shown in Figure 6 indicate that alum was unable to enhance 
the immune response against the 1338aa peptide. On the other hand, peptide-loaded CS 
nanoparticles without pIC, known for their capacity to increase IgG responses against 
various protein antigens [6, 7, 35-37], failed to generate peptide-specific IgG responses. 
These results underline the difficulty in generating an immune response against poorly 
immunogenic peptides. With regard to the behavior of the formulation adjuvanted with 
either pIC, PADRE or both, the results were variable, exhibiting from 1 to 3 responding 
animals out of 5 immunized mice. Among the formulations tested, the composition 
containing both pIC and PADRE was capable of generating significant IgG levels in 3 
out of 5 mice. These results suggest that both T helper and immunostimulant signals are 
required in order to achieve satisfactory antibody responses. In addition, the display of 
the peptide on the nanoparticle surface also appears to be critical. Indeed, the number of 
responding mice was greater when both components, pIC and PADRE, were adsorbed 
rather than entrapped.  
The HPV L2 epitope 17-36aa [13], present in the peptide 1338aa, has already been 
tested in mice [38] although at an higher antigen dose (40 g). In this study it was 
observed that the Freund`s adjuvant was unable to stimulate an effective immune 
response against this peptide, thus confirming the low immunogenicity of this antigen. 
However, the conjugation of this peptide to other T Helper peptide (P25) and to the 
immunostimulant Pam2Cys (a TLR2 agonist), resulted very effective in terms of IgG 
responses. From the comparison of these previous data with those obtained in the 
current study, we could formulate different hypotheses. First, there is the possibility that 
either the antigen (17-36aa) or the immunostimulants (P25 and Pam2Cys), or their 
combination were more appropriate for enhancing the immune response. In this sense, it 
is important to keep in mind that, although sharing the same epitope, the peptide 1338aa 
presents a longer amino acid chain and an additional six aspartic segment in the C-
terminus region, which could potentially lead to a different processing and presentation 
by the immune cells [3]. A second hypothesis could be that the conjugation to the T 
helper peptide to the peptide antigen facilitates its presentation to the immune system.  
The poor immunogenicity of peptide-based antigens has been associated, among other 
factors, to their inability to establish a highly repetitive epitope pattern, which results in 
a limited recognition by the APCs [39]. Based on this, the adsorption of the peptide 
1338aa onto the surface of the nanoparticles was supposed to adequately display the 
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required epitope patterns repeatedly in a nanometric structure, resembling a virus. This 
hypothesis was partially confirmed by the higher response elicited by the prototypes 
with adsorbed antigen (NP A2), as compared to the prototypes entrapping the same (NP 
E2). However, the possibility to further improve the presentation of the peptide epitopes 
cannot be discarded. As the epitope region of the peptide was connected directly with 
the six aspartic segment used for adsorption to the nanoparticle, it is possible that part of 
the active region got embedded in the nanoparticle matrix hindering its recognition by 
immune cells. The addition of a generic peptide spacer between the particle binding 
motif and the target peptide could avoid this possibility and provide for a more efficient 
presentation of the target peptide to B cells. Furthermore, while CS/TPP nanoparticles 
have demonstrated capacity for sustained release of proteins [7, 33], the release profile 
with these peptides has not been studied and should be explored in detail in further 
studies. On the other hand, according to the data presented, and in agreement with 
previous studies [24, 40], the pIC is firmly associated to the nanoparticles and its release 
may take longer than expected. As indicated previously, the introduction of pIC into the 
nanoparticles was expected to potentiate DC maturation [14] under the assumption that 
it would be released in endocytic vesicles along with the bound peptides. It has already 
been observed that for an optimal immune response with pIC, it is important that its 
delivery occurs simultaneously with the antigen of interest [41].  
Therefore, this study provides an overall illustration of the potential of peptide-based 
antigens in conjunction with immunostimulatory molecules and it also provides insights 
into the complexity of the engineering process. Probably, a large array of different 
peptide and immunostimulant combinations should be performed according to their 
structural organization and size in order to assess the value of nanotechnology in the 
design of novel peptide-based nanovaccines.  
 
4. CONCLUSIONS 
Here we report for the first time, a chitosan nanostructure designed to co-deliver a 
TLR3 agonist (Poly (I:C)) and a T-helper peptide peptide (PADRE) and function as 
adjuvant system for a HPV-derived peptide antigen (1338aa). These nanoparticles are 
produced by ionic gelation, a mild and gentle method which permits, by a subtle 
modification of the formulation procedure, either the encapsulation or the adsorption of 
the target peptides. The capacity of combining different materials (polysaccharides, 
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polynucleotides and polyamino acids) in the form of nanoparticles, and the possibility to 
freeze-dry them highlights the versatility of this system and opens the possibility of 
integrating other immune stimulants. The capacity of inducing an immune response 
towards this particularly poor immunogenic antigen 1338aa is in contrast to the low 
efficacy observed in the same study for alum salts. In conclusion, the preliminary data 
presented here shows the potential of these new prototypes as vaccine adjuvants for the 
delivery of peptide-based antigens.  
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Annex 1. UPLC conditions and peptide retention times 
 
1338aa in dig.: 1338aa dissolved in Chitosan/TPP/Poly (I:C) nanoparticle digested 
matrix; PADRE in dig.: PADRE dissolved in Chitosan/TPP/Poly (I:C) nanoparticle 
digested matrix. 
 
 
Annex 2. Calculation of the peptides charge at specific pH 
Calculation was realized with the following equation: 
 
In which Z represents the Net charge of the peptide sequence, Ni the number of 
arginine, lysine and histidine residues and the N-terminus, and pKai, their pKa. The Nj 
represents the number of aspartic acid, glutamic acid, cysteine and tyrosine residues and 
C-terminus, and the pKaj, their pKa. 
Note: In both predictions, the non-standard residue ciclohexylalanine had to be ignored 
and the D-Alanine was replaced by the L-Alanine for calculation purposes which 
increases the error. However both amino acids are neutral so the influence in the pI and 
charge according pH should be negligible. In the other hand the aspartic tail should 
always be quite dominant in terms of peptide charge properties. 
 
 
 
 
(b) 
(a) 
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Annex 3. Comparison between UPLC peaks from digested blank nanoparticles and 
peptide-loaded nanoparticles, and the free PADRE and 1338aa peptides in digested 
nanoparticle matrix. 
 
 
Comparison between UPLC peaks of digested peptide-loaded nanoparticles (A: 
encapsulated B: surface adsorbed) with blank nanoparticles (C) and with free PADRE 
and 1338aa peptides in digested nanoparticle matrix as controls (D); *: Peaks from 
residues of digested nanoparticles; **: Peak from PADRE peptide; ***: Peak from 
1338aa peptide. 
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Annex 4. Optimization of freeze drying conditions with CS/TPP/pIC nanoparticles 
NP B Vol. (ml)  [NP B] (v/v)% [Tre] (w/v)% Size (nm)  PdI  
0.1 25 5  294 ± 8  0.2  
  
2.5  332 ± 19  0.3  
  
1  437 ± 47  0.5  
 
42 10  320 ± 20  0.2  
  
5  322 ± 4  0.2  
  
2.5  363 ± 53  0.3  
 
NP B Vol.: Initial volume of CS/TPP/pIC nanoparticle in the freeze-drying assay; [NP 
B] (v/v) %: Nanoparticle concentration; [Tre] (v/v) %: Initial trehalose concentration 
(Means ± S.D., n=3). 
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ABSTRACT 
 
The clinical use of safe and effective nanoemulsions (AS03 and MF59®), as vaccine 
adjuvants has shown the potential of lipid materials in the formulation of adjuvant 
systems. Based on this evidence, the objective of this work has been to engineer 
nanostructures combining a number of lipid materials presenting immunostimulant 
properties, with the polysaccharide chitosan, and to explore their potential vaccine 
adjuvanticity. Thus, using Lysophosphatidylcholine (LS), Linoleic Acid (LA) and 
Squalene (SQ), we designed two nanoemulsions (LA:LS and SQ:LA:LS) and by 
combining with Chitosan (CS), two nanocapsules (LA:LS:CS and SQ:LA:LS:CS). The 
prototypes were produced by the solvent displacement technique and exhibited a 
nanometric size (< 200 nm) and, either a positive (between +39 and +37 mV) or a 
negative (between -28 and -36 mV) surface charge, depending on the presence of CS in 
the formulation. The SQ-containing formulations showed the best stability profile upon 
storage (stable for 3 months at 4 ºC and 1 month at room temperature) and also upon 
incubation in physiological simulated media (stable for 24 hours in DMEM and RPMI 
with FBS). The formulations were evaluated for complement activation (all active it 
except LA:LS), cytotoxicity (IC50 between 16 and 47 μg/ml), cytokines production (IL-
8 increased release) and Reactive Oxygen Species (ROS) production (increased ROS 
levels). Due to their higher stability and IC50, the SQ-containing formulations were 
chosen for a preliminary association assay with three different peptide antigen models 
(association between 7 - 45%). The formulations were found to have a low IC50 and 
low antigen association and need to be further optimized in order to form an adequate 
vaccine adjuvant.  
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1. INTRODUCTION 
 
Vaccination is considered, nowadays, the most cost-effectiveness public health 
intervention [1]. The progressive refinement of antigens, regarding their precision and 
purity, has raised the need of innovative adjuvants that may compensate for their lack of 
danger signals [2]. In particular, the recent development of synthetic peptide-based 
antigens, aimed at targeting specific epitopes of the pathogens [3], has prompted the 
research oriented to the design of novel vaccine adjuvants. 
Recently, the nanoemulsion-based adjuvants named as AS03 and MF59®, have proven 
to be superior than the widely established alum salts [4, 5] for some specific antigens 
such as influenza (Pandemrix and Focetria) [6]. These formulations are known to 
provoke the recruitment of leukocytes to the adjuvant region and their activation [7, 8], 
a fact that could be associated to the emission of danger signals by specific components 
of the formulation, but also to their nanometric size [9, 10].  
Based on this knowledge, we have assumed that it is possible to engineer nano-
emulsions with robust adjuvant properties and an acceptable toxicity profile. With this 
idea in mind, we have selected lysophosphatidylcholine (LS) as a surfactant [11] for the 
formulation of nanoemulsions containing oils, such as linoleic acid (LA) and squalene 
(SQ), all of them known for their adjuvant properties.  
Indeed, LS is an endogenous lysophospholipid produced by the hydrolysis of the 
phosphatidylcholine of the cell membranes (Annex 1) and exhibits a specific 
immunostimulant behavior [12]. It is recognized as an endogenous danger signal 
released by cells during infection or trauma [13]. It is also known to work as a 
chemoattractant for T cells [14, 15], monocytes [16, 17] and professional phagocytes 
[12, 17, 18]. These chemotactic properties have been already confirmed following 
intracutaneous administration in humans [19]. Furthermore, LS has been shown to 
activate lymphocytes [20-22] and monocytes [23] promoting their differentiation in 
dendritic cells [24] and their subsequent maturation [25], as well as stimulate the 
antibody production by B cells [21]. Some authors have already proposed to take 
advantage of LS immunostimulant properties and used it as a simple mixture with the 
antigen model hen egg lysozyme (HEL). The results, after subcutaneous administration 
to mice, indicated that LS has adjuvant properties comparable to those of alum salts in 
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terms of humoral response (IgG) [13]. Other authors have also reported the absorption 
enhancing capacity of LS following its co-administration with proteins by the nasal 
route [26].  
With regard to the oils selected to formulate the nanoemulsions, linoleic acid (LA) is an 
unsaturated lipid (18:2(n-6)) that it is present in emulsions for parenteral nutrition [27, 
28]. It has been reported to act as a chemoattractant [29, 30], a promoter of neutrophiles 
activation [28, 30, 31] and an activator of the Nuclear factor-kappa B (NF-kB) [32], 
which is involved in the stimulation of both the innate and adaptive immune response 
[33]. On the other hand, squalene is a triterpene oil already used in MF59 and AS03 
[34]. Due to its highly hydrophobic nature, squalene was selected to act as a reservoir 
for the slow release of lysophosphatidylcholine and linoleic acid, thus potentially 
reducing their toxicity and improving their presentation to the immune system [35, 36].  
The above indicated nanoemulsions were also coated with Chitosan (CS), with the final 
purpose of increasing the nanoemulsion intranasal adjuvant capability. Indeed, CS is a 
positively charged and biodegradable polysaccharide [37] that exhibits mucoadhesive 
properties [38]. In fact, in previous works from our group, we have found the possibility 
to enhance the immune response of the recombinant hepatitis B virus surface antigen 
(rHBsAg) administered intranasally upon its association to CS nanocapsules [39].  
Taking this into account, the objective of this work could be summarized as the rational 
design of nanometric adjuvants consisting of oils, surfactants and chitosan. Two 
nanoemulsions (containing LA and LS and with or without SQ) and two CS 
nanocapsules formulations (containing LA and LS and with or without SQ) were 
developed and evaluated in terms of: (i) stability in simulated physiological mediums 
and storage conditions; (ii) in vitro toxicity; (iii) capacity to stimulate the production of 
proinflammatory cytokines and reactive oxygen species (ROS) by immune cells; (iv) 
ability to activate the complement in plasma; (v) capability to associate peptide-based 
antigens. 
 
 
 
 
2. MATERIALS AND METHODS 
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2.1. Materials 
Ultrapure CS hydrochloride salt, with a molecular weight of 50 - 150 kDa and a 
deacetylation degree of 75 - 90% (Protasan UP Cl 113), was purchased from 
Novamatrix (Norway). The deacetylation degree of the CS used was confirmed by 
elemental analysis to be of 75 ± 2%.  
Synthetic Lysophosphatidylcholine (LS) 18:0 (1-stearoyl-2-hydroxy-sn-glycero-3-
phosphocholine) (Purity >99%; MW: 523.7; CMC: 4 μM) was obtained from Avanti 
Polar Lipids (Alabama, USA). 
Linoleic acid (LA) (L1376), Trehalose (D-(+)-Trehalose dehydrate) and TFA 
( rifluoroacetic acid ≥99%), were obtained from Sigma–Aldrich (Madrid, Spain).  
Squalene (SQ) was purchased from Merck KGaA (Darmstadt, Germany). 
DMEM (Dulbecco's Modified Eagle Medium) and RPMI (Roswell Park Memorial 
Institute medium) and FBS (Fetal Bovine Serum) were purchased to Life Technologies 
Corporation (CA, USA). Acetonitrile (Supragradient HPLC) and Ethanol was purchased 
from Scharlab (Barcelona, Spain). Water HPLC Gradient was purchased from Fisher 
Chemical (Thermo Fisher Scientific, USA). 
 
2.2. Preparation of nanoemulsions and nanocapsules  
Two nanoemulsions (LA:LS and SQ:LA:LS) and two nanocapsule formulations 
(LA:LS:CS and SQ:LA:LS:CS) were prepared by solvent displacement technique. For 
the LA:LS and LA:LS:CS, an organic phase composed of LA and LS (10 and 2 mg/ml, 
respectively) in 2 ml of ethanol was poured over 10 ml of ultrapure water containing CS 
(0.2 mg/ml) or not, under magnetic stirring. Formulations composed of SQ:LA:LS and 
SQ:LA:LS:CS, were prepared using the same procedure but with a organic phase 
composed of SQ, LA and LS (5, 2 and 2 mg/ml, respectively) in 2 ml of ethanol and the 
aqueous phase was 10 ml of ultrapure water or CS aqueous solution (0.1 mg/ml), 
respectively. The stirring was maintained for 5 minutes and then the ethanol was 
removed by evaporation under vacuum (Büchi Labortechnik AG, Flawil, Switzerland) 
to a final volume of 5 ml. Finally, the nanoemulsions and nanocapsules were isolated by 
ultracentrifugation at 61.740 g for 1 h, at 15 ºC in an Ultracentrifuge Optima L90 K 
with rotor Beckman Type 70.1 Ti (Beckman Coulter, CA, USA). The lipid phase 
recovered (1 ml) was then diluted in ultrapure water and characterized. 
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To determine the nanoparticles concentration, 0.5 ml of the lipid phase obtained after 
ultracentrifugation, was dehydrated in a lyophilizer VirTis Genesis 25L (Model SQ EL-
85, SP Scientific, Pennsylvania, USA) using a freeze drying cycle. In resume, the 
samples were frozen overnight in a -20 °C freezer and then transferred to the 
lyophilizer. In here, it were submitted to an initial drying step for 24 h at -35 °C at 2-10 
millitorr (mtorr) followed by a secondary drying for another 24 h at 0 °C and finally a 
third step of 16 hours at 20 °C at the same pressure. After the dehydration, the 
formulation was weighted and the concentration calculated. 
 
2.3. Physicochemical characterization 
The particle size distribution and polydispersity index (PdI) of the formulations were 
evaluated by Dynamic Light Scattering (DLS) and its surface charge (zeta potential) by 
Electrophoretic Light Scattering (ELS) using a Zetasizer Nano ZS90 (Malvern 
Instruments, UK). Each analysis was performed in triplicate at 25 ºC with a detection 
angle of 173º, after a ten-fold dilution of the isolated formulation in distilled water. 
The morphological characterization of the particles was performed with transmission 
electronic microscopy (TEM) (Philips CM 12, Eindhoven, Netherlands). Briefly, the 
samples were placed on copper grids with Formvar films and then stained with 2% 
(w/v) phosphotungstic acid solution. Afterwards, the grids were left overnight in an 
oven at 60 ºC to dry and then they were observed with TEM. 
The pH was determined with a Sartorius Docu-pH Benchtop Meters (ThermoFisher 
Scientific, USA). 
 
2.4. Nanoemulsions and nanocapsules stability 
2.4.1. Stability during storage as an aqueous suspension  
The blank nanoemulsions and nanocapsules were diluted a ten-fold in ultrapure water, 
stored at 4 ºC and then the size and surface charge were evaluated after 1, 3 and 6 
months. These formulations were also stored at room temperature (RT) at the same 
dilution for up to one month, after which, the size and surface charge were evaluated.  
2.4.2. Stability upon dispersion in simulated biological medium 
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The blank nanoemulsions and nanocapsules were diluted ten-fold in two different 
simulated physiological mediums, namely DMEM and RPMI supplemented with 10% 
FBS, and their size was monitored for up to 24 hours at 37 ºC. 
 
2.5. Freeze drying studies 
The capacity of the formulations to be freeze-dried and recover its initial characteristics 
after reconstitution, was assessed using trehalose as cryoprotectant at different (w/v) 
concentrations (5%, 2.5% and 0%) and using the same freeze drying cycle protocol 
described in 2.2. The nanoemulsions and nanocapsules suspensions were diluted a ten-
fold in the trehalose solution at a final volume of 0.8 ml. After freeze drying, the 
nanoparticles were reconstituted with ultrapure water (0.8 ml) and the particle size and 
PdI were analyzed. 
 
2. 6. Analysis of complement activation 
The formulations ability to activate the complement cascade was studied through the 
evaluation of the hydrolysis of the C3 complement factor by Western-blot. A pool of 
human plasma from healthy donors was incubated with three different concentrations 
(10, 100 and 1000 μg/ml) of the formulations in the presence of a veronal buffer (pH 
7.4). Equal volumes of plasma, buffer and formulation (50 μl each) were mixed together 
and incubated at 37 °C for 1 h. Cobra venom factor (CVF) (Quidel Corporation; San 
Diego, CA) and PBS were used as positive and negative controls, respectively. After 
incubation, the mixture was centrifuged at 16,000×g for 30 min. Supernatants 
containing complement proteins were loaded (2 μl) onto a 10% SDS-PAGE gel and 
then transferred to a PVDF membrane (Immun-Blot, Bio-Rad; Hercules, CA) using the 
Transblot Semidry Transfer Equipment (Bio-Rad; Hercules, CA). PVDF membranes 
were blocked overnight at 4 °C with 5% non-fat dry milk in TBST. Then the membrane 
was washed and incubated for 90 min at RT with a mouse mAb against human C3 
dilute 1:1000. After intensive washes, membranes were incubated with secondary 
polyclonal goat anti-mouse IgG Abs conjugated with alkaline phosphatase diluted 
1:2000 at RT for 1 h. The membrane was finally revealed with BCIP. 
 
2.7. In vitro studies 
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2.7.1. Cells and culture 
The adherent RAW 264.7 murine macrophage and the human promyeloblast cell line 
HL60 were purchased from ATCC (Manassas, VA). The cells were cultured in RPMI 
supplemented with 10% (v/v) heated-inactivated fetal bovine serum (FBS) (PAA; 
Pasching, Austria), 2 mM glutamine and 100 U/ml of penicillin/streptomycin (hereafter 
called complete medium), at 37 °C in 5% CO2 atmosphere. Cells were split every day to 
maintain 70–80% confluent cultures. 
The human peripheral blood mononuclear cells (PBMCs) were obtained from three 
healthy donors (the project was approved by the Clinical Research Ethical Committee 
of Galicia 2013/272, and written informed consent for participation in the study was 
obtained from the donors). Briefly, 15 ml of heparinized blood were diluted with equal 
volume of PBS and centrifuged through a Ficoll-Hypaque gradient in a relation 7:3 
(Blood diluted:ficoll) at 1600 rpm for 30 minutes at 20 ºC, in order to separate 
mononuclear leukocyte, granulocyte and eritrocyte. The mononuclear cells in the 
interface between Ficoll and plasma were collected with a Pasteur pipette and wash 
twice with complete medium by centrifugation at 1200 rpm for 5 minutes at 20 ºC. 
 
2.7.2. Citotoxicity evaluation: xCELLigence® system  
The cytotoxicity of the formulations was evaluated by the xCELLingence® RTCA DP 
(Roche Diagnostics; Penzberg, Germany), following the manufacturer's instructions. 
This instrument measures the variations of impedance caused by cell growth when cells 
are incubated on plates containing electrodes. The xCELLigence® device was placed 
inside the incubator (37 °C and 5% CO2) and 1.5 × 10
4
 RAW 264.7 cells per well were 
incubated with 200 μl RPMI 10% FBS for 20-23 h until the exponential phase was 
reached. At that point, nanocapsules and nanoemulsions were added at six different 
concentrations (250, 125, 62.5, 31.25, 15.63 and 7.81 μg/ml) and incubated for 48 h at 
37 ºC. The culture medium and the formulations alone (without cells) were used as 
negative controls. Continuous monitoring of impedance (that is correlated with cell 
viability) was performed during the whole procedure with intervals of 15 min between 
each impedance measurement. 
2.7.3. Cytokine production: FlowCytomix™ system 
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The cytokine production was evaluated by flow cytometry (FC500, Beckman-Coulter, 
FL, USA), with a Human Th1/Th2 11plex FlowCytomix™ Multiplex Kit (eBioscience, 
Vienna, Austria), following manufacturer instructions. 
 he formulations were incubated at the concentration of 10 and 100 μg/ml, in 1 × 105 of 
PBMC, for 24 hours at 37 ºC. As positive control it was used the phytohaemagglutinin 
(PHA) plus the lipopolysaccharide (LPS) (InvivoGen, San Diego, CA) to activate both 
B cells and T cells, respectively. As negative control it was used the culture medium. 
Two independent experiments, each one in duplicate, were performed for each of the 
samples tested. 
 
2.7.4. Reactive Oxygen Species (ROS) production 
The formulations effect in the intracellular ROS production was evaluated by measuring 
the oxidation of 2’,7-dichlorofluorescein diacetate (DCFH-DA). This marker can be 
oxidized by ROS and converted to the fluorescent compound. In resume, the 
formulations were incubated at 10 and 100 μg/ml concentration, in 1x105 HL60 cells in 
96 well plates, during 1 and 12 hours at 37 ºC. After the incubation, cells were collected 
and centrifuged at 100 g for 5 minutes, resuspended in PBS containing 5 μM of DCFH-
DA and then incubated at 37 ºC during 30 minutes. Finally, cells were washed twice 
with PBS and analysed by flow cytometry. The Mean Fluorescence Intensity (MFI) was 
normalized to negative control. As positive control it was used 10 µM of phorbol 12-
myristate 13-acetate (PMA). As negative control it was used complete medium. 
 
2.8. Peptide-based antigen loading 
To evaluate the capacity of the nanoemulsion SQ:LA:LS and nanocapsule 
SQ:LA:LS:CS to associate peptide-based antigens, three model peptide-based antigens 
from the simian immunodeficiency virus (SIV) (68-4, 69-2 and 69-4), with different 
physicochemical properties (Table 1), were associated to the formulations. In brief, an 
aliquot (0.005 ml) of the peptide solution (10 mg/ml) was poured over an aliquot (0.095 
ml) of the isolated formulation to obtain a final concentration of 0.5 mg/ml antigen 
(with a theoretical loading of 3.5% and 3.3% for SQ:LA:LS and SQ:LA:LS:CS, 
respectively). The resulting dispersions were incubated for up to two hours under 
agitation at 300 rpm in a plate agitator at room temperature (RT). Afterwards, the 
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physicochemical properties of the loaded formulations were evaluated and the peptide 
association efficiency was determined. A preliminary stability test at room temperature 
for one week was also realized with the loaded formulations.  
 
2.9. Determination of peptide association efficiency (PA)  
The peptide association (PA) was evaluated through the determination of the free 
peptide in solution (indirect measurement) (IPA) and the released peptide after particle 
disruption (direct measurement) (DPA). The loaded formulation nanoparticles were 
isolated using  Amicon Ultra-0.5 mL Centrifugal Filters 30 kDa (Merck Millipore, 
USA) by ultracentrifugation at 10,000 g for 10 minutes at 15 ºC in a Universal 32 
centrifuge (Hettich, Tuttlingen, Germany). The filtrate (about 0.3 ml) was recovered for 
the determination of the free peptide. The nanoparticles retained in the filter were 
recovered with 2 cycles of reverse centrifugation of 30 seconds in a microcentrifuge. To 
disrupt the nanoemulsion and nanocapsule, the formulation was diluted a ten-fold in an 
ACN 100% solution and then incubated one hour under agitation (300 rpm) in a plate 
agitator at room temperature. 
The peptide concentration was determined by Ultra Performance Liquid 
Chromatography (UPLC), using standard curves of the peptides in the two media 
depending if realizing direct (nanoparticles degraded matrix) or indirect evaluation 
(nanoparticles suspending medium). The UPLC analysis was performed on an Acquity 
H-UPLC Class system with a Tunable UV (TUV) detector equipped with an Acquity 
UPLC BEH C18 1.7 μm 130 Å 2.1 x 100 mm Column (Waters Corporation, Milford 
Massachusetts, USA ). The mobile Phase A consisted of 0.1% TFA (v/v) in HPLC 
gradient water and the Phase B of 0.1% TFA (v/v) in HPLC gradient ACN. The 
chromatography conditions are described in the Annex 3.  
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3. RESULTS AND DISCUSSION 
 
The main objective of the present work was to design nanosystems, constituted by 
Lysophosphatidylcholine (LS), Linoleic Acid (LA) and Squalene (SQ), as vaccine 
adjuvant systems for peptide based antigens. These components were selected because 
of their chemotactic (LS and LA) and immunostimulant properties (LS) and the 
possibility to synergize these properties by combining them in the form of 
nanoemulsions. Based on previous work from our group [40], Chitosan (CS) 
nanocapsules derived from these nanoemulsions were also developed to be used for 
intranasal administration. Hence, two nanoemulsion prototypes (LA:LS and SQ:LA:LS) 
and two CS nanocapsule prototypes (LA:LS:CS and SQ:LA:LS:CS) were prepared by 
solvent displacement technique (Figure 1) and characterized in terms of 
physicochemical characteristics (size, surface charge and pH), stability in storage 
conditions (4 ºC and RT) and in simulated physiological mediums (DMEM and RPMI 
w/FBS). Additionally, the systems were characterized for their capacity to initiate the 
complement and stimulate the production of cytokines and ROS, as well as their 
cytotoxicity. Finally, the capacity of the SQ-containing formulations to associate 
peptide antigens was also evaluated. 
 
Table 1. Model peptide antigens molecular weight (MW) and estimated isoelectric 
point (pI), charge at pH 4 (Charge at pH 4) and grand average of hydropathy (GRAVY).  
 
MW, pI and GRAVY were calculated with online software [41]. * The calculation of the 
charge at pH 4 is shown in the Annex 2.  
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Figure 1. Representation of the LA:LS (A), LA:LS:CS (B), SQ:LA:LS (C) and 
SQ:LA:LS:CS (D) formulations based on Lysophosphatidylcholine (LS), Linoleic Acid 
(LA), Squalene (SQ) and Chitosan (CS) with indication of particle size distribution 
values determined by DLS and surface charge by ELS. 
 
3.1. Physicochemical characterization of blank nanoemulsions and nanocapsules 
From the rational combination of the mention components it was possible to form four 
different nanometric systems through the solvent displacement technique. Accordingly, 
both the linoleic  acid:lysophosphatidylcholine (LA:LS) and squalene:linoleic  
acid:lysophosphatidylcholine (SQ:LA:LS)  nanoemulsions, as well as the nanocapsules 
linoleic acid:lysophosphatidylcholine:chitosan (LA:LS:CS) and squalene:linoleic  
acid:lysophosphatidylcholine:chitosan (SQ:LA:LS:CS),  presented a nanometric size (< 
200 nm) and small PdI (Table 2). The particles without CS had a negative surface 
charge probably due to the negatively charged LA (pKa = 4.77 [42]). The pKa of LA 
also helps explains the low pH of the formulation (< 5).  
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Table 2. Physicochemical characterization of the formulations  
 
Ratio: mass ratio (w/w), PdI: Polydispersity Index, ζ: surface charge; Conc.: particle 
concentration (mg/ml).  
 
Their nanometric size and round shape of the developed nanosystems was further 
confirmed by TEM evaluation (Figure 2).  
 
 
Figure 2. TEM images showing the morphology of LA:LS (A1 & A2), LA:LS:CS (B1 & 
B2), SQ:LA:LS (C1 & C2) and SQ:LA:LS:CS formulations (D1 & D2). In all cases the 
scale bar is of 200 nm 
 
3.2. Stability of the nanoemulsions and nanocapsules 
3.2.1. Stability in supplemented DMEM and RPMI with FBS 
The SQ:LA:LS and SQ:LA:LS:CS maintained their nanometric size and PdI in DMEM 
(Figure 3A) and RPMI with FBS (Figure 3B) for up to 24 hours, while the LA:LS and 
LA:LS:CS aggregated soon after their dilution in the mediums. The SQ-containing 
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formulations seem to resist better in these mediums which indicates that SQ is 
contributing for the stability of the systems in these conditions. 
 
 
Figure 3. Evaluation of particle size distribution values (Size) and Polydispersity Index 
(PdI) over time in DMEM (A) and RPMI with FBS (B) of SQ:LA:LS and SQ:LA:LS:CS 
formulations. 
 
3.2.2. Stability in aqueous suspension 
All formulations maintained their nanometric size for up to three months at 4 ºC (Table 
3), with the exception of LA:LS that aggregated after one month. After three months, 
however, the SQ:LA:LS already showed a drastic decrease in the surface charge (-42%), 
which could be related with alterations in the LA disposition and/or ionization, and after 
six months this formulation had aggregated. The nanoemulsion SQ:LA:LS:CS was 
remarkably stable, as its physicochemical characteristics were almost unchanged for up 
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to six months (decrease of size and zeta potential of about 6% and 1% respectively, and 
a rise in PdI of 12%).  
 
Table 3. Physicochemical characterization of the systems over time at 4 ºC.  
 
PdI: Polydispersity Index; ζ: Surface charge; Aggr.: Formulation Aggregated. N/A: Not 
Available 
 
At room temperature, the SQ:LA:LS:CS was again the most stable formulation (Table 
4), while the LA:LS nanoemulsion had already aggregated after fifteen days in these 
conditions. The fragility of this system compared with the SQ:LA:LS:CS indicates that 
both SQ and CS contribute for the nanoemulsion stability. The CS possibly helps 
maintains the structure through complexation with ionized species in the nanoemulsion 
surface while the SQ provides a highly hydrophobic core in which the LA and LS are 
more soluble than in water, decreasing the migration of these molecules from the 
emulsion and/or the Ostwald ripening process [43].  
 
Table 4. Physicochemical characterization of the systems over time at room 
temperature (RT) 
 
PdI: Polydispersity Index; ζ: Surface charge; Aggr.: Formulation Aggregated. N/A: Not 
Available 
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3.3. Freeze drying studies 
As expected from previous works [44], the use of trehalose was fundamental for the 
successful resuspension of these particles. The optimal trehalose concentration for 
SQ:LA:LS and for LA:LS:CS and SQ:LA:LS:CS  was 2.5 and 5%, respectively (Figure 
4). The presence of SQ in the formulation was found to improve the dispersibility of the 
freeze-dried formulation, a result that confirms the stabilizing role of the component.  
 
 
Figure 4. Evaluation of particle size distribution values (Size) and Polydispersity Index 
(PdI) after resuspension of freeze dry formulations at different Trehalose (Tre) 
concentrations percentage (w/v). 
 
3.4. Complement cascade activation by the nanoemulsions and nanocapsules 
The complement system is a fundamental component of the innate immune system and 
it is constituted by a complex network of plasma proteins that play an important role in 
the host defense due to its capacity to elicit and potentiate the immune system activation 
[45, 46] and even enhance both B [47] and T cell [48] responses. The complement 
system has three known cascades of activation (classical, lectin and alternative), which 
differ in the initial stimuli and following reactions but all share a common step that is 
the cleavage of the complement protein C3 into the anaphylatoxin C3a and the opsonin 
C3b factors. The total scheme leading to C3 hydrolysis and following reactions, is 
rather complex and have been thoroughly described elsewhere [45, 46]. As all 
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complement cascades share this step, it is possible to evaluate the capacity of a 
formulation to activate the complement through the determination of the C3 hydrolysis 
by Western-blot. Accordingly, when the formulations were incubated at 1000 μg/ml in 
human plasma for 1 hour at 37 ºC, it was observed that all, except the LA:LS, were able 
to induce the C3 cleavage (Figure 5). The C3 hydrolysis product (MW~43) bands, 
correspondent to these formulations, presented a two-fold signal intensity compared 
with the negative control, which corresponds to the C3 basal degradation. Given that the 
complement is activated by interaction with the particles surfaces, it would be 
expectable that the CS presence would be a major determinant in this process. However, 
both SQ:LA:LS and SQ:LA:LS:CS activate the complement with the same intensity.  
 
 
Figure 5. Analysis by Western-blot of C3 complement factor split products in human 
plasma pool after incubation with LA:LS (A), LA:LS:CS (B), SQ:LA:LS (C) and 
SQ:LA:LS:CS (D) at 10, 100 and 1000 μg/ml. C−: pool of human plasma containing 
complement protein incubated with PBS; C+: pool of human plasma containing 
complement protein incubated cobra venom factor. Marked on light blue is the C3 
protein (about 115 kDa). Marked on red are the C3 split products (about 43 kDa). MW: 
molecular weight of the protein marker (kDa). 
 
This result suggests that the CS might not be involved in the complement activation, 
which is in agreement with previous work with CS covered nanocapsules [39] or 
nanoparticles [49], where it was not observed complement activation. Therefore, the 
most probable trigger of the complement is the LS and/or LA although this would imply 
that the nanocapsule surface is not completely covered with CS. It has been already 
described that the LS exposure to IgM can start a complement cascade by the classical 
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route [50] and it is a possible cause for the results observed in here. The lack of 
complement activation by the LA:LS could result of its poor stability in the 
physiological simulated mediums. The rapid nanoemulsion disaggregation could 
possibly disrupt the complement adsorption and avoid the cascade reaction. 
 
3.5. In vitro assays 
3.5.1. Citotoxicity of the nanoemulsions and nanocapsules 
The xCELLigence® system permitted to monitor the cell viability reduction in a time 
and dose-dependent manner upon contact with the formulations (Figure 6) and 
determine the formulations IC50 at the experimental endpoint (48 hours) (Table 6).  
 
 
Figure 6. Raw 264.7 cells were incubated with LA:LS (A), LA:LS:CS (B), SQ:LA:LS 
(C) and SQ:LA:LS:CS (D) formulations at six different concentrations (250, 125, 62.5, 
31.25, 15.625 and 7.81 μg/ml — black, grey, dark blue, light blue, red, light red lines, 
respectively) for 48 h. The normalized Cell Index is the cell viability relative to the 
negative control (% viable cells) and is expressed as percentage. 
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The  formulations were relatively toxic (IC 50 < 50 μg/ml), with the LA:LS as the most 
toxic one and the SQ:LA:LS:CS as the less toxic at the experimental endpoint (LA:LS > 
LA:LS:LCS > SQ:LA:LS > SQ:LA:LS:CS). In all cases, the main mechanism of cell 
death identified was apoptosis (data not shown), which is less harmful for the tissues 
than necrosis. 
The greater toxicity of the LA:LS and LA:LS:CS could be related to the greater 
concentration of LA in these formulations (4 mg/ml) compared with the other 
formulations (0.8 mg/ml). A reduction of the LA concentration in future compositions 
can possible decrease the toxicity of the formulations and also permit a rise in the final 
pH to values more adequate for in vivo administration. It is also possible that the 
formulations with SQ were less toxic because of a stronger attachment of the LA and 
LS to the highly hydrophobic nucleus of SQ. Nevertheless, one should be aware that 
these in vitro conditions do not simulated perfectly the in vivo conditions, as hardly such 
high concentration of nanoemulsion or nanocapsule would remain confined to a region 
and interacting with the same immune cells for 48 hours. 
 
3.5.2. Cytokine production by PMBC upon incubation with nanoemulsions and 
nanocapsules 
In order to evaluate the capacity of the developed systems to activate and stimulate the 
immune cells, these formulations were incubated at 10 and 100 μg/ml with a PBMC 
sample (which is constituted by lymphocytes (T cells, B cells, and NK cells), 
monocytes, and dendritic cells) for 24 hours at 37 ºC. The immune cells cytokines 
expression profile was determined using the Human  h1/ h2 11plex FlowCytomix™ 
Multiplex Kit, which allows a simultaneous quantification of several cytokines (IL-
12p70, IFN γ, IL-2,  NF β, IL-10, IL-4, IL-6, IL-5, IL-8, IL-1β and  NF α). 
Surprisingly, from all the cytokines evaluated, the formulations only stimulated the 
secretion of interleukin-8 (IL-8 or CXCL8) (Table 6), a pro inflammatory cytokine. 
While the LA:LS and SQ:LA:LS were capable to stimulate this secretion at 10 μg/ml, 
the other formulations only had effect at the 100 μg/ml concentration.  he IL-8 has 
chemoattractant properties and also stimulates the respiratory burst in phagocytes [51], 
which can be useful for the objective intended. Considering previous work with LS, it 
would be expectable an increased secretion of IFN-γ,  NF-α [21] and IL-1β [23]. 
However, it is possible that the formulations cytotoxicity did not allow the normal 
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function of the cells, preventing the full expression of cytokines. Optimally, the 
developed lipidic systems should permit a slow release of LS and LA, as their 
hydrophobic character would delay its dispersion in water. This slow release would 
diminish the free LA and LS in solution decreasing their potential toxicity and 
extending their adjuvant action. These molecules would act as danger signals that would 
provoke the migration of leucocytes towards the adjuvant systems. The nanometric size 
of the systems would then enhance its uptake by the phagocytes, increasing the 
recognition of the associated antigen by the immune cells. Finally, the LS presence and 
the nanometric size itself would provoke the activation of these cells against the 
associated antigens. However, in this in vitro model the nanoparticles are confined 
already with the immune cells, making it impossible to assess the potential chemotactic 
properties of the system. Such confinement and high concentration of the formulation 
could also potentiate the formulation toxicity and decrease its immunostimulant 
properties.  
 
3.5.3. ROS production 
The capability of the formulations to trigger the respiratory burst was evaluate in a 
HL60 cell line, a human promyelocytic leukemia cell line that has been widely used for 
the study of cells differentiation in the presence of specific stimulus [52]. The ROS 
production can be a result of cellular stress [53], induced apoptosis [54] or immune cells 
activation [55]. The cytometry evaluation indicated that all prototypes at the 
concentration of 100 μg/ml, stimulated the ROS production after 1 hour of incubation 
but after 12 hours there was no signal of ROS (Table 6). A hypothesis for such results 
is that the initial ROS production is due to cellular stress and eventual apoptosis (as it 
was observed in the cytotoxicity assays) leading to decreased ROS levels after 12 hours. 
However, the most toxic prototype, LA:LS, generated lower levels of ROS than the rest 
of the systems, which suggest additional causes for this respiratory burst profile.  
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Table 6. Resume of the formulation’s complement activation, half maximal inhibitory 
concentration (IC50) after 48 hours, Interleukin-8 (IL-8) secretion and Reactive Oxygen 
Species (ROS) production.  
 
Results with a 2-fold (+) or 4-fold (++) signal compared with the signal of the negative 
control were considered positive.  
 
3.6. Peptide-based antigen association 
Based on their stability profile, SQ-containing formulations were considered the most 
promising ones and were selected for the association of the model peptide-based 
antigens. The loading method was designed to permit the interaction of both peptide and 
particles at maximum possible concentration, in order to increase the probability of 
interaction between both elements. In other hand, this two steps method also avoids that 
the antigen enters in contact with the organic phase (that could denature the antigen). 
As model antigens, we selected three peptides (68-4, 69-2 and 69-4) that present amino 
acid sequences homologous to specific epitopes from the simian immunodeficiency 
virus (SIV), which makes them interesting antigen models, as this virus is an 
exceptional model for HIV vaccine research [56]. These three peptides present similar 
molecular weight (MW) but different hydrophobic character (estimated by the grand 
average of hydropathy (GRAVY) index) and isoelectric point (pI) (Table 1). This was 
designed to permit the assessment of the capacity of the developed systems to associate 
peptide-based antigens with different characteristics. The SQ:LA:LS particles withstood 
well the filtration process, with only a small variation in size or surface charge (7% and 
4% decrease, respectively) and even a substantial decrease in the PdI (37%) (Figure 7). 
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Figure 7. Evaluation of particle size distribution values (Size), Polydispersity Index 
(PdI) and surface charge (Zeta potential) of the blank (Ultraf. Blank) and loaded 
(Ultraf. 68-4, 69-2 and 69-4) SQ:LA:LS (A) and SQ:LA:LS (B) formulations after 
ultrafiltration. 
 
When incubated with the peptides, the surface charge decreased slightly in all cases and 
even the size and PdI presented lower values, with the exception of the peptide 69-2, 
where it was observed an increase in size and PdI. The SQ:LA:LS:CS formulation after 
filtration presented a great increase in size, PdI and surface charge (24, 25 and 44% 
increase, respectively) but when incubated with the peptides and filtrated, these particles 
showed similar physicochemical properties to the original formulation (Figure 6). 
Preliminary stability studies indicate that the SQ:LA:LS and SQ:LA:LS:CS loaded and 
filtered formulations are stable for at least one week at room temperature (Figure 8).  
 
 190 
 
 
Figure 8. Preliminary evaluation of particle size distribution values (Size) and 
Polydispersity Index (PdI) over time of loaded and filtered SQ:LA:LS (B) and 
SQ:LA:LS:CS (B) formulations with different peptides (68-4, 69-2 and 69-4, 
respectively) at room temperature (RT). 
 
The association efficiency was relatively poor in both systems (Table 7). However, it is 
possible to identify a correlation between the GRAVY index (69-2 > 68-4 > 69-4) 
(Table 1) and the association (69-2 > 68-4 > 69-4). Most notably, the greatest 
association in both systems was achieved with the peptide 69-2, the most hydrophobic 
of the peptides, followed by the 68-4, the second most hydrophobic. This parameter 
seems to be more important for these systems than pI or the peptide charge, which is 
coherent with the formulation hydrophobic character. It would be expectable that the CS 
shell would decrease the association of the 69-2 and 68-4 peptides (due to their positive 
charge) but apparently this shell does not interfere with the association of positively 
charged peptides, which indicates the system is flexible enough to permit the 
association of differently charged peptides. 
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Table 7. Association efficiency of the different peptides (68-4, 69-2 and 69-4) to the 
SQ:LA:LS and SQ:LA:LS:CS nanoparticles  
 
IPA: Peptide association by indirect peptide evaluation; DPA: Peptide association by 
direct peptide evaluation 
 
CONCLUSION 
 
Here, we report the design and characterization of novel nanoemulsions and 
nanocapsules based on molecules with immune stimulant properties and chemotactic 
action (lysophosphatidylcholine and linoleic acid), as new vaccine adjuvant systems. 
The inclusion of squalene and chitosan in the composition seems to increase the 
formulations stability and can potentially further enhance the systems adjuvanticity.  
The developed systems were capable of activating the complement system, however 
they were also found to be cytotoxic. The squalene based formulations presented lower 
toxicity and were capable to associate peptide-based antigens with different 
physicochemical characteristics albeit with low efficiency. Overall, the formulation 
composition should be optimized in order to improve the system toxicity profile while 
maintaining its adjuvant potential. Additional studies should also be realized to improve 
the formulations capability to associate antigens. The exceptional properties of the 
lysophosphatidylcholine as adjuvant material and surfactant should stimulate the further 
improvement of the exposed prototypes as vaccine adjuvant systems. 
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SUPPORTING INFORMATION 
 
Annex 1. Illustration of lysophosphatidylcholine generation by hydrolysis of the 
phosphatidylcholine  
 
 
Annex 2. Calculation of the peptide charge at pH 4 
Charge at pH 4 is a predicted value calculated by the following equation:
 
In which Z represents the Net charge of the peptide sequence, Ni the number of 
arginine, lysine and histidine residues and the N-terminus and pKai, their pKa. The Nj 
represents the number of aspartic acid, glutamic acid, cysteine and tyrosine residues and 
C-terminus and and pKaj, their pKa. 
 
 
Annex 3. Chromatography conditions and peptide retention times 
 
 
 
 
 
Min.: Time in minutes; A (%): Phase A (TFA 0.1% in H2O); B (%): Phase B (TFA 
0.1% in ACN); Col. Temp.: Column Temperature; Inj. Vol.: Injection Volume; λ: 
Wavelength; RT (min): Retention Time in minutes 
2b 
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OVERALL DISCUSSION 
 
Nanotechnology holds great potential for the improvement of the present and future 
vaccines through the development of safer and more efficient adjuvant systems. 
Supported by the great expertise of our group in this field, distinct strategies with 
different biomaterials were evaluated in the present work for diverse antigens, all based 
on a common element: nanometric delivery systems. 
The nanometric delivery systems in described here, were developed through the 
combination of polysaccharides, polyamino acids, polynucleotides and lipids with 
intrinsic adjuvant properties. The objective was to explore a synergistic effect between 
these components when organized into nanostructures with adequate physicochemical 
characteristics, with the final goal of increasing the efficiency of antigen delivery and 
presentation to the immune system. 
 In terms of polysaccharides, we used both cationic polymers like chitosan (CS), a 
biodegradable and mucoadhesive polymer [1], and anionic polymers such as dextran 
sulfate (DS) and alginate (ALG), which present immunostimulant properties [2, 3]. As 
polyaminoacids polyarginine (PARG) and protamine (PR) were used due to their ability 
to enhance mucosal delivery and increase cellular internalization [4, 5]. As 
polynucleotide, a synthetic analog of the viral double-stranded RNA (dsRNA) poly 
(I:C) was used as a TLR3 agonist [6] to potentiate both humoral and cellular immune 
responses [7, 8] and finally, as lipids we used squalene (SQ), an oil present in 
nanoemulsion adjuvant systems in the market, which attest for its safety and 
immunoadjuvant properties [9], linoleic acid (LA) that presents chemotactic action 
humans [10] and lysophosphatidylcholine (LS) that presents not only chemotactic 
action, but also immunostimulant action and surfactant properties [11, 12]. 
The referred biomaterials were combined through specific nanotechnology formulation 
techniques like ionic gelation, layer by layer and solvent displacement techniques, 
according to the biomaterials physicochemical characteristics and the nature of the 
antigen of interest. In total, it were developed three types of different nanocarriers: i) 
Nanoparticles based on the gelification of chitosan with TPP in the presence of poly 
(I:C) (CS/TPP/pIC); ii) Multi-enveloping systems based on virus-like particles (VLP); 
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iii) Nanoemulsions and nanocapsules based on lysophosphatidylcholine (LS) and 
linoleic acid (LA) (Figure 1).  
 
 
Figure 1. Illustration of the different nanocarriers developed as vaccine adjuvant 
systems. 
 
As model antigens, we chose two different classes of subunit antigens with increasing 
presence in the field of vaccination due to their exceptional safety profile [13]: Virus-
like particles (VLP) and peptide-based antigens (Table 1). Concretely, as VLP-type 
antigen, the hepatitis B recombinant surface antigen (HB) was selected and the peptide-
based antigens were those from the Human Papillomavirus (HPV) and three other 
model peptides with different physicochemical characteristics. 
 
Table 1. Summary of the type, origin, molecular weight (MW), isoelectric point (pI) 
and grand average of hydropathy (GRAVY) of the different antigens used in this study. 
Antigen type Virus  Code  MW (kDa) pI GRAVY 
VLP Hepatitis B HB > 3000 4.6 N/A 
Peptide-Based HPV 1338aa 3.4 3.94 N/A 
 
N/A    68-4 2.3 12.2 -1.665 
  
   69-2 2.3 3.8 -0.455 
  
   69-4 2.5 7.1 -1.995 
 203 
 
1. Delivery systems for VLP antigens - Development and physicochemical 
characterization  
Inspired by the nanoparticulated nature of the VLP that presents an exceptional 
immunogenicity as compared to other subunit antigen, we have designed a strategy 
specifically intended to modulate the immune response by enveloping the VLP antigen 
with a number of biomaterials with immunoadjuvant properties.  
The VLP model antigen selected was the hepatitis B antigen (HB), which presents a 
nanometric size (22 nm) and negative surface charge (-33 mV). Based on this negative 
charge, the cationic polyamino acids protamine and polyarginine were adsorbed first to 
its surface to form the HB:Protamine (HB:PR) and HB:Polyarginine (HB:PARG) 
structures and, then, the anionic polymers dextran sulfate (DS) and alginate (ALG) or 
poly (I:C) (pIC) were adsorbed over the positive polymers, to originate HB:protamine: 
dextran sulfate (HB:PR:DS), HB:polyarginine:alginate (HB:PARG:ALG) or 
HB:polyarginine:poly (I:C) (HB:PARG:pIC) structures, respectively (Table 2). 
 
Table 2. Physicochemical characterization of the Hepatitis B (HB) virus-like particle 
(VLP) antigen alone or multi-enveloped by different polymers.  
Formulation  Code  Size (nm) PdI  ζ (mV) Antigen (%) 
HB VLP  HB   22 ± 1  0.4  - 33 ± 2  N/A 
HB:Protamine  HB:PR   24 ± 3  0.3  + 32 ± 5  67 ± 2 
HB:Protamine: 
Dextran sulfate 
HB:PR:DS   35 ± 4  0.3  - 50 ± 0  67 ± 2 
HB:Polyarginine  HB:PARG   27 ± 4  0.3  + 52 ± 4  65 ± 3 
HB:Polyarginine: 
Alginate  
HB:PARG:ALG  39 ± 7  0.4  - 52 ± 0  65 ± 3 
HB:Polyarginine: 
Poly (I:C)  
HB:PARG:pIC   33 ± 6  0.4  - 41 ± 8  65 ± 3 
PdI: Polydispersity Index; ζ: surface charge; Antigen (%): Antigen enveloping 
efficiency  
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The multi-enveloping strategy allowed the formation of very small systems (< 40 nm) 
with a variable surface charge depending on the final composition of the consecutive 
polymeric layers. These systems presented a high enveloping efficiency of the antigen 
(> 60%) and were stable in aqueous suspension at room temperature for at least one 
month and in PBS for at least 4 hours. 
The humoral responses observed in mice after administration of the HB:PR, HB:PR:DS, 
HB:PARG:ALG and HB:PARG:pIC systems by the intramuscular (i.m.) (Figure 2) and 
intranasal (i.n.) (Figure 3) route, indicate that the multi-enveloping strategy could in 
general increase the immune response against the associated antigen and generate a 
protective antibody titer (>10 mIU/ml).  
 
 
Figure 2. Systemic humoral (IgG) immune response observed in mice upon 
intramuscular (10 μg, 0 and 4 weeks) immunization with Hepatitis B antigen coated 
with Protamine (HB:PR), Protamine and Dextran Sulfate (HB:PR:DS), Polyarginine 
and Alginate (HB:PARG:ALG) or Polyarginine and poly (I:C) (HB:PARG:pIC). 
Hepatitis B antigen adsorbed to Alum (HB:Alum) was used as positive control. The plot 
represents the anti-HB IgG average quantified at different time points after primary 
immunization (mean ± SEM, n = 10). 
 
However, despite their diverse composition and structure, the IgG titers achieved by the 
multi-enveloping antigen systems were lower than those obtained when using alum-
adsorbed antigen, which suggests an intrinsic limitation of this multi-enveloping 
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strategy. It is possible that the coating of the antigen surface by the polymers and the 
very small size of these systems somehow hinders the antigen recognition by immune 
cells and leads to less intense immune responses. 
 
 
Figure 3. Systemic humoral (IgG) immune response observed in mice upon intranasal 
(10 μg, 0, 4 and 16 weeks) immunization with Hepatitis B antigen coated with 
Protamine (HB:PR), Protamine and Dextran Sulfate (HB:PR:DS), Polyarginine and 
Alginate (HB:PARG:ALG) or Polyarginine and poly (I:C) (HB:PARG:pIC). Hepatitis B 
antigen dispersed in PBS (HB in PBS) was used as positive control. The plot represents 
the anti-HB IgG average quantified at different time points after primary immunization 
(mean ± SEM, n = 10). 
 
The highest antibody response was achieved with the HB:PARG:pIC composition. 
Interestingly, when comparing the IgG1/IgG2a ratio between the alum-adsorbed antigen 
and the HB:PARG:pIC formulation, it was observed that while the alum generated an 
Th2 biased response, the HB:PARG:pIC generated a Th1 biased response (Figure 4). 
This increased activation of Th1 cells by the HB:PARG:pIC formulation can be an 
interesting advantage of this system, as these cells stimulate the development of cell-
mediated immune responses capable of eliminating virus infected cells [14]. 
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Figure 4. Ratio of IgG1 and IgG2a subtypes in the serum of mice immunized with the 
multi-enveloped system comprising the Hepatitis B antigen coated with polyarginine 
and poly (I:C) (HB:PARG:pIC) (grey squares), and with the same antigen adsorbed to 
alum (HB:Alum) (black circle). 
 
2. Adjuvant systems for Peptide-based antigens - Development and 
physicochemical characterization  
Peptide-based antigens present an enormous potential for the development of future 
vaccines due to their purity and highly precise composition [15]. However, on the 
contrary to VLP antigens, these antigens present in general poor immunogenicity [13, 
16] and consequently need robust adjuvant systems in order to generate effective 
immune responses. In this sense, we have developed different adjuvant systems with 
increasing complexity to activate the immune responses against these antigens.  
The great versatility of chitosan in the constitution of nanometric systems for the 
delivery of both polynucleotides [17] and proteins [18, 19] motivated us to design a 
novel nanostructure capable of co-deliver a potent immunostimulant (Poly (I:C)) and a 
T-helper peptide (PADRE) [20] as adjuvant system for the highly specific but poorly 
inmunogenic HPV-derived peptide antigen 1338aa. The gelification of the chitosan by 
TPP in the presence of Poly (I:C) at the mass ratio chitosan/TPP/pIC 4/1/04 permitted 
the constitution of a nanometric system (284 nm), with low PdI (0.2) and strong positive 
charge (> +40 mV) (Table 6) and with poly (I:C) encapsulation close to 100%. 
Furthermore, the poly (I:C) remained encapsulated after freeze drying and/or incubation 
with strong polyanions (heparin), and was released without observable damage after 
 207 
 
enzymatic digestion of the nanoparticle with chitosanase (Figure 5). This mild and 
straightforward method was selected to avoid the degradation of the poly (I:C) and the 
peptides and in addition, to allow for the association of both peptides in different 
arrangements (i.e. surface adsorbed or entrapped inside the particles) and study the 
influence of these different peptide displays on the biological performance of the 
nanosystem.  
 
Table 6. Physicochemical characterization of Chitosan/TPP/Poly (I:C) nanoparticles 
without peptide and with the peptides 1338aa and PADRE, either adsorbed onto the 
nanostructure surface or entrapped inside the matrix. (Means ± S.D., n=3).   
Formulation   Code  
Size  
(nm) 
PdI  ζ (mV) Antigen (%) 
Chitosan/pIC without peptide 
(Blank)  
 NP B   284 ± 15  0.2 + 41 ± 1 N/A 
Chitosan/pIC-1338aa 
Adsorbed  
NP A1  299 ± 23  0.2 + 49 ± 5 39 ± 1 
Chitosan/pIC/PADRE -1338aa 
Adsorbed  
NP A2  274 ± 9  0.2 + 47 ± 5 50 ± 5 
Chitosan/pIC/PADRE -1338aa 
Entrapped  
NP E2  290 ± 28  0.2 + 48 ± 4 67 ± 8 
PdI: Polydispersity Index; ζ: Surface charge; Antigen (%): Antigen association 
efficiency  
 
By inducing the gelification of the chitosan with TPP in the presence of the Poly (I:C) 
and the peptides PADRE and 1338aa, it was possible to incorporate both peptides 
within the nanoparticle structure and constitute the Chitosan/Poly (I:C)/PADRE-1338aa 
Entrapped (NP E) formulation. On the other hand, by incubating the peptides PADRE 
and 1338aa together or the peptide 1338aa alone with preformed particles allowed the 
constitution of the particles Chitosan/Poly (I:C)/PADRE-1338aa Adsorbed (NP A2) and 
Chitosan/Poly (I:C)-1338aa Adsorbed (NP A1) formulations, respectively, in which the 
peptides were associated to the nanoparticle surface. Although presenting a different 
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peptide disposition, the size, PdI and surface charge of the three different systems did 
not change significantly (Table 6). This supports the robustness of the preparation 
method and indicates the versatility of the nanoparticles enabling the integration other 
immune stimulants in the future. 
 
 
Figure 5. Agarose gel assay on pIC release from NP B (Chitosan/TPP/Poly (I:C) 
without peptides): 1) DNA Ladder; 2) 8 μg pIC; 3) 4 μg pIC; 4) 2 μg pIC; 5) 1 μg pIC; 
6) 0.5 μg pIC in solution; 7) NP B Supernatant; 8) NP B Pellet; 9) NP B Pellet 
incubated with Heparin; 10) NP B Pellet digested with chitosanase; 11) NP B Pellet 
Freeze dried; 12) NP B Pellet Freeze dried and incubated with Heparin; 13) NP B 
Pellet Freeze dried incubated with chitosanase. 
 
The final goal was to explore the synergistic effect of chitosan, poly (I:C) and PADRE 
peptide assembled together in a nanostructure but also the influence of the peptides 
disposition in the biological outcome. 
The preliminary in vivo efficacy assay highlighted the importance of the peptide 
presentation form, with the Chitosan/Poly (I:C)/PADRE-1338aa Adsorbed particles, 
presenting the highest capacity to produce humoral responses (Figure 6). This capacity 
of inducing an immune response towards this particularly poor immunogenic antigen is 
in contrast to the lack of efficacy observed with alum salts. The results show the 
potential of this nanoparticle prototype for antigen delivery and the same time, also 
indicate the interest of our strategy to combine these nanometric antigen delivery 
systems with immunostimulants for the generation of an effective adjuvant systems. 
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Figure 6. 1338aa peptide-specific IgG responses in the sera diluted 1/50 of mice 
immunized by the intramuscular route with nanoparticles without peptides (NP B), 
nanoparticles with surface adsorbed 1338a (NP A1), with surface adsorbed 1338aa and 
PADRE (NP A2), with both peptides entrapped in the matrix (NP E) or with alum-
adsorbed 1338aa. (#/5):  number of responsive mice in the total 5 mice per group; an 
O.D. 4 times higher than the mean O.D. values of NP B immunized mice serum (0.2) 
was considered a positive response.  
 
 
The general lack of immunogenicity of peptide-based antigens inspired us to further 
developed adjuvant systems for these antigens. Considering the success of already 
marketed nanoemulsion-based adjuvants like MF59 and ASO3 [9] and the promising 
results obtained chitosan based nanocapsules both for intramuscular [21] and intranasal 
route [22], we decided to develop novel nanoemulsions and nanocapsules based on 
materials with known adjuvant properties like squalene and chitosan, combined with 
materials less studied in this field such as linoleic acid and lysophosphatidylcholine, 
which present chemotactic and immunostimulant properties. With the objective to 
obtain a synergistic effect of these components through their organization in the form of 
nanostructures, we designed four lipid based nanosystems, namely:  
(i) linoleic acid:lysophosphatidylcholine (LA:LS) and  
(ii) squalene:linoleic acid:lysophosphatidylcholine (SQ:LA:LS) nanoemulsions and  
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(iii) linoleic acid:lysophosphatidylcholine:chitosan (LA:LS:CS) and  
(iv) squalene:linoleic acid:lysophosphatidylcholine:chitosan (SQ:LA:LS:CS) 
nanocapsules.  
These four systems were prepared by the solvent displacement technique and presented 
nanometric size (< 200 nm) with low polydispersity (< 0.2). The nanoemulsions 
presented a highly negative surface charge (< -20 mV) due to the presence of linoleic 
acid, and the nanocapsules had high positive surface charge (> + 30 mV) due to the 
surrounding chitosan shell (Table 7).  
 
Table 7. Physicochemical characterization of the lysophosphatidylcholine and linoleic 
acid based nanoemulsions and nanocapsules. (Means ± S.D., n=3).   
Formulation Size (nm)  PdI  ζ (mV)  
LA:LS   135 ± 21  0.2  - 36 ± 3  
LA:LS:CS   152 ± 11  0.2  + 39 ± 5  
SQ:LA:LS   176 ± 16  0.2  - 28 ± 7  
SQ:LA:LS:CS   189 ± 15  0.2  + 37 ± 8  
PdI: Polydispersity Index; ζ: Surface charge 
 
With the exception of the LA:LS composition, the systems presented in general good 
stability in storage conditions (4 ºC and room temperature) and in simulated 
physiological media (DMEM and RPMI with FBS) and could be adequately converted 
to a dried form by lyophilization. Additionally, these particles were characterized for 
their capacity to initiate the complement system and stimulate the production of 
cytokines and ROS, as well as their cytotoxicity. The inclusion of squalene and chitosan 
in the composition seemed to increase formulation stability and is eventually expected 
to further enhance the systems adjuvanticity. Due to their lower toxicity, the squalene 
containing formulations were chosen to do preliminary association studies with three 
peptide-based model antigens (denoted as 68-4, 69-2 and 69-4) with similar molecular 
weights but different isoelectric points and hydrophobicity (see Table 1). Interestingly, 
it was found that the main characteristic affecting the efficiency of association was the 
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hydrophobicity of the peptides, which is compatible with the hydrophobic character of 
our lipid-based nanosystems and could be useful in the further optimization of peptide 
association (Table 8). 
 
Table 8. Physicochemical characterization and loading efficiency of the SQ:LA:LS and 
SQ:LA:LS:CS formulations loaded with the peptide-based antigens 68-4, 69-2 and 69-
4. (Means ± S.D., n=3).   
Formulation   Peptide  Size (nm)  PdI  ζ (mV)  Antigen (%)  
SQ:LA:LS    68-4   154 ± 8  0.2  - 22 ± 9       16 ± 10 
 
  69-2   200 ± 29  0.3  - 22 ± 2       24 ± 14  
 
  69-4   153 ± 11  0.1  - 23 ± 7         7 ± 1  
SQ:LA:LS:CS    68-4   177 ± 14  0.2  + 36 ± 5       23 ± 5 
 
  69-2   187 ± 26  0.2  + 34 ± 6       45 ± 9 
 
  69-4   180 ± 13  0.2  + 37 ± 4       18 ± 3 
PdI: Polydispersity Index; ζ: Surface charge; Antigen (%): Antigen association 
efficiency  
 
 
As a general conclusion from the results obtained during the present thesis: several 
types of polymeric and lipidic nanocarriers have been developed by the combination of 
different biomaterials in order to explore different strategies to enhance the efficacy of 
antigen delivery to and presentation by immunocompetent cells. These nanosystems 
have shown capacity to associate diverse immunomodulator molecules together with 
antigens of different nature such as virus-like particles or peptide-based antigens. The 
adjuvant properties of these nanostructures were explored by in vitro and in vivo studies 
and present great potential as future vaccine delivery systems. Altogether, this work 
reflects the high versatility of possibilities offered by nanotechnology for the 
development of new adjuvant systems.  
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CONCLUSIONES 
 
El trabajo experimental recogido en la presente memoria se ha centrado en el diseño y 
desarrollo de nuevos nanosistemas transportadores de antígeno constituidos por 
diferentes biomateriales, y en la evaluación de su capacidad para vehiculizar antígenos, 
tras su administración por vía parenteral o por vía nasal. De los resultados obtenidos, se 
pueden extraer las siguientes conclusiones: 
 
1. Utilizando como antígeno particulado modelo, el antígeno recombinante de superficie 
de la hepatitis B (rHBsAg), se ha logrado obtener sistemas de tamaño nanométrico por 
medio del recubrimiento secuencial del antígeno mediante protamina y sulfato de 
dextrano, mediante poliarginina y alginato o mediante poliarginina y poly (I:C). Esta 
estrategia ha permitido, en general, incrementar la respuesta humoral frente al antígeno 
recubierto, tras su administración por vía parenteral y nasal. . De entre las formulaciones 
evaluadas, aquélla que contiene el agente inmunoestimulante poly (I:C), es la que ha 
permitido alcanzar los niveles más elevados de IgG entre los sistemas testados y 
modular la respuesta inmune hacia un tipo predominantemente Th1 (celular).    
 
2. Se ha desarrollado un nuevo sistema adyuvante basado en la gelificación del 
quitosano con TPP, capaz de vehiculizar simultáneamente un inmunoestimulante (Poly 
(I:C)),  un péptido T-helper (PADRE)  y un antígeno peptídico (1338aa) y que permite 
tanto la encapsulación de los péptidos como su adsorción a la superficie de las 
nanopartículas. Los resultados obtenidos tras la evaluación in vivo de estas 
formulaciones llevaron a concluir que la disposición de los péptidos a la superficie de la 
nanopartícula es la configuración preferible para una  inmunización efectiva 
 
3. A través de la técnica de desplazamiento del solvente se han desarrollado nuevos 
nanoemulsiones y nanocápsulas con potencial adyuvante, basadas en 
lisofosfatidilcolina, acido linoléico, escualeno y quitosano, estables en distintas 
condiciones de acondicionamiento y soluciones fisiológicas simuladas y que pueden ser 
liofilizados y resuspendidos sin pérdida de sus características fisicoquímicas originales. 
El escualeno y el quitosano contribuyeron de manera significativa a incrementar la 
estabilidad de los sistemas. Los estudios de asociación de antígenos peptídicos pusieron 
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de manifiesto la capacidad de estos sistemas para vehiculizar antígenos peptídicos con 
distintas características fisicoquímicas. 
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CONCLUSIONS 
 
The experimental work reported in this thesis has been oriented towards the design and 
development of new nanometric antigen delivery systems, composed by different 
biomaterials and the evaluation of their the capacity to deliver antigens upon parenteral 
or nasal administration. The results obtained led us to the following conclusions: 
 
1. Using the recombinant hepatitis B surface antigen (rHBsAg) as a model virus-like 
particle (VLP) antigen, it was possible to develop nanometric systems through the 
sequential enveloping of the VLP antigen with protamine and dextran sulfate, with 
polyarginine and alginate or with polyarginine and poly (I:C). This strategy has led to a 
general increase of the humoral response against the multi-enveloped antigen and the 
generation of protective IgG titers (> 10 mIU/ml) upon parenteral and nasal 
administration. The association of the poly (I:C) to the system generated the highest IgG 
titers among the multi-enveloping systems and also permitted the modulation of the 
immune response towards a predominant Th1 type response (cellular). 
    
2. A new adjuvant system has been developed based on the ionic gelation of chitosan 
with TPP, capable of co-delivering an immunostimulant (Poly (I:C)), a T-helper peptide 
(PADRE) and a peptide-based antigen (1338aa). This system permits, either the 
entrapment or the adsorption of the antigenic peptide onto the nanoparticle surface. The 
results of the in vivo studies showed the capacity of this system to potentiate the 
humoral response against the associated antigen and indicated that the peptide display 
on the nanoparticle surface is critical for an effective immunization.  
 
3. Using the solvent displacement technique, it was possible to develop new 
nanoemulsions and nanocapsules with adjuvant potential, based on 
lysophosphatidylcholine, linoleic acid, squalene and chitosan. These nanosystems were 
found to be stable under different storage conditions and suspension media and could be 
freeze dried and resuspended without losing their initial physicochemical properties. 
Squalene and chitosan contributed to the stability of the system. Preliminary studies 
indicated the ability of these systems to associate peptide-based antigen with different 
physicochemical characteristics. 
 
